Joel Neal, MD, PhD

5.0/5

Biography

Dr. Neal holds a medical degree and a doctoral degree in Tumor Cell Biology from Northwestern University in Chicago, Illinois. Subsequently, he completed a fellowship in oncology, rotating through the Dana-Farber Cancer Institute and Massachusetts General Hospital in Boston, Massachusetts. He is currently a Professor in the Division of Oncology at the Stanford Cancer Institute at Stanford University in Palo Alto, California. Dr Neal鈥檚 primary clinical interest is in thoracic oncology. In addition to maintaining an active practice, he focuses on the design and conduct of clinical trials involving targeted therapies and immunotherapy for lung cancer and mesothelioma. He has published dozens of articles in the field of thoracic oncology, including in Lancet Oncology, Nature Medicine, and the Journal of Clinical Oncology. He is a member of the International Association of the Study of Lung Cancer (IASLC), is a study chair and thoracic core committee member within the ECOG-ACRIN cooperative group, and has presented at a number of American Society of Clinical Oncology (ASCO) annual meetings.

View Full Biography

Professional Summary

Education & Certifications

Residency: Beth Israel Deaconess Medical Center Internal Medicine Residency (2007) MA
Medical Education: Northwestern University Feinberg School of Medicine (2004) IL
Fellowship: Dana Farber Cancer Institute Hematology Oncology Fellowship (2010) MA
- Board Certification: American Board of Internal Medicine, Medical Oncology (2010)

View More Education & Certifications

Publications

Glycogen synthase kinase-3 inhibits the DNA binding activity of NFATc
Neal, J. W., & Clipstone, N. A. (2001). Glycogen synthase kinase-3 inhibits the DNA binding activity of NFATc. JOURNAL OF BIOLOGICAL CHEMISTRY, 276(5), 3666鈥�3673.
Calcineurin mediates the calcium-dependent inhibition of adipocyte differentiation in 3T3-L1 cells
Neal, J. W., & Clipstone, N. A. (2002). Calcineurin mediates the calcium-dependent inhibition of adipocyte differentiation in 3T3-L1 cells. JOURNAL OF BIOLOGICAL CHEMISTRY, 277(51), 49776鈥�49781.
A constitutively active NFATc1 mutant induces a transformed phenotype in 3T3-L1 fibroblasts
Neal, J. W., & Clipstone, N. A. (2003). A constitutively active NFATc1 mutant induces a transformed phenotype in 3T3-L1 fibroblasts. JOURNAL OF BIOLOGICAL CHEMISTRY, 278(19), 17246鈥�17254.
- Induction of FucT-VII by the Ras/MAP kinase cascade in Jurkat T cells
  Barry, S. M., Zisoulis, D. G., Neal, J. W., Clipstone, N. A., & Kansas, G. S. (2003). Induction of FucT-VII by the Ras/MAP kinase cascade in Jurkat T cells. BLOOD, 102(5), 1771鈥�1778.
- Targeted therapies: optimal first-line therapy for NSCLC with EGFR mutations.
  Neal, J. W., & Sequist, L. V. (2010). Targeted therapies: optimal first-line therapy for NSCLC with EGFR mutations. Nature Reviews. Clinical Oncology, 7(2), 71鈥�72.
- Exciting New Targets in Lung Cancer Therapy: ALK, IGF-1R, HDAC, and Hh
  Neal, J. W., & Sequist, L. V. (2010). Exciting New Targets in Lung Cancer Therapy: ALK, IGF-1R, HDAC, and Hh. CURRENT TREATMENT OPTIONS IN ONCOLOGY, 11(1-2), 36鈥�44.
- AMG-386, a selective angiopoietin-1/-2-neutralizing peptibody for the potential treatment of cancer
  Neal, J., & Wakelee, H. (2010). AMG-386, a selective angiopoietin-1/-2-neutralizing peptibody for the potential treatment of cancer. CURRENT OPINION IN MOLECULAR THERAPEUTICS, 12(4), 487鈥�95.
- The SATURN trial: the value of maintenance erlotinib in patients with non-small-cell lung cancer
  Neal, J. W. (2010). The SATURN trial: the value of maintenance erlotinib in patients with non-small-cell lung cancer. FUTURE ONCOLOGY, 6(12), 1827鈥�1832.
- One Allele's Loss Is Another's Gain: Alterations of NKX2-8 in Non-Small Cell Lung Cancer
  Neal, J. W., & Shaw, A. T. (2011). One Allele's Loss Is Another's Gain: Alterations of NKX2-8 in Non-Small Cell Lung Cancer. CLINICAL CANCER RESEARCH, 17(4), 638鈥�639.
- Targeting FGFR, Ephrins, Mer, MET, and PDGFR-alpha in Non-small Cell Lung Cancer
  Riess, J. W., & Neal, J. W. (2011). Targeting FGFR, Ephrins, Mer, MET, and PDGFR-alpha in Non-small Cell Lung Cancer. JOURNAL OF THORACIC ONCOLOGY, 6(11), S1797鈥揝1798.
- Current Management of Small Cell Lung Cancer
  Neal, J. W., Gubens, M. A., & Wakelee, H. A. (2011). Current Management of Small Cell Lung Cancer. CLINICS IN CHEST MEDICINE, 32(4), 853-?
- Complex Role of Histone Deacetylase Inhibitors in the Treatment of Non-Small-Cell Lung Cancer
  Neal, J. W., & Sequist, L. V. (2012). Complex Role of Histone Deacetylase Inhibitors in the Treatment of Non-Small-Cell Lung Cancer. JOURNAL OF CLINICAL ONCOLOGY, 30(18), 2280鈥�2282.
- Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non-Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study
  Lynch, T. J., Bondarenko, I., Luft, A., Serwatowski, P., Barlesi, F., Chacko, R., 鈥� Reck, M. (2012). Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non-Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study. JOURNAL OF CLINICAL ONCOLOGY, 30(17), 2046鈥�2054.
- A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours
  Diaz-Padilla, I., Siu, L. L., San Pedro-Salcedo, M., Razak, A. R. A., Colevas, A. D., Shepherd, F. A., 鈥� Wakelee, H. A. (2012). A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours. BRITISH JOURNAL OF CANCER, 107(4), 604鈥�11.
- A Phase I Study of Erlotinib and Hydroxychloroquine in Advanced Non-Small-Cell Lung Cancer
  Goldberg, S. B., Supko, J. G., Neal, J. W., Muzikansky, A., Digumarthy, S., Fidias, P., 鈥� Sequist, L. V. (2012). A Phase I Study of Erlotinib and Hydroxychloroquine in Advanced Non-Small-Cell Lung Cancer. JOURNAL OF THORACIC ONCOLOGY, 7(10), 1602鈥�1608.
- First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors.
  Nguyen, K.-S. H., & Neal, J. W. (2012). First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors. Biologics : Targets & Therapy, 6, 337鈥�45.
- Targeting fibroblast growth factor receptor and discoidin domain receptor 2 in non-small-cell lung cancer.
  Riess, J. W., & Neal, J. W. (2012). Targeting fibroblast growth factor receptor and discoidin domain receptor 2 in non-small-cell lung cancer. Journal of Thoracic Oncology , 7(16), S385鈥�6.
- Aflibercept in lung cancer
  Neal, J. W., & Wakelee, H. A. (2013). Aflibercept in lung cancer. EXPERT OPINION ON BIOLOGICAL THERAPY, 13(1), 115鈥�20.
- A case series of NSCLC patients with different molecular characteristics and choroidal metastases: improvement in vision with treatment including pemetrexed and bevacizumab.
  Riess, J. W., Nagpal, S., Das, M., Neal, J. W., Kim, J. W., & Wakelee, H. A. (2013). A case series of NSCLC patients with different molecular characteristics and choroidal metastases: improvement in vision with treatment including pemetrexed and bevacizumab. Journal of Thoracic Oncology , 8(2), e17鈥�8.
- A Patient With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer With Development of Leptomeningeal Carcinomatosis While on Targeted Treatment With Crizotinib
  Riess, J. W., Nagpal, S., Neal, J. W., & Wake, H. A. (2013). A Patient With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer With Development of Leptomeningeal Carcinomatosis While on Targeted Treatment With Crizotinib. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 11(4), 389鈥�94.
- REGULATION OF THE GLUCOSE-H+ SYMPORTER BY METABOLITE-ACTIVATED ATP-DEPENDENT PHOSPHORYLATION OF HPR IN LACTOBACILLUS-BREVIS
  Ye, J. J., Neal, J. W., Cui, X. W., Reizer, J., & Saier, M. H. (1994). REGULATION OF THE GLUCOSE-H+ SYMPORTER BY METABOLITE-ACTIVATED ATP-DEPENDENT PHOSPHORYLATION OF HPR IN LACTOBACILLUS-BREVIS. JOURNAL OF BACTERIOLOGY, 176(12), 3484鈥�3492.
- Prolonged Survival in Non-Small Cell Lung Cancer (NSCLC) Patients with Leptomeningeal Metastases (LM) in the Modern Treatment Era
  Riess, J. W., Nagpal, S., Iv, M., Zeineh, M., Gubens, M. A., Neal, J. W., & Wakelee, H. A. (2012). Prolonged Survival in Non-Small Cell Lung Cancer (NSCLC) Patients with Leptomeningeal Metastases (LM) in the Modern Treatment Era. JOURNAL OF THORACIC ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.
- Cell-free DNA as a Biomarker of Residual Disease Following Radiation Therapy for Non-small Cell Lung Cancer
  Bratman, S. V., Eclov, N. C., Modlin, L. A., Neal, J., Loo, B. W., Wu, G., 鈥� Diehn, M. (2012). Cell-free DNA as a Biomarker of Residual Disease Following Radiation Therapy for Non-small Cell Lung Cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 84(3), S713鈥揝713.
- First-line use of EGFR tyrosine kinase inhibitors in patients with NSCLC containing EGFR mutations.
  Neal, J. W., & Sequist, L. V. (2010). First-line use of EGFR tyrosine kinase inhibitors in patients with NSCLC containing EGFR mutations. Clinical Advances in Hematology & Oncology : H&O, 8(2), 119鈥�126.
- Cetuximab monotherapy in patients with advanced non-small cell lung cancer after prior epidermal growth factor receptor tyrosine kinase inhibitor therapy.
  Neal, J. W., Heist, R. S., Fidias, P., Temel, J. S., Huberman, M., Marcoux, J. P., 鈥� Sequist, L. V. (2010). Cetuximab monotherapy in patients with advanced non-small cell lung cancer after prior epidermal growth factor receptor tyrosine kinase inhibitor therapy. Journal of Thoracic Oncology , 5(11), 1855鈥�1858.
- A phase II multicenter study of aflibercept (AFL) in combination with cisplatin (C) and pemetrexed (P) in patients with previously untreated advanced/metastatic nonsquamous non-small cell lung cancer (NSCLC).
  Chen, H., Modiano, M. R., Neal, J. W., Brahmer, J. R., Rigas, J. R., Jotte, R. M., 鈥� Wakelee, H. A. (2012). A phase II multicenter study of aflibercept (AFL) in combination with cisplatin (C) and pemetrexed (P) in patients with previously untreated advanced/metastatic nonsquamous non-small cell lung cancer (NSCLC). JOURNAL OF CLINICAL ONCOLOGY, 30(15).
- The SELECT study: A multicenter phase II trial of adjuvant erlotinib in resected epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC)
  Neal, J. W., Pennell, N. A., Govindan, R., Lanuti, M., Rosovsky, R. P. G., Heist, R. S., 鈥� Sequist, L. V. (2012). The SELECT study: A multicenter phase II trial of adjuvant erlotinib in resected epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). JOURNAL OF CLINICAL ONCOLOGY, 30(15).
- The Select Study: A Multicenter Phase II Trial Of Adjuvant Erlotinib In Resected Epidermal Growth Factor Receptor (EGFR) Mutation-positive Non-small Cell Lung Cancer (NSCLC)
  Neal, J. W., Pennell, N. A., Govindan, R., Heist, R. S., Shaw, A. T., Muzikansky, A., 鈥� Sequist, L. V. (2012). The Select Study: A Multicenter Phase II Trial Of Adjuvant Erlotinib In Resected Epidermal Growth Factor Receptor (EGFR) Mutation-positive Non-small Cell Lung Cancer (NSCLC). JOURNAL OF THORACIC ONCOLOGY, 7(9), S209鈥揝209.
- A Case Series of Lengthy Progression-Free Survival With Pemetrexed-Containing Therapy in Metastatic Non-Small-Cell Lung Cancer Patients Harboring ROS1 Gene Rearrangements.
  Riess, J. W., Padda, S. K., Bangs, C. D., Das, M., Neal, J. W., Adrouny, A. R., 鈥� Wakelee, H. A. (2013). A Case Series of Lengthy Progression-Free Survival With Pemetrexed-Containing Therapy in Metastatic Non-Small-Cell Lung Cancer Patients Harboring ROS1 Gene Rearrangements. Clinical Lung Cancer, 14(5), 592鈥�95.
- Isolation and mutational analysis of circulating tumor cells from lung cancer patients with magnetic sifters and biochips.
  Earhart, C. M., Hughes, C. E., Gaster, R. S., Ooi, C. C., Wilson, R. J., Zhou, L. Y., 鈥� Wang, S. X. (2013). Isolation and mutational analysis of circulating tumor cells from lung cancer patients with magnetic sifters and biochips. Lab on a Chip, 14(1), 78鈥�88.
- Prolonged survival of patients with non-small-cell lung cancer with leptomeningeal carcinomatosis in the modern treatment era.
  Riess, J. W., Nagpal, S., Iv, M., Zeineh, M., Gubens, M. A., Ramchandran, K., 鈥� Wakelee, H. A. (2014). Prolonged survival of patients with non-small-cell lung cancer with leptomeningeal carcinomatosis in the modern treatment era. Clinical Lung Cancer, 15(3), 202鈥�6.
- Isolation and mutational analysis of circulating tumor cells from lung cancer patients with magnetic sifters and biochips
  Earhart, C. M., Hughes, C. E., Gaster, R. S., Ooi, C. C., Wilson, R. J., Zhou, L. Y., 鈥� Wang, S. X. (2014). Isolation and mutational analysis of circulating tumor cells from lung cancer patients with magnetic sifters and biochips. LAB ON A CHIP, 14(1), 78鈥�88.
- A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer.
  Chen, H., Modiano, M. R., Neal, J. W., Brahmer, J. R., Rigas, J. R., Jotte, R. M., 鈥� Wakelee, H. A. (2014). A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer. British Journal of Cancer, 110(3), 602鈥�8.
- Template for reporting results of biomarker testing of specimens from patients with non-small cell carcinoma of the lung.
  Cagle, P. T., Sholl, L. M., Lindeman, N. I., Alsabeh, R., Divaris, D. X. G., Foulis, P., 鈥� Yu, P. P. (2014). Template for reporting results of biomarker testing of specimens from patients with non-small cell carcinoma of the lung. Archives of Pathology & Laboratory Medicine, 138(2), 171鈥�74.
- An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage.
  Newman, A. M., Bratman, S. V., To, J., Wynne, J. F., Eclov, N. C. W., Modlin, L. A., 鈥� Diehn, M. (2014). An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nature Medicine, 20(5), 548鈥�54.
- Immune correlates of talactoferrin alfa in biopsied tumor of relapsed/refractory metastatic non-small cell lung cancer patients.
  Riess, J. W., Bhattacharya, N., Blenman, K. R. M., Neal, J. W., Hwang, G., Pultar, P., 鈥� Wakelee, H. A. (2014). Immune correlates of talactoferrin alfa in biopsied tumor of relapsed/refractory metastatic non-small cell lung cancer patients. Immunopharmacology and Immunotoxicology, 36(2), 182鈥�86.
- An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage
  Newman, A. M., Bratman, S. V., To, J., Wynne, J. F., Eclov, N. C. W., Modlin, L. A., 鈥� Diehn, M. (2014). An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. NATURE MEDICINE, 20(5), 552鈥�58.
- A Case Series of NSCLC Patients with Different Molecular Characteristics and Choroidal Metastases Improvement in Vision with Treatment Including Pemetrexed and Bevacizumab
  Riess, J. W., Nagpal, S., Das, M., Neal, J. W., Kim, J. W., & Wakelee, H. A. (2013). A Case Series of NSCLC Patients with Different Molecular Characteristics and Choroidal Metastases Improvement in Vision with Treatment Including Pemetrexed and Bevacizumab. JOURNAL OF THORACIC ONCOLOGY, 8(2), E17鈥揈18.
- Review of the current targeted therapies for non-small-cell lung cancer.
  Nguyen, K.-S. H., Neal, J. W., & Wakelee, H. (2014). Review of the current targeted therapies for non-small-cell lung cancer. World Journal of Clinical Oncology, 5(4), 576鈥�87.
- Unicentric, multifocal castleman disease of the mediastinum associated with cerebellitis.
  Hamaji, M., Neal, J. W., & Burt, B. M. (2015). Unicentric, multifocal castleman disease of the mediastinum associated with cerebellitis. Annals of Thoracic Surgery, 99(1), e7鈥�9.
- Decade in review-targeted therapy: successes, toxicities and challenges in solid tumours.
  Neal, J. W., & Sledge, G. W. (2014). Decade in review-targeted therapy: successes, toxicities and challenges in solid tumours. Nature Reviews. Clinical Oncology, 11(11), 627鈥�28.
- Pemetrexed in patients with thymic malignancies previously treated with chemotherapy.
  Liang, Y., Padda, S. K., Riess, J. W., West, R. B., Neal, J. W., & Wakelee, H. A. (2015). Pemetrexed in patients with thymic malignancies previously treated with chemotherapy. Lung Cancer , 87(1), 34鈥�38.
- GLI1, CTNNB1 and NOTCH1 protein expression in a thymic epithelial malignancy tissue microarray.
  Riess, J. W., West, R., Dean, M., Klimowicz, A. C., Neal, J. W., Hoang, C., & Wakelee, H. A. (2015). GLI1, CTNNB1 and NOTCH1 protein expression in a thymic epithelial malignancy tissue microarray. Anticancer Research, 35(2), 669鈥�76.
- Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer.
  Heist, R. S., Duda, D. G., Sahani, D. V., Ancukiewicz, M., Fidias, P., Sequist, L. V., 鈥� Jain, R. K. (2015). Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer. Proceedings of the National Academy of Sciences of the United States of America, 112(5), 1547鈥�52.
- Diffuse High Intensity PD-L1 Staining in Thymic Epithelial Tumors.
  Padda, S. K., Riess, J. W., Schwartz, E. J., Tian, L., Kohrt, H. E., Neal, J. W., 鈥� Wakelee, H. A. (2015). Diffuse High Intensity PD-L1 Staining in Thymic Epithelial Tumors. Journal of Thoracic Oncology , 10(3), 500鈥�508.
- Developing biomarker-specific end points in lung cancer clinical trials
  Neal, J. W., Gainor, J. F., & Shaw, A. T. (2015). Developing biomarker-specific end points in lung cancer clinical trials. NATURE REVIEWS CLINICAL ONCOLOGY, 12(3), 135鈥�46.
- Adjuvant molecularly targeted therapy-epidermal growth factor tyrosine kinase inhibition and beyond.
  Neal, J. W., & Sequist, L. V. (2013). Adjuvant molecularly targeted therapy-epidermal growth factor tyrosine kinase inhibition and beyond. Translational Lung Cancer Research, 2(5), 411鈥�14.
- MET inhibitors in combination with other therapies in non-small cell lung cancer.
  Padda, S., Neal, J. W., & Wakelee, H. A. (2012). MET inhibitors in combination with other therapies in non-small cell lung cancer. Translational Lung Cancer Research, 1(4), 238鈥�53.
- Rociletinib in EGFR-Mutated Non-Small-Cell Lung Cancer
  Sequist, L. V., Soria, J.-C., Goldman, J. W., Wakelee, H. A., Gadgeel, S. M., Varga, A., 鈥� Camidge, D. R. (2015). Rociletinib in EGFR-Mutated Non-Small-Cell Lung Cancer. NEW ENGLAND JOURNAL OF MEDICINE, 372(18), 1700鈥�1709.
- Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor.
  Piotrowska, Z., Niederst, M. J., Karlovich, C. A., Wakelee, H. A., Neal, J. W., Mino-Kenudson, M., 鈥� Sequist, L. V. (2015). Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor. Cancer Discovery, 5(7), 713鈥�22.
- Dovitinib and erlotinib in patients with metastatic non-small cell lung cancer: A drug-drug interaction
  Das, M., Padda, S. K., Frymoyer, A., Zhou, L., Riess, J. W., Neal, J. W., & Wakelee, H. A. (2015). Dovitinib and erlotinib in patients with metastatic non-small cell lung cancer: A drug-drug interaction. LUNG CANCER, 89(3), 280鈥�86.
- Relationship of Driver Oncogenes to Long-Term Pemetrexed Response in Non-Small-Cell Lung Cancer
  Liang, Y., Wakelee, H. A., & Neal, J. W. (2015). Relationship of Driver Oncogenes to Long-Term Pemetrexed Response in Non-Small-Cell Lung Cancer. CLINICAL LUNG CANCER, 16(5), 366鈥�73.
- Adjuvant therapy for EGFR mutant and ALK positive NSCLC: Current data and future prospects.
  Chuang, J. C., Neal, J. W., Niu, X.-M., & Wakelee, H. A. (2015). Adjuvant therapy for EGFR mutant and ALK positive NSCLC: Current data and future prospects. Lung Cancer , 90(1), 1鈥�7.
- Rapid Onset of Retinal Toxicity From High-Dose Hydroxychloroquine Given for Cancer Therapy.
  Leung, L.-S. B., Neal, J. W., Wakelee, H. A., Sequist, L. V., & Marmor, M. F. (2015). Rapid Onset of Retinal Toxicity From High-Dose Hydroxychloroquine Given for Cancer Therapy. American Journal of Ophthalmology, 160(4), 799鈥�805 e1.
- Management of Dermatologic Complications of Lung Cancer Therapies.
  Pugliese, S. B., Neal, J. W., & Kwong, B. Y. (2015). Management of Dermatologic Complications of Lung Cancer Therapies. Current Treatment Options in Oncology, 16(10), 50-?
- Pruritus as a Paraneoplastic Symptom of Thymoma
  Padda, S. K., Shrager, J. B., Riess, J. W., Pagtama, J. Y., Tisch, A. J. H., Kwong, B. Y., 鈥� Wakelee, H. A. (2015). Pruritus as a Paraneoplastic Symptom of Thymoma. JOURNAL OF THORACIC ONCOLOGY, 10(11), E110鈥揈112.
- Rapid Onset of Retinal Toxicity From High-Dose Hydroxychloroquine Given for Cancer Therapy.
  Leung, L.-S. B., Neal, J. W., Wakelee, H. A., Sequist, L. V., & Marmor, M. F. (2015). Rapid Onset of Retinal Toxicity From High-Dose Hydroxychloroquine Given for Cancer Therapy. American Journal of Ophthalmology, 160(4), 799鈥�805 e1.
- Management of Dermatologic Complications of Lung Cancer Therapies.
  Pugliese, S. B., Neal, J. W., & Kwong, B. Y. (2015). Management of Dermatologic Complications of Lung Cancer Therapies. Current Treatment Options in Oncology, 16(10), 368-?
- Long-Term Survival of a Patient With Non-Small-Cell Lung Cancer Harboring a V600E Mutation in the BRAF Oncogene.
  Myall, N. J., Neal, J. W., Cho-Phan, C. D., Zhou, L. Y., Stehr, H., Zhou, L., 鈥� Wakelee, H. A. (2016). Long-Term Survival of a Patient With Non-Small-Cell Lung Cancer Harboring a V600E Mutation in the BRAF Oncogene. Clinical Lung Cancer, 17(2), e17鈥�21.
- Outcomes After Combined Modality Therapy for EGFR-Mutant and Wild-Type Locally Advanced NSCLC
  Mak, R. H., Doran, E., Muzikansky, A., Kang, J., Neal, J. W., Baldini, E. H., 鈥� Sequist, L. V. (2011). Outcomes After Combined Modality Therapy for EGFR-Mutant and Wild-Type Locally Advanced NSCLC. ONCOLOGIST, 16(6), 886鈥�95.
- Crizotinib as first line therapy for advanced ALK-positive non-small cell lung cancers.
  Chuang, J. C., & Neal, J. W. (2015). Crizotinib as first line therapy for advanced ALK-positive non-small cell lung cancers. Translational Lung Cancer Research, 4(5), 639鈥�41.
- Integrated digital error suppression for improved detection of circulating tumor DNA
  Newman, A. M., Lovejoy, A. F., Klass, D. M., Kurtz, D. M., Chabon, J. J., Scherer, F., 鈥� Alizadeh, A. A. (2016). Integrated digital error suppression for improved detection of circulating tumor DNA. NATURE BIOTECHNOLOGY, 34(5), 547鈥�55.
- Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients
  Chabon, J. J., Simmons, A. D., Lovejoy, A. F., Esfahani, M. S., Newman, A. M., Haringsma, H. J., 鈥� Diehn, M. (2016). Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. NATURE COMMUNICATIONS, 7.
- Concordant and Discordant EGFR Mutations in Patients With Multifocal Adenocarcinomas: Implications for EGFR-Targeted Therapy.
  Chuang, J. C., Shrager, J. B., Wakelee, H. A., & Neal, J. W. (2016). Concordant and Discordant EGFR Mutations in Patients With Multifocal Adenocarcinomas: Implications for EGFR-Targeted Therapy. Clinical Therapeutics, 38(7), 1567鈥�76.
- Acute, Unilateral Breast Toxicity From Gemcitabine in the Setting of Thoracic Inlet Obstruction.
  Weiskopf, K., Creighton, D., Lew, T., Caswell, J. L., Ouyang, D., Shah, A. T., 鈥� Telli, M. L. (2016). Acute, Unilateral Breast Toxicity From Gemcitabine in the Setting of Thoracic Inlet Obstruction. Journal of Oncology Practice / American Society of Clinical Oncology, 12(8), 763鈥�64.
- GLI1, CTNNB1 and NOTCH1 Protein Expression in a Thymic Epithelial Malignancy Tissue Microarray.
  Riess, J. W., West, R., Dean, M., Klimowicz, A. C., Neal, J. W., Hoang, C., & Wakelee, H. A. (2015). GLI1, CTNNB1 and NOTCH1 Protein Expression in a Thymic Epithelial Malignancy Tissue Microarray. Anticancer Research, 35(2), 669鈥�76.
- Molecular profiling of single circulating tumor cells from lung cancer patients
  Park, S.-M., Wong, D. J., Ooi, C. C., Kurtz, D. M., Vermesh, O., Aalipour, A., 鈥� Gambhir, S. S. (2016). Molecular profiling of single circulating tumor cells from lung cancer patients. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 113(52), E8379鈥揈8386.
- PS01.22: Novel 3-Dimensional Preclinical Models: Topic: Medical Oncology.
  Salahudeen, A., De La O, S., Padda, S. K., Neal, J. W., Wakelee, H., & Kuo, C. (2016). PS01.22: Novel 3-Dimensional Preclinical Models: Topic: Medical Oncology. Journal of Thoracic Oncology , 11(11S), S282-?
- PS01.04: A Phase II Study of Etirinotecan Pegol (NKTR-102) in Patients with Refractory Brain Metastases and Advanced Lung Cancer: Topic: Medical Oncology.
  Neal, J. W., Wakelee, H., Padda, S. K., Bertrand, S., Acevedo, B., Holmes Tisch, A., 鈥� Nagpal, S. (2016). PS01.04: A Phase II Study of Etirinotecan Pegol (NKTR-102) in Patients with Refractory Brain Metastases and Advanced Lung Cancer: Topic: Medical Oncology. Journal of Thoracic Oncology , 11(11S), S271鈥揝272.
- ERBB2-Mutated Metastatic Non-Small Cell Lung Cancer: Response and Resistance to Targeted Therapies.
  Chuang, J. C., Stehr, H., Liang, Y., Das, M., Huang, J., Diehn, M., 鈥� Neal, J. W. (2017). ERBB2-Mutated Metastatic Non-Small Cell Lung Cancer: Response and Resistance to Targeted Therapies. Journal of Thoracic Oncology .
- Corrigendum: Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.
  Chabon, J. J., Simmons, A. D., Lovejoy, A. F., Esfahani, M. S., Newman, A. M., Haringsma, H. J., 鈥� Diehn, M. (2016). Corrigendum: Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. Nature Communications, 7, 13513-?
- Elusive Target of Angiogenesis in Small-Cell Lung Cancer.
  Neal, J. W., & Wakelee, H. A. (2017). Elusive Target of Angiogenesis in Small-Cell Lung Cancer. Journal of Clinical Oncology , JCO2016716084-?
- Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial
  Neal, J. W., Dahlberg, S. E., Wakelee, H. A., Aisner, S. C., Bowden, M., Huang, Y., 鈥� Ramalingam, S. S. (2016). Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial. LANCET ONCOLOGY, 17(12), 1661鈥�71.
- PS01.67: Case Series of MET Exon 14 Skipping Mutation-Positive Non-Small Cell Lung Cancers and Response to Crizotinib: Topic: Medical Oncology.
  Wang, S. X., Zhang, B. M., Wakelee, H., Diehn, M., Kunder, C. A., & Neal, J. W. (2016). PS01.67: Case Series of MET Exon 14 Skipping Mutation-Positive Non-Small Cell Lung Cancers and Response to Crizotinib: Topic: Medical Oncology. Journal of Thoracic Oncology , 11(11S), S312鈥揝313.
- MINI01.02: Response and Plasma Genotyping from听Phase I/II Trial of Ensartinib (X-396) in Patients (pts) with ALK+听NSCLC: Topic: Medical Oncology.
  Horn, L., Wakelee, H., Reckamp, K. L., Blumenschein, G., Infante, J. R., Carter, C. A., 鈥� Lovly, C. M. (2016). MINI01.02: Response and Plasma Genotyping from听Phase I/II Trial of Ensartinib (X-396) in Patients (pts) with ALK+听NSCLC: Topic: Medical Oncology. Journal of Thoracic Oncology , 11(11S), S256鈥揝257.
- Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry
  Gautschi, O., Milia, J., Filleron, T., Wolf, J., Carbone, D. P., Owen, D., 鈥� Drilon, A. (2017). Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry. JOURNAL OF CLINICAL ONCOLOGY, 35(13), 1403-?
- Case Series of MET Exon 14 Skipping Mutation-positive Non-Small Cell Lung Cancers and Response to Crizotinib.
  Wang, S. X., Zhang, B., Wakelee, H. A., Diehn, M., Kunder, C., & Neal, J. W. (2017). Case Series of MET Exon 14 Skipping Mutation-positive Non-Small Cell Lung Cancers and Response to Crizotinib. International Journal of Radiation Oncology, Biology, Physics, 98(1), 239-?
- Identification of a Novel Somatic Mutation Leading to Allele Dropout for EGFR L858R Genotyping in Non-Small Cell Lung Cancer.
  Costa, H. A., Neal, J. W., Bustamante, C. D., & Zehnder, J. L. (2017). Identification of a Novel Somatic Mutation Leading to Allele Dropout for EGFR L858R Genotyping in Non-Small Cell Lung Cancer. Molecular Diagnosis & Therapy.
- Chart Review Versus an Automated Bioinformatic Approach to Assess Real-World Crizotinib Effectiveness in Anaplastic Lymphoma Kinase鈥揚ositive Non鈥揝mall-Cell Lung Cancer
  Bui, N., Henry, S., Wood, D., Wakelee, H. A., & Neal, J. W. (2017). Chart Review Versus an Automated Bioinformatic Approach to Assess Real-World Crizotinib Effectiveness in Anaplastic Lymphoma Kinase鈥揚ositive Non鈥揝mall-Cell Lung Cancer. JCO: Clinical Cancer Informatics.
- Vorinostat and Concurrent Stereotactic Radiosurgery for Non-Small Cell Lung Cancer Brain Metastases: A Phase 1 Dose Escalation Trial.
  Choi, C. Y., Wakelee, H. A., Neal, J. W., Pinder-Schenck, M. C., Yu, H.-H. M., Chang, S. D., 鈥� Soltys, S. G. (2017). Vorinostat and Concurrent Stereotactic Radiosurgery for Non-Small Cell Lung Cancer Brain Metastases: A Phase 1 Dose Escalation Trial. International Journal of Radiation Oncology, Biology, Physics, 99(1), 16鈥�21.
- Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling.
  Chaudhuri, A. A., Chabon, J. J., Lovejoy, A. F., Newman, A. M., Stehr, H., Azad, T. D., 鈥� Diehn, M. (2017). Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling. Cancer Discovery.
- Comparison of Circulating Tumor DNA Analysis and Surveillance Imaging After Treatment for Localized Lung Cancer
  Chaudhuri, A. A., Chabon, J. J., Lovejoy, A. F., Newman, A., Stehr, H., Azad, T. D., 鈥� Diehn, M. (2017). Comparison of Circulating Tumor DNA Analysis and Surveillance Imaging After Treatment for Localized Lung Cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. ELSEVIER SCIENCE INC.
- Ultrasensitive Detection of Circulating Tumor DNA in Non-Small Cell Lung Cancer by Deep Sequencing
  Diehn, M., Bratman, S. V., Newman, A. M., Neal, J. W., Wakelee, H. A., Merritt, R. E., 鈥� Alizadeh, A. (2014). Ultrasensitive Detection of Circulating Tumor DNA in Non-Small Cell Lung Cancer by Deep Sequencing. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. ELSEVIER SCIENCE INC.
- Circulating Tumor DNA Analysis during Radiation Therapy for Localized Lung Cancer Predicts Treatment Outcome
  Chaudhuri, A. A., Lovejoy, A. F., Chabon, J. J., Newman, A., Stehr, H., Merriott, D. J., 鈥� Diehn, M. (2017). Circulating Tumor DNA Analysis during Radiation Therapy for Localized Lung Cancer Predicts Treatment Outcome. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. ELSEVIER SCIENCE INC.
- Circulating Tumor DNA Concentrations Reflect Metabolic Tumor Volume in NSCLC
  Modlin, L. A., Bratman, S. V., Newman, A. M., Eclov, N. C. W., Neal, J. W., Wakelee, H. A., 鈥� Diehn, M. (2014). Circulating Tumor DNA Concentrations Reflect Metabolic Tumor Volume in NSCLC. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. ELSEVIER SCIENCE INC.
- CAPP-Seq Circulating Tumor DNA Analysis for Early Detection of Tumor Progression After Definitive Radiation Therapy for Lung Cancer
  Chaudhuri, A. A., Lovejoy, A. F., Chabon, J. J., Newman, A., Stehr, H., Say, C., 鈥� Diehn, M. (2016). CAPP-Seq Circulating Tumor DNA Analysis for Early Detection of Tumor Progression After Definitive Radiation Therapy for Lung Cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. ELSEVIER SCIENCE INC.
- Circulating Tumor DNA Detects Minimal Residual Disease and Predicts Outcome in Localized Lung Cancer
  Chaudhuri, A., Lovejoy, A., Chabon, J., Newman, A., Stehr, H., Say, C., 鈥� Diehn, M. (2017). Circulating Tumor DNA Detects Minimal Residual Disease and Predicts Outcome in Localized Lung Cancer. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC.
- Circulating Tumor DNA Quantitation for Early Response Assessment of Immune Checkpoint Inhibitors for Lung Cancer
  Merriott, D. J., Chaudhuri, A. A., Jin, M., Chabon, J. J., Newman, A., Stehr, H., 鈥� Diehn, M. (2017). Circulating Tumor DNA Quantitation for Early Response Assessment of Immune Checkpoint Inhibitors for Lung Cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. ELSEVIER SCIENCE INC.
- Noninvasive and Ultrasensitive Quantitation of Circulating Tumor DNA by Hybrid Capture and Deep Sequencing
  Bratman, S. V., Newman, A. M., To, J., Wynne, J. F., Neal, J. W., Wakelee, H., 鈥� Diehn, M. (2013). Noninvasive and Ultrasensitive Quantitation of Circulating Tumor DNA by Hybrid Capture and Deep Sequencing. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. ELSEVIER SCIENCE INC.
- Mid-radiation Therapy PET/CT for Prognostication and Detection of Early Progression in Patients With Stage III Non-small Cell Lung Cancer
  Gensheimer, M. F., Hong, J. C., Chang-Halpenny, C. N., Eclov, N., To, J., Murphy, J. D., 鈥� Loo, B. W. (2017). Mid-radiation Therapy PET/CT for Prognostication and Detection of Early Progression in Patients With Stage III Non-small Cell Lung Cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 99(2), E456.
- Randomized Phase 2 Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Single-Agent Chemotherapy in Previously Treated KRAS Mutant Advanced Non-Small Cell Lung Cancer (NSCLC)
  Gerber, D. E., Socinski, M. A., Neal, J. W., Wakelee, H. A., Shirai, K., Sequist, L. V., 鈥� Brahmer, J. R. (2014). Randomized Phase 2 Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Single-Agent Chemotherapy in Previously Treated KRAS Mutant Advanced Non-Small Cell Lung Cancer (NSCLC). INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 90, S36.
- Prognostic Value of Pretreatment FDG-PET Parameters in High-dose Image-guided Radiotherapy for Oligometastatic Non-Small-cell Lung Cancer.
  Chin, A. L., Kumar, K. A., Guo, H. H., Maxim, P. G., Wakelee, H., Neal, J. W., 鈥� Gensheimer, M. F. (2018). Prognostic Value of Pretreatment FDG-PET Parameters in High-dose Image-guided Radiotherapy for Oligometastatic Non-Small-cell Lung Cancer. Clinical Lung Cancer.
- ERLOTINIB (E) AND DOVITINIB (TKI258) (D) IN PATIENTS (PTS) WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC): A SIGNIFICANT PHARMACOKINETIC (PK) INTERACTION
  Das, M., Padda, S. K., Zhou, L., Frymoyer, A., Neal, J. W., & Wakelee, H. A. (2013). ERLOTINIB (E) AND DOVITINIB (TKI258) (D) IN PATIENTS (PTS) WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC): A SIGNIFICANT PHARMACOKINETIC (PK) INTERACTION. JOURNAL OF THORACIC ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.
- Programmed death receptor ligand-1 (PD-L1) expression in a thymoma (T) tissue microarray (TMA)
  Padda, S. K., Riess, J., Schwartz, E. J., Tian, L., Kohrt, H. E., Neal, J. W., 鈥� Wakelee, H. A. (2014). Programmed death receptor ligand-1 (PD-L1) expression in a thymoma (T) tissue microarray (TMA). JOURNAL OF CLINICAL ONCOLOGY, 32(15).
- Commentary: Treatment Considerations for Patients With Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Brain Metastases in the Era of Tyrosine Kinase Inhibitors.
  Vaca, S. D., Connolly, I. D., Ho, C., Neal, J., & Hayden Gephart, M. (2017). Commentary: Treatment Considerations for Patients With Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Brain Metastases in the Era of Tyrosine Kinase Inhibitors. Neurosurgery.
- Tumor Evolution, Heterogeneity, and Therapy for Our Patients With Advanced Cancer: How Far Have We Come?
  El-Deiry, W. S., Taylor, B., & Neal, J. W. (2017). Tumor Evolution, Heterogeneity, and Therapy for Our Patients With Advanced Cancer: How Far Have We Come? American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Meeting, 37, e8鈥揺15.
- Rociletinib-associated cataracts in EGFR-mutant NSCLC
  Piotrowska, Z., Liu, E., Varga, A., Thakur, M., Narayanan, V., Liu, S. V., 鈥� Sequist, L. V. (2016). Rociletinib-associated cataracts in EGFR-mutant NSCLC. ANNALS OF ONCOLOGY, 27.
- ENERGY METABOLISM IN LUNG ADENOCARCINOMA
  Hoang, C., Xu, Y., Shi, Z., Lin, Y., Merritt, R. E., Shrager, J., 鈥� Wakelee, H. A. (2013). ENERGY METABOLISM IN LUNG ADENOCARCINOMA. JOURNAL OF THORACIC ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.
- Mid-radiotherapy PET/CT for prognostication and detection of early progression in patients with stage III non-small cell lung cancer
  Gensheimer, M. F., Hong, J. C., Chang-Halpenny, C., Zhu, H., Eclov, N. C. W., To, J., 鈥� Loo, B. W. (2017). Mid-radiotherapy PET/CT for prognostication and detection of early progression in patients with stage III non-small cell lung cancer. RADIOTHERAPY AND ONCOLOGY, 125(2), 338鈥�43.
- The Persistent Promise of Combining HGF/MET and EGFR Inhibition in Non-Small Cell Lung Cancer
  Chuang, J. C., & Neal, J. W. (2017). The Persistent Promise of Combining HGF/MET and EGFR Inhibition in Non-Small Cell Lung Cancer. CANCER, 123(15), 2798鈥�2801.
- A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors
  Jahchan, N. S., Dudley, J. T., Mazur, P. K., Flores, N., Yang, D., Palmerton, A., 鈥� Sage, J. (2014). A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH.
- PEMETREXED IN PATIENTS WITH THYMIC MALIGNANCIES PREVIOUSLY TREATED WITH CHEMOTHERAPY
  Liang, Y., Padda, S. K., Riess, J. W., West, R., Neal, J. W., & Wakelee, H. A. (2014). PEMETREXED IN PATIENTS WITH THYMIC MALIGNANCIES PREVIOUSLY TREATED WITH CHEMOTHERAPY. JOURNAL OF THORACIC ONCOLOGY, 9(10), S226.
- STAGE 1 RESULTS OF A 2-STAGE PHASE II TRIAL OF SINGLE AGENT AMRUBICIN IN PATIENTS WITH PREVIOUSLY TREATED THYMIC MALIGNANCIES
  Wakelee, H., Riess, J., Pedro-Salcedo, M. S., Padda, S., Ramchandran, K., Gubens, M., & Neal, J. (2013). STAGE 1 RESULTS OF A 2-STAGE PHASE II TRIAL OF SINGLE AGENT AMRUBICIN IN PATIENTS WITH PREVIOUSLY TREATED THYMIC MALIGNANCIES. JOURNAL OF THORACIC ONCOLOGY, 8, 22鈥�23.
- CNS activity of ensartinib in ALK1 non-small cell lung cancer (NSCLC) patients (pts)
  Reckamp, K. L., Wakelee, H. A., Patel, S., Blumenschein, G., Neal, J. W., Gitlitz, B., 鈥� Horn, L. (2017). CNS activity of ensartinib in ALK1 non-small cell lung cancer (NSCLC) patients (pts). ANNALS OF ONCOLOGY, 28.
- PROGRAMMED DEATH RECEPTOR LIGAND-1 (PD-L1) EXPRESSION IN A THYMOMA TISSUE MICROARRAY (TMA)
  Padda, S. K., Riess, J. W., Schwartz, E. J., Tian, L., Kohrt, H. E., Neal, J. W., 鈥� Wakelee, H. A. (2014). PROGRAMMED DEATH RECEPTOR LIGAND-1 (PD-L1) EXPRESSION IN A THYMOMA TISSUE MICROARRAY (TMA). JOURNAL OF THORACIC ONCOLOGY, 9(10), S212.
- Vorinostat and Concurrent Stereotactic Radiosurgery for Non-Small Cell Lung Cancer Brain Metastases: A Phase 1 Dose-Escalation Trial
  Modlin, L. A., Choi, C. Y. H., Gibbs, I. C., Wakelee, H. A., Neal, J., Pinder-Schenck, M. C., 鈥� Soltys, S. G. (2015). Vorinostat and Concurrent Stereotactic Radiosurgery for Non-Small Cell Lung Cancer Brain Metastases: A Phase 1 Dose-Escalation Trial. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. ELSEVIER SCIENCE INC.
- Molecular and Clinicopathologic Features Associated with PD-L1 Expression in Lung Adenocarcinoma
  Yang, S., Steiner, D., Berry, G. J., Neal, J. W., Zehnder, J. L., & Kunder, C. A. (2017). Molecular and Clinicopathologic Features Associated with PD-L1 Expression in Lung Adenocarcinoma. JOURNAL OF MOLECULAR DIAGNOSTICS. ELSEVIER SCIENCE INC.
- CORRELATIVE ANALYSIS OF CIRCULATING BIOMARKERS FROM A PHASE 1B/2 TRIAL OF CABOZANTINIB (C) WITH OR WITHOUT ERLOTINIB (E) IN PATIENTS (PTS) WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC)
  Padda, S. K., Rosenberg-Hasson, Y., Neal, J. W., Gettinger, S. N., Engelman, J. A., Jaenne, P. A., 鈥� Zhou, L. (2013). CORRELATIVE ANALYSIS OF CIRCULATING BIOMARKERS FROM A PHASE 1B/2 TRIAL OF CABOZANTINIB (C) WITH OR WITHOUT ERLOTINIB (E) IN PATIENTS (PTS) WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC). JOURNAL OF THORACIC ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.
- Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer
  Gerber, D. E., Socinski, M. A., Neal, J. W., Wakelee, H. A., Shirai, K., Sequist, L. V., 鈥� Kelly, R. J. (2018). Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer. LUNG CANCER, 117, 44鈥�49.
- A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer.
  Jahchan, N., Joel, D., Mazur, P., Neal, J., Khatri, P., Butte, A., & Sage, J. (2014). A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer. CLINICAL CANCER RESEARCH, 20.
- Response and Plasma Genotyping from Phase I/II Trial of Ensartinib (X-396) in Patients (Pts) with ALK plus NSCLC
  Horn, L., Wakelee, H., Reckamp, K., Blumenschein, G., Infante, J., Carter, C., 鈥� Lovly, C. (2017). Response and Plasma Genotyping from Phase I/II Trial of Ensartinib (X-396) in Patients (Pts) with ALK plus NSCLC. JOURNAL OF THORACIC ONCOLOGY, 12(1), S1159.
- PRURITUS AS A PARANEOPLASTIC SYMPTOM OF THYMOMA
  Padda, S. K., Pagtama, J. Y., Tisch, A. H., Neal, J. W., Riess, J. W., Loo, B. W., 鈥� Wakelee, H. A. (2014). PRURITUS AS A PARANEOPLASTIC SYMPTOM OF THYMOMA. JOURNAL OF THORACIC ONCOLOGY, 9(10), S240鈥揝241.
- A Phase II Study of Etirinotecan Pegol (NKTR-102) in Patients with Refractory Brain Metastases and Advanced Lung Cancer
  Nagpal, S., Wakelee, H., Padda, S., Bertrand, S., Acevedo, B., Tisch, A. H., 鈥� Neal, J. (2017). A Phase II Study of Etirinotecan Pegol (NKTR-102) in Patients with Refractory Brain Metastases and Advanced Lung Cancer. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC.
- Computed Tomography (CT) Characteristics Associated with the Proposed IASLC/ITMIG TNM Pathologic Staging System for Thymoma
  Padda, S. K., Terrone, D., Khuong, A., Tian, L., Neal, J. W., Riess, J. W., 鈥� Wakelee, H. A. (2015). Computed Tomography (CT) Characteristics Associated with the Proposed IASLC/ITMIG TNM Pathologic Staging System for Thymoma. JOURNAL OF THORACIC ONCOLOGY, 10(9), S196.
- GLI1, NOTCH1 AND CTNNB1 EXPRESSION BY AUTOMATED QUANTITATIVE IMMUNOFLUORESCENCE (AQUA) IN A THYMIC MALIGNANCY TISSUE MICROARRAY (TMA)
  Riess, J. W., West, R., Padda, S. K., Dean, M., Klimowicz, A., Huong, C., 鈥� Wakelee, H. A. (2013). GLI1, NOTCH1 AND CTNNB1 EXPRESSION BY AUTOMATED QUANTITATIVE IMMUNOFLUORESCENCE (AQUA) IN A THYMIC MALIGNANCY TISSUE MICROARRAY (TMA). JOURNAL OF THORACIC ONCOLOGY, 8, S944.
- Case Series of HER2 Mutated Metastatic Lung Adenocarcinoma and Response to HER2 Targeted Therapies
  Chuang, J., Neal, J. W., & Wakelee, H. A. (2015). Case Series of HER2 Mutated Metastatic Lung Adenocarcinoma and Response to HER2 Targeted Therapies. JOURNAL OF THORACIC ONCOLOGY, 10(9), S549.
- VeriStrat (R) and Epidermal Growth Factor Receptor Mutation Status in a Phase 1b/2 Study of Cabozantinib plus /- Erlotinib in Non-Small Cell Lung Cancer
  Padda, S. K., Lara, P., Gettinger, S. N., Engelman, J. A., Jaenne, P. A., West, H., 鈥� Wakelee, H. A. (2015). VeriStrat (R) and Epidermal Growth Factor Receptor Mutation Status in a Phase 1b/2 Study of Cabozantinib plus /- Erlotinib in Non-Small Cell Lung Cancer. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC.
- First-in-human evaluation of CO-1686, an irreversible, selective, and potent tyrosine kinase inhibitor of EGFR T790M.
  Sequist, L. V., Soria, J.-C., Gadgeel, S. M., Wakelee, H. A., Camidge, D. R., Varga, A., 鈥� Goldman, J. W. (2013). First-in-human evaluation of CO-1686, an irreversible, selective, and potent tyrosine kinase inhibitor of EGFR T790M. JOURNAL OF CLINICAL ONCOLOGY, 31(15).
- A Phase lb Study of Erlotinib and Momelotinib for EGFR TKI Naive EGFR Mutated Metastatic Non-Small Cell Lung Cancer
  Padda, S., Reckamp, K., Koczywas, M., Neal, J., Brachmann, C., Kawashima, J., 鈥� Wakelee, H. (2017). A Phase lb Study of Erlotinib and Momelotinib for EGFR TKI Naive EGFR Mutated Metastatic Non-Small Cell Lung Cancer. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC.
- STAGE 1 RESULTS OF A 2-STAGE PHASE II TRIAL OF SINGLE AGENT AMRUBICIN IN PATIENTS WITH PREVIOUSLY TREATED THYMIC MALIGNANCIES
  Wakelee, H. A., Riess, J. W., San Pedro-Salcedo, M., Padda, S. K., Ramchandran, K., Gubens, M. A., & Neal, J. W. (2013). STAGE 1 RESULTS OF A 2-STAGE PHASE II TRIAL OF SINGLE AGENT AMRUBICIN IN PATIENTS WITH PREVIOUSLY TREATED THYMIC MALIGNANCIES. JOURNAL OF THORACIC ONCOLOGY, 8, S731.
- GLI1, NOTCH1 AND CTNNB1 EXPRESSION BY AUTOMATED QUANTITATIVE IMMUNOFLUORESCENCE (AQUA) IN A THYMIC MALIGNANCY TISSUE MICROARRAY (TMA)
  Riess, J., West, R., Padda, S., Dean, M., Klimowicz, A., Huong, C., 鈥� Wakelee, H. (2013). GLI1, NOTCH1 AND CTNNB1 EXPRESSION BY AUTOMATED QUANTITATIVE IMMUNOFLUORESCENCE (AQUA) IN A THYMIC MALIGNANCY TISSUE MICROARRAY (TMA). JOURNAL OF THORACIC ONCOLOGY, 8, 25.
- Phase II trial of carboplatin, abraxane, and bevacizumab in NSCLC
  Heist, R. S., Duda, G. D., Sahani, D., Ancukiewicz, M., Fidias, P., Sequist, L. V., 鈥� Jain, R. K. (2011). Phase II trial of carboplatin, abraxane, and bevacizumab in NSCLC. JOURNAL OF CLINICAL ONCOLOGY, 29(15).
- Phase II Trial of Single Agent Amrubicin in Patients with Previously Treated Advanced Thymic Malignancies
  Wakelee, H. A., Padda, S. K., Burns, M., Spittler, A. J., Riess, J. W., San Pedro-Salcedo, M., 鈥� Loehrer, P. J. (2015). Phase II Trial of Single Agent Amrubicin in Patients with Previously Treated Advanced Thymic Malignancies. JOURNAL OF THORACIC ONCOLOGY, 10(9), S195.
- A multicenter randomized phase II trial of erlotinib with and without hydroxychloroquine (HCQ) in TKI-naive patients (pts) with epidermal growth factor receptor (EGFR) mutant advanced non-small cell lung cancer (NSCLC)
  Neal, J. W., Wakelee, H. A., Feliciano, J. L., Goldberg, S. B., Morgensztern, D., Das, M. S., 鈥� Sequist, L. V. (2014). A multicenter randomized phase II trial of erlotinib with and without hydroxychloroquine (HCQ) in TKI-naive patients (pts) with epidermal growth factor receptor (EGFR) mutant advanced non-small cell lung cancer (NSCLC). JOURNAL OF CLINICAL ONCOLOGY, 32(15).
- COMPUTED TOMOGRAPHY (CT) CHARACTERISTICS ASSOCIATED WITH MASAOKA-KOGA PATHOLOGIC STAGE IN THYMOMA
  Padda, S. K., Terrone, D., Khuong, A., Tian, L., Neal, J. W., Riess, J. W., 鈥� Wakelee, H. A. (2014). COMPUTED TOMOGRAPHY (CT) CHARACTERISTICS ASSOCIATED WITH MASAOKA-KOGA PATHOLOGIC STAGE IN THYMOMA. JOURNAL OF THORACIC ONCOLOGY, 9(10), S222.
- FIRST-IN-HUMAN EVALUATION OF CO-1686, AN IRREVERSIBLE, HIGHLY, SELECTIVE TYROSINE KINASE INHIBITOR OF MUTATIONS OF EGFR (ACTIVATING AND T790M)
  Soria, J.-C., Sequist, L. V., Gadgeel, S., Goldman, J., Wakelee, H., Varga, A., 鈥� Allen, A. (2013). FIRST-IN-HUMAN EVALUATION OF CO-1686, AN IRREVERSIBLE, HIGHLY, SELECTIVE TYROSINE KINASE INHIBITOR OF MUTATIONS OF EGFR (ACTIVATING AND T790M). JOURNAL OF THORACIC ONCOLOGY, 8, S141鈥揝142.
- Phase 1/2 Trial of the Oral EGFR/HER2 Inhibitor AP32788 in Non-Small Cell Lung Cancer (NSCLC)
  Doebele, R., Horn, L., Spira, A., Piotrowska, Z., Costa, D., Neal, J., 鈥� Janne, P. (2017). Phase 1/2 Trial of the Oral EGFR/HER2 Inhibitor AP32788 in Non-Small Cell Lung Cancer (NSCLC). JOURNAL OF THORACIC ONCOLOGY, 12(1), S1072鈥揝1073.
- Outcomes of Moderately Hypofractionated Intensity-Modulated Thoracic Radiotherapy with Concurrent Chemotherapy for Treatment of Non-Small Cell Lung Cancer
  Xiang, M., Gensheimer, M. F., Maxim, P. G., Wakelee, H. A., Neal, J. W., Diehn, M., & Loo, B. W. (2017). Outcomes of Moderately Hypofractionated Intensity-Modulated Thoracic Radiotherapy with Concurrent Chemotherapy for Treatment of Non-Small Cell Lung Cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 99(2), E504.
- VIETNAMESE NON-SMALL CELL LUNG CANCER PATIENTS IN CALIFORNIA: MOLECULAR PROFILES AND CLINICAL CHARACTERISTICS
  Nguyen, K.-S. H., Das, M., Ramchandran, K., Shrager, J., Merritt, R. E., Hoang, C., 鈥� Neal, J. W. (2013). VIETNAMESE NON-SMALL CELL LUNG CANCER PATIENTS IN CALIFORNIA: MOLECULAR PROFILES AND CLINICAL CHARACTERISTICS. JOURNAL OF THORACIC ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.
- Novel systemic therapy against malignant pleural mesothelioma
  Mancuso, M. R., & Neal, J. W. (2017). Novel systemic therapy against malignant pleural mesothelioma. TRANSLATIONAL LUNG CANCER RESEARCH, 6(3), 295鈥�314.
- Noninvasive and ultrasensitive quantitation of circulating tumor DNA by hybrid capture and deep sequencing.
  Bratman, S. V., Newman, A. M., To, J., Wynne, J. F., Neal, J. W., Wakelee, H. A., 鈥� Alizadeh, A. A. (2014). Noninvasive and ultrasensitive quantitation of circulating tumor DNA by hybrid capture and deep sequencing. JOURNAL OF CLINICAL ONCOLOGY, 32(15).
- A Highly Sensitive Next-Generation Sequencing Platform for Detection of NSCLC EGFR T790M Mutation in Urine and Plasma
  Wakelee, H., Melnikova, V., Karlovich, C., Gadgeel, S., Reckamp, K., Goldman, J. W., 鈥� Sequist, L. (2017). A Highly Sensitive Next-Generation Sequencing Platform for Detection of NSCLC EGFR T790M Mutation in Urine and Plasma. JOURNAL OF THORACIC ONCOLOGY, 12(1), S384鈥揝385.
- Improved survival among lung cancer patients taking antidepressants
  Zingone, A., Brown, D., Bowman, E., Vidal, O., Neal, J., Sage, J., & Ryan, B. M. (2015). Improved survival among lung cancer patients taking antidepressants. CANCER RESEARCH, 75.
- Circulating Tumor DNA Detects Residual Disease and Anticipates Tumor Progression Earlier Than CT Imaging
  Chaudhuri, A. A., Chabon, J. J., Lovejoy, A. F., Newman, A. M., Stehr, H., Azad, T. D., 鈥� Diehn, M. (2017). Circulating Tumor DNA Detects Residual Disease and Anticipates Tumor Progression Earlier Than CT Imaging. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. ELSEVIER SCIENCE INC.
- PALLIATIVE CARE AND ANTI-CANCER CARE INTEGRATION: DESCRIPTION OF THREE MODELS OF CARE DELIVERY AT A TERTIARY MEDICAL CENTER
  Ramchandran, K. J., Fronk, J., Trieu, S., Wakelee, H. A., Das, M., Neal, J. W., 鈥� Blayney, D. (2013). PALLIATIVE CARE AND ANTI-CANCER CARE INTEGRATION: DESCRIPTION OF THREE MODELS OF CARE DELIVERY AT A TERTIARY MEDICAL CENTER. JOURNAL OF THORACIC ONCOLOGY, 8, S1324.
- Computed Tomography Features associated With the Eighth Edition TNM Stage Classification for Thymic Epithelial Tumors
  Padda, S. K., Terrone, D., Tian, L., Khuong, A., Neal, J. W., Riess, J. W., 鈥� Wakelee, H. A. (2018). Computed Tomography Features associated With the Eighth Edition TNM Stage Classification for Thymic Epithelial Tumors. JOURNAL OF THORACIC IMAGING, 33(3), 176鈥�83.
- SELECT: A multicenter phase II trial of adjuvant erlotinib in resected early-stage EGFR mutation-positive NSCLC.
  Pennell, N. A., Neal, J. W., Chaft, J. E., Azzoli, C. G., Janne, P. A., Govindan, R., 鈥� Sequist, L. V. (2014). SELECT: A multicenter phase II trial of adjuvant erlotinib in resected early-stage EGFR mutation-positive NSCLC. JOURNAL OF CLINICAL ONCOLOGY, 32(15).
- Cabozantinib (C), erlotinib (E) or the combination (E plus C) as second-or third-line therapy in patients with EGFR wild-type (wt) non-small cell lung cancer (NSCLC): A randomized phase 2 trial of the ECOG-ACRIN Cancer Research Group (E1512).
  Neal, J. W., Dahlberg, S. E., Wakelee, H. A., Aisner, S. C., Bowden, M., Carbone, D. P., & Ramalingam, S. S. (2015). Cabozantinib (C), erlotinib (E) or the combination (E plus C) as second-or third-line therapy in patients with EGFR wild-type (wt) non-small cell lung cancer (NSCLC): A randomized phase 2 trial of the ECOG-ACRIN Cancer Research Group (E1512). JOURNAL OF CLINICAL ONCOLOGY, 33(15).
- A Randomized Phase 2 Trial of Cabozantinib, Erlotinib or the Combination as 2nd or 3rd Line Therapy in EGFR Wild-Type NSCLC: ECOG-ACRIN E1512
  Neal, J. W., Dahlberg, S. E., Wakelee, H. A., Aisner, S. C., Bowden, M., Carbone, D. P., & Ramalingam, S. S. (2015). A Randomized Phase 2 Trial of Cabozantinib, Erlotinib or the Combination as 2nd or 3rd Line Therapy in EGFR Wild-Type NSCLC: ECOG-ACRIN E1512. JOURNAL OF THORACIC ONCOLOGY, 10(9), S373.
- Phase II trial of single agent amrubicin (A) in patients (pts) with previously treated advanced thymic malignancies (TM).
  Wakelee, H. A., Padda, S. K., Burns, M., Spittler, A. J., Riess, J., San Pedro-Salcedo, M., 鈥� Loehrer, P. J. (2015). Phase II trial of single agent amrubicin (A) in patients (pts) with previously treated advanced thymic malignancies (TM). JOURNAL OF CLINICAL ONCOLOGY, 33(15).
- Survival and risk factors for progression after resection of the dominant tumor in multifocal, lepidic-type pulmonary adenocarcinoma
  Gao, R. W., Berry, M. F., Kunder, C. A., Khuong, A. A., Wakelee, H., Neal, J. W., 鈥� Shrager, J. B. (2017). Survival and risk factors for progression after resection of the dominant tumor in multifocal, lepidic-type pulmonary adenocarcinoma. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 154(6), 2092-+.
- Phase I/II trial of X-396 in patients (pts) with ALK plus non-small cell lung cancer (NSCLC): Correlation with plasma and tissue genotyping and response to therapy (tx)
  Horn, L., Wakelee, H., Blumenschein, G., Reckamp, K., Waqar, S., Carter, C. A., 鈥� Lovly, C. (2016). Phase I/II trial of X-396 in patients (pts) with ALK plus non-small cell lung cancer (NSCLC): Correlation with plasma and tissue genotyping and response to therapy (tx). ANNALS OF ONCOLOGY, 27.
- Circulating Tumor DNA Quantitation for Early Response Assessment of Immune Checkpoint Inhibitors for Metastatic Non-Small Cell Lung Cancer
  Chaudhuri, A. A., Nabet, B. Y., Merriott, D. J., Jin, M., Chen, E. L., Chabon, J. J., 鈥� Diehn, M. (2018). Circulating Tumor DNA Quantitation for Early Response Assessment of Immune Checkpoint Inhibitors for Metastatic Non-Small Cell Lung Cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. ELSEVIER SCIENCE INC.
- Antimicrobial resistance due to antibiotic use for EGFR inhibitor related papulopustular skin reaction
  Hirotsu, K., Subramanian, A., Neal, J., Li, S., Pugliese, S., & Kwong, B. (2018). Antimicrobial resistance due to antibiotic use for EGFR inhibitor related papulopustular skin reaction. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 138(5), S176.
- Infiltrating the Blood-Brain Barrier in ALK-Positive Lung Cancer.
  Zweig, J. R., & Neal, J. W. (2018). Infiltrating the Blood-Brain Barrier in ALK-Positive Lung Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO2018788554.
- Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study
  Horn, L., Infante, J. R., Reckamp, K. L., Blumenschein, G. R., Leal, T. A., Waqar, S. N., 鈥� Wakelee, H. A. (2018). Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study. CLINICAL CANCER RESEARCH, 24(12), 2771鈥�79.
- Synchronous primary lung adenocarcinomas harboring distinct MET Exon 14 splice site mutations.
  Wang, S. X., Lei, L., Guo, H. H., Shrager, J., Kunder, C. A., & Neal, J. W. (2018). Synchronous primary lung adenocarcinomas harboring distinct MET Exon 14 splice site mutations. Lung Cancer (Amsterdam, Netherlands), 122, 187鈥�91.
- The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)
  Brahmer, J. R., Govindan, R., Anders, R. A., Antonia, S. J., Sagorsky, S., Davies, M. J., 鈥� Herbst, R. S. (2018). The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC). JOURNAL FOR IMMUNOTHERAPY OF CANCER, 6, 75.
- Osimertinib for EGFR-Mutant Lung Cancer with Brain Metastases: Results from a Single-Center Retrospective Study.
  Xie, L., Nagpal, S., Wakelee, H. A., Li, G., Soltys, S. G., & Neal, J. W. (2018). Osimertinib for EGFR-Mutant Lung Cancer with Brain Metastases: Results from a Single-Center Retrospective Study. The Oncologist.
- Lengthy progression-free survival and intracranial activity of cabozantinib in patients with crizotinib and ceritinib-resistant ROS1-positive non-small-cell lung cancer.
  Sun, T. Y., Niu, X., Chakraborty, A., Neal, J. W., & Wakelee, H. A. (2018). Lengthy progression-free survival and intracranial activity of cabozantinib in patients with crizotinib and ceritinib-resistant ROS1-positive non-small-cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer.
- Ensartinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients: Updated Data
  Leal, T., Wakelee, H., Reckamp, K., Waqar, S., Patel, S., Blumenschein, G., 鈥� Horn, L. (2018). Ensartinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients: Updated Data. JOURNAL OF THORACIC ONCOLOGY, 13(9), S156.
- Comparison of Genomic Driver Oncogenes in Vietnamese Patients With Non-Small-Cell Lung Cancer in the United States and Vietnam.
  Nguyen, K.-S. H., Stehr, H., Zhou, L., Nguyen, A.-H., Hiep, P. N., Van Cau, N., 鈥� Neal, J. W. (2018). Comparison of Genomic Driver Oncogenes in Vietnamese Patients With Non-Small-Cell Lung Cancer in the United States and Vietnam. Journal of Global Oncology, (4), 1鈥�9.
- SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.
  Pennell, N. A., Neal, J. W., Chaft, J. E., Azzoli, C. G., Janne, P. A., Govindan, R., 鈥� Sequist, L. V. (2018). SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO1800131.
- Natural Disease History, Outcomes, and Co-mutations in a Series of Patients With BRAF-Mutated Non-small-cell Lung Cancer.
  Myall, N. J., Henry, S., Wood, D., Neal, J. W., Han, S. S., Padda, S. K., & Wakelee, H. A. (2018). Natural Disease History, Outcomes, and Co-mutations in a Series of Patients With BRAF-Mutated Non-small-cell Lung Cancer. Clinical Lung Cancer.
- EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes.
  Marcoux, N., Gettinger, S. N., O'Kane, G., Arbour, K. C., Neal, J. W., Husain, H., 鈥� Sequist, L. V. (2018). EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO1801585.
- Co-Mutations, Natural History, and Outcomes of BRAF-Mutated Non-Small Cell Lung Cancer at a Single Academic Cancer Center
  Myall, N., Henry, S., Wood, D., Neal, J., & Wakelee, H. (2018). Co-Mutations, Natural History, and Outcomes of BRAF-Mutated Non-Small Cell Lung Cancer at a Single Academic Cancer Center. JOURNAL OF THORACIC ONCOLOGY, 13(10), S489鈥揝490.
- Safety, PK, and Preliminary Antitumor Activity of the Oral EGFR/HER2 Exon 20 Inhibitor TAK-788 in NSCLC
  Neal, J., Doebele, R., Riely, G., Spira, A., Horn, L., Piotrowska, Z., 鈥� Janne, P. (2018). Safety, PK, and Preliminary Antitumor Activity of the Oral EGFR/HER2 Exon 20 Inhibitor TAK-788 in NSCLC. JOURNAL OF THORACIC ONCOLOGY, 13(10), S599.
- Case series of MET exon 14 skipping mutation-positive non-small-cell lung cancers with response to crizotinib and cabozantinib.
  Wang, S. X., Zhang, B. M., Wakelee, H. A., Koontz, M. Z., Pan, M. G., Diehn, M., 鈥� Neal, J. W. (2019). Case series of MET exon 14 skipping mutation-positive non-small-cell lung cancers with response to crizotinib and cabozantinib. Anti-Cancer Drugs.
- Increased Galectin-1 Expression in Thymic Epithelial Tumors.
  Riess, J. W., Kong, C. S., West, R. B., Padda, S. K., Neal, J. W., Wakelee, H. A., & Le, Q.-T. (2018). Increased Galectin-1 Expression in Thymic Epithelial Tumors. Clinical Lung Cancer.
- Safety and anti-tumor effects of MAGE-A10c796 TCR T-cells in two clinical trials
  Lam, V. K., Hong, D. S., Heymach, J. V., Blumenschein, G., Butler, M. O., Johnson, M., 鈥� Amado, R. G. (2018). Safety and anti-tumor effects of MAGE-A10c796 TCR T-cells in two clinical trials. ANNALS OF ONCOLOGY, 29.
- Utility of 18F FDG PET/CT in patients with advanced thymic neoplasms
  Davidzon, G., Wakelee, H., Neal, J., Mittra, E., Quon, A., & Iagaru, A. (2012). Utility of 18F FDG PET/CT in patients with advanced thymic neoplasms. JOURNAL OF NUCLEAR MEDICINE, 53.
- Tumor Evolution, Heterogeneity, and Therapy for Our Patients With Advanced Cancer: How Far Have We Come?
  El-Deiry, W. S., Taylor, B., & Neal, J. W. (2017). Tumor Evolution, Heterogeneity, and Therapy for Our Patients With Advanced Cancer: How Far Have We Come? American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting, (37), e8鈥揺15.
- Relationship between anti-depressant use and lung cancer survival.
  Zingone, A., Brown, D., Bowman, E. D., Vidal, O., Sage, J., Neal, J., & Ryan, B. M. (2017). Relationship between anti-depressant use and lung cancer survival. Cancer Treatment and Research Communications, 10, 33鈥�39.
- Natural history, treatment (tx) patterns, and outcomes in MET dysregulated non-small cell lung cancer (NSCLC) patients (pts)
  Wolf, J., Baik, C., Heist, R. S., Neal, J. W., Mansfield, A. S., Buettner, R., 鈥� Awad, M. M. (2018). Natural history, treatment (tx) patterns, and outcomes in MET dysregulated non-small cell lung cancer (NSCLC) patients (pts). EUROPEAN JOURNAL OF CANCER, 103, E131.
- Steroid-Sparing Therapy for Tyrosine Kinase Inhibitor-Induced Pneumonitis
  Sun, T. Y., Sung, A. W., & Neal, J. W. (2019). Steroid-Sparing Therapy for Tyrosine Kinase Inhibitor-Induced Pneumonitis. JOURNAL OF THORACIC ONCOLOGY, 14(4), E75鈥揈77.
- Steroid-Sparing Therapy for Tyrosine Kinase Inhibitor-Induced Pneumonitis.
  Sun, T. Y., Sung, A. W., & Neal, J. W. (2019). Steroid-Sparing Therapy for Tyrosine Kinase Inhibitor-Induced Pneumonitis. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 14(4), e75鈥揺77.
- Dovitinib and erlotinib in patients with metastatic non-small cell lung cancer: A drug-drug interaction.
  Das, M., Padda, S. K., Frymoyer, A., Zhou, L., Riess, J. W., Neal, J. W., & Wakelee, H. A. (2015). Dovitinib and erlotinib in patients with metastatic non-small cell lung cancer: A drug-drug interaction. Lung Cancer (Amsterdam, Netherlands), 89(3), 280鈥�6.
- Relationship of Driver Oncogenes to Long-Term Pemetrexed Response in Non--Small-Cell Lung Cancer.
  Liang, Y., Wakelee, H. A., & Neal, J. W. (2015). Relationship of Driver Oncogenes to Long-Term Pemetrexed Response in Non--Small-Cell Lung Cancer. Clinical Lung Cancer, 16(5), 366鈥�73.
- Association of Antibiotic Resistance With Antibiotic Use for Epidermal Growth Factor Receptor Inhibitor-Related Papulopustular Eruption.
  Hirotsu, K., Dang, T. M., Li, S., Neal, J. W., Pugliese, S., Subramanian, A., & Kwong, B. Y. (2019). Association of Antibiotic Resistance With Antibiotic Use for Epidermal Growth Factor Receptor Inhibitor-Related Papulopustular Eruption. JAMA Dermatology.
- Clinical and Pathological Variables Influencing Noninvasive Detection of Early Stage Lung Cancer Using Circulating Tumor DNA
  Chabon, J., Chaudhuri, A., Azad, T., Kurtz, D., Stehr, H., Liu, C. L., 鈥� Diehn, M. (2017). Clinical and Pathological Variables Influencing Noninvasive Detection of Early Stage Lung Cancer Using Circulating Tumor DNA. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC.
- A Phase 1b Study of Erlotinib and Momelotinib for TKI-Naive EGFR-Mutated Metastatic Non-Small Cell Lung
  Padda, S., Reckamp, K., Koczywas, M., Neal, J., Kawashima, J., Kong, S., 鈥� Wakelee, H. (2017). A Phase 1b Study of Erlotinib and Momelotinib for TKI-Naive EGFR-Mutated Metastatic Non-Small Cell Lung. JOURNAL OF THORACIC ONCOLOGY, 12(11), S2142鈥揝2143.
- EGFR Genotyping of Matched Urine, Plasma , and Tumor Tissue in Patients With Non-Small-Cell Lung Cancer Treated With Rociletinib, an EGFR Tyrosine Kinase Inhibitor
  Goldman, J. W., Karlovich, C., Sequist, L., Melnikova, V., Franovic, A., Gadgeel, S. M., 鈥� Wakelee, H. A. (2018). EGFR Genotyping of Matched Urine, Plasma , and Tumor Tissue in Patients With Non-Small-Cell Lung Cancer Treated With Rociletinib, an EGFR Tyrosine Kinase Inhibitor. JCO PRECISION ONCOLOGY, 2, 1鈥�13.
- Response to Ensartinib in TKI Naive ALK plus NSCLC Patients
  Wakelee, H., Sanborn, R., Nieva, J., Waqar, S., Brzezniak, C., Bauman, J., 鈥� Horn, L. (2017). Response to Ensartinib in TKI Naive ALK plus NSCLC Patients. JOURNAL OF THORACIC ONCOLOGY, 12(11), S1826.
- Natural Disease History, Outcomes, and Co-mutations in a Series of Patients With BRAF-Mutated Non-small-cell Lung Cancer
  Myall, N. J., Henry, S., Wood, D., Neal, J. W., Han, S. S., Padda, S. K., & Wakelee, H. A. (2019). Natural Disease History, Outcomes, and Co-mutations in a Series of Patients With BRAF-Mutated Non-small-cell Lung Cancer. CLINICAL LUNG CANCER, 20(2), E208鈥揈217.
- Synchronous primary lung adenocarcinomas harboring distinct MET Exon 14 splice site mutations
  Wang, S. X. Y., Lei, L., Guo, H. H., Shrager, J., Kunder, C. A., & Neal, J. W. (2018). Synchronous primary lung adenocarcinomas harboring distinct MET Exon 14 splice site mutations. LUNG CANCER, 122, 187鈥�91.
- Case series of MET exon 14 skipping mutation-positive non-small-cell lung cancers with response to crizotinib and cabozantinib
  Wang, S. X. Y., Zhang, B. M., Wakelee, H. A., Koontz, M. Z., Pan, M. G., Diehn, M., 鈥� Neal, J. W. (2019). Case series of MET exon 14 skipping mutation-positive non-small-cell lung cancers with response to crizotinib and cabozantinib. ANTI-CANCER DRUGS, 30(5), 537鈥�41.
- Increased Galectin-1 Expression in Thymic Epithelial Tumors
  Riess, J. W., Kong, C. S., West, R. B., Padda, S. K., Neal, J. W., Wakelee, H. A., & Le, Q.-T. (2019). Increased Galectin-1 Expression in Thymic Epithelial Tumors. CLINICAL LUNG CANCER, 20(3), E356鈥揈361.
- Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.
  Mazieres, J., Drilon, A., Lusque, A., Mhanna, L., Cortot, A. B., Mezquita, L., 鈥� Gautschi, O. (2019). Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Annals of Oncology : Official Journal of the European Society for Medical Oncology.
- Prognostic Value of Pretreatment FDG-PET Parameters in High-dose Image-guided Radiotherapy for Oligometastatic Non-Small-cell Lung Cancer
  Chin, A. L., Kumar, K. A., Guo, H. H., Maxim, P. G., Wakelee, H., Neal, J. W., 鈥� Gensheimer, M. F. (2018). Prognostic Value of Pretreatment FDG-PET Parameters in High-dose Image-guided Radiotherapy for Oligometastatic Non-Small-cell Lung Cancer. CLINICAL LUNG CANCER, 19(5), E581鈥揈588.
- Organoid-based characterization of patient tumors and microenvironments at single cell resolution
  Salahudeen, A. A., Zhu, J., Ju, J., Batish, A., Sutha, K., Neal, J. T., 鈥� Kuo, C. J. (2018). Organoid-based characterization of patient tumors and microenvironments at single cell resolution. CANCER RESEARCH, 78(13).
- Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes.
  Aredo, J. V., Padda, S. K., Kunder, C. A., Han, S. S., Neal, J. W., Shrager, J. B., & Wakelee, H. A. (2019). Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes. Lung Cancer (Amsterdam, Netherlands), 133, 144鈥�50.
- Comparison of Genomic Driver Oncogenes in Vietnamese Patients With Non-Small-Cell Lung Cancer in the United States and Vietnam
  Nguyen, K.-S. H., Stehr, H., Zhou, L., Anh-Hoa Nguyen, Pham Nhu Hiep, Nguyen Van Cau, 鈥� Neal, J. W. (2018). Comparison of Genomic Driver Oncogenes in Vietnamese Patients With Non-Small-Cell Lung Cancer in the United States and Vietnam. JOURNAL OF GLOBAL ONCOLOGY, 4.
- Lengthy Progression-Free Survival and Intracranial Activity of Cabozantinib in Patients with Crizotinib and Ceritinib-Resistant ROS1-Positive Non-Small Cell Lung Cancer
  Sun, T. Y., Niu, X., Chakraborty, A., Neal, J. W., & Wakelee, H. A. (2019). Lengthy Progression-Free Survival and Intracranial Activity of Cabozantinib in Patients with Crizotinib and Ceritinib-Resistant ROS1-Positive Non-Small Cell Lung Cancer. JOURNAL OF THORACIC ONCOLOGY, 14(2), E21鈥揈24.
- Review of the current targeted therapies for non-small-cell lung cancer
  Nguyen, K.-S. H., Neal, J. W., & Wakelee, H. (2014). Review of the current targeted therapies for non-small-cell lung cancer. WORLD JOURNAL OF CLINICAL ONCOLOGY, 5(4), 576鈥�87.
- MET inhibitors in combination with other therapies in non-small cell lung cancer
  Padda, S., Neal, J. W., & Wakelee, H. A. (2012). MET inhibitors in combination with other therapies in non-small cell lung cancer. TRANSLATIONAL LUNG CANCER RESEARCH, 1(4), 238鈥�53.
- Osimertinib for EGFR-Mutant Lung Cancer with Brain Metastases: Results from a Single-Center Retrospective Study
  Xie, L., Nagpal, S., Wakelee, H. A., Li, G., Soltys, S. G., & Neal, J. W. (2019). Osimertinib for EGFR-Mutant Lung Cancer with Brain Metastases: Results from a Single-Center Retrospective Study. ONCOLOGIST, 24(6), 836鈥�43.
- Plasma genotyping of patients enrolled on the expansion phase VII trial of X-396 in patients (pts) with ALK plus non-small cell lung cancer (NSCLC).
  Horn, L., Wakelee, H. A., Reckamp, K. L., Blumenschein, G. R., Infante, J. R., Carter, C. A., 鈥� Lovly, C. M. (2016). Plasma genotyping of patients enrolled on the expansion phase VII trial of X-396 in patients (pts) with ALK plus non-small cell lung cancer (NSCLC). JOURNAL OF CLINICAL ONCOLOGY, 34(15).
- Inter- and intra-patient heterogeneity of resistance mechanisms to the mutant EGFR selective inhibitor rociletinib.
  Chabon, J. ., Simmons, A., Newman, A. M., Lovejoy, A. F., Esfahani, M. S., Haringsma, H., 鈥� Diehn, M. (2016). Inter- and intra-patient heterogeneity of resistance mechanisms to the mutant EGFR selective inhibitor rociletinib. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.
- Infiltrating the Blood-Brain Barrier in ALK-Positive Lung Cancer
  Zweig, J. R., & Neal, J. W. (2018). Infiltrating the Blood-Brain Barrier in ALK-Positive Lung Cancer. JOURNAL OF CLINICAL ONCOLOGY, 36(26), 2677-+.
- Commentary: Treatment Considerations for Patients With Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Brain Metastases in the Era of Tyrosine Kinase Inhibitors
  Vaca, S. D., Connolly, I. D., Ho, C., Neal, J., & Gephart, M. H. (2018). Commentary: Treatment Considerations for Patients With Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Brain Metastases in the Era of Tyrosine Kinase Inhibitors. NEUROSURGERY, 82(1), E6鈥揈14.
- Adjuvant molecularly targeted therapy-epidermal growth factor tyrosine kinase inhibition and beyond
  Neal, J. W., & Sequist, L. V. (2013). Adjuvant molecularly targeted therapy-epidermal growth factor tyrosine kinase inhibition and beyond. TRANSLATIONAL LUNG CANCER RESEARCH, 2(5), 411鈥�14.
- First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors
  Nguyen, K.-S. H., & Neal, J. W. (2012). First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors. BIOLOGICS-TARGETS & THERAPY, 6, 337鈥�45.
- Impact of KEAP1/NFE2L2/CUL3 mutations on duration of response to EGFR tyrosine kinase inhibitors in EGFR mutated non-small cell lung cancer.
  Hellyer, J. A., Stehr, H., Das, M., Padda, S. K., Ramchandran, K., Neal, J. W., 鈥� Wakelee, H. A. (2019). Impact of KEAP1/NFE2L2/CUL3 mutations on duration of response to EGFR tyrosine kinase inhibitors in EGFR mutated non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands), 134, 42鈥�45.
- Epidermal growth factor receptor (EGFR) genotyping of matched urine, plasma and tumor tissue from non-small cell lung cancer (NSCLC) patients (pts) treated with rociletinib.
  Wakelee, H. A., Gadgeel, S. M., Goldman, J. W., Reckamp, K. L., Karlovich, C. A., Melnikova, V., 鈥� Sequist, L. V. (2016). Epidermal growth factor receptor (EGFR) genotyping of matched urine, plasma and tumor tissue from non-small cell lung cancer (NSCLC) patients (pts) treated with rociletinib. JOURNAL OF CLINICAL ONCOLOGY, 34(15).
- Integrated digital error suppression for noninvasive detection of circulating tumor DNA in NSCLC.
  Newman, A. M., Lovejoy, A. F., Klass, D. M., Kurtz, D. M., Chabon, J. J., Scherer, F., 鈥� Diehn, M. (2016). Integrated digital error suppression for noninvasive detection of circulating tumor DNA in NSCLC. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.
- Response to comment on "Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes".
  Aredo, J. V., Padda, S. K., Kunder, C. A., Han, S. S., Neal, J. W., Shrager, J. B., & Wakelee, H. A. (2019). Response to comment on "Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes". Lung Cancer (Amsterdam, Netherlands).
- Association of Antibiotic Resistance With Antibiotic Use for Epidermal Growth Factor Receptor Inhibitor-Related Papulopustular Eruption
  Hirotsu, K., Dang, T. M., Li, S., Neal, J. W., Pugliese, S., Subramanian, A., & Kwong, B. Y. (2019). Association of Antibiotic Resistance With Antibiotic Use for Epidermal Growth Factor Receptor Inhibitor-Related Papulopustular Eruption. JAMA DERMATOLOGY, 155(7), 848鈥�50.
- Role of KEAP1/NFE2L2 mutations in the chemotherapeutic response of non-small cell lung cancer patients.
  Jeong, Y., Hellyer, J. A., Stehr, H., Hoang, N. T., Niu, X., Das, M., 鈥� Diehn, M. (2019). Role of KEAP1/NFE2L2 mutations in the chemotherapeutic response of non-small cell lung cancer patients. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research.
- Phase II trial of single agent amrubicin in patients with previously treated advanced thymic malignancies.
  Hellyer, J. A., Gubens, M. A., Cunanan, K. M., Padda, S. K., Burns, M., Spittler, A. J., 鈥� Loehrer, P. J. (2019). Phase II trial of single agent amrubicin in patients with previously treated advanced thymic malignancies. Lung Cancer (Amsterdam, Netherlands), 137, 71鈥�75.
- ctDNA analysis for personalization of consolidation immunotherapy in localized non-small cell lung cancer.
  Moding, E. J., Liu, Y., Nabet, B., Chabon, J. J., Chaudhuri, A., Hui, A. B., 鈥� Diehn, M. (2019). ctDNA analysis for personalization of consolidation immunotherapy in localized non-small cell lung cancer. JOURNAL OF CLINICAL ONCOLOGY, 37(15).
- Osimertinib with chemotherapy for EGFR-mutant NSCLC at progression: Safety profile and survival analysis.
  Neal, J. W., Hausrath, D., Wakelee, H. A., Cunanan, K., Liu, S. V., Banwait, M., 鈥� Piotrowska, Z. (2019). Osimertinib with chemotherapy for EGFR-mutant NSCLC at progression: Safety profile and survival analysis. JOURNAL OF CLINICAL ONCOLOGY, 37(15).
- Randomized phase II study of adjuvant afatinib for three months versus two years in patients with resected stage I-III EGFR mutant NSCLC.
  Chaft, J. E., Costa, D. B., Muzikansky, A., Shrager, J. B., Lanuti, M., Huang, J., 鈥� Neal, J. W. (2019). Randomized phase II study of adjuvant afatinib for three months versus two years in patients with resected stage I-III EGFR mutant NSCLC. JOURNAL OF CLINICAL ONCOLOGY, 37(15).
- Antitumor activity of TAK-788 in NSCLC with EGFR exon 20 insertions.
  Janne, P. A., Neal, J. W., Camidge, D. R., Spira, A. I., Piotrowska, Z., Horn, L., 鈥� Riely, G. J. (2019). Antitumor activity of TAK-788 in NSCLC with EGFR exon 20 insertions. JOURNAL OF CLINICAL ONCOLOGY, 37(15).
- Characterization of circulating tumor cells and its PD-L1 expression with high-sensitivity liquid biopsy panel in non-small cell lung cancer patients
  Liu, X., Ao, Z., Preiss, J. S., Neal, J., Zhou, L. Y., Sambucetti, L., & Wakelee, H. A. (2019). Characterization of circulating tumor cells and its PD-L1 expression with high-sensitivity liquid biopsy panel in non-small cell lung cancer patients. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH.
- A Phase Ib/IIa randomized pilot study to investigate the safety and tolerability of autologous T-cells with enhanced T-cell receptors specific to NY-ESO-1/LAGE-1a (GSK3377794) alone, or in combination with pembrolizumab, in advanced non-small cell lung cancer
  Reckamp, K. L., Akerley, W., Edelman, M. J., Halmos, B., He, K., Johnson, M., 鈥� Lam, V. (2019). A Phase Ib/IIa randomized pilot study to investigate the safety and tolerability of autologous T-cells with enhanced T-cell receptors specific to NY-ESO-1/LAGE-1a (GSK3377794) alone, or in combination with pembrolizumab, in advanced non-small cell lung cancer. CANCER RESEARCH, 79(13).
- Clinical and molecular characteristics of responders versus non-responders to immune checkpoint inhibitors (ICI) in NSCLC.
  Shah, A., Padda, S. K., & Neal, J. W. (2019). Clinical and molecular characteristics of responders versus non-responders to immune checkpoint inhibitors (ICI) in NSCLC. JOURNAL OF CLINICAL ONCOLOGY, 37(8).
- Antitumor activity of TAK-788 in NSCLC With EGFR exon 20 insertions
  Jaenne, P., Neal, J. W., Camidge, D. R., Spira, A., Piotrowska, Z., Horn, L., 鈥� Riely, G. J. (2019). Antitumor activity of TAK-788 in NSCLC With EGFR exon 20 insertions. ANNALS OF ONCOLOGY, 30.
- Rash and Efficacy in Anaplastic Lymphoma Kinase Positive (ALK plus ) Non-Small Cell Lung Cancer Patients Treated with Ensartinib
  Wakelee, H., Reckamp, K., Leal, T., Chiappori, A., Waqar, S., Zeman, K., 鈥� Horn, L. (2019). Rash and Efficacy in Anaplastic Lymphoma Kinase Positive (ALK plus ) Non-Small Cell Lung Cancer Patients Treated with Ensartinib. JOURNAL OF THORACIC ONCOLOGY, 14(10), S566.
- STK11/LKB1 Genomic Alterations Are Associated with Inferior Clinical Outcomes with Chemo-Immunotherapy in Non-Squamous NSCLC
  Skoulidis, F., Arbour, K., Hellmann, M., Patil, P., Marmarelis, M., Owen, D., 鈥� Heymach, J. (2019). STK11/LKB1 Genomic Alterations Are Associated with Inferior Clinical Outcomes with Chemo-Immunotherapy in Non-Squamous NSCLC. JOURNAL OF THORACIC ONCOLOGY, 14(10), S294鈥揝295.
- A Single-Cell Resolution Map of EMT and Drug Resistance States for Evaluating NSCLC Clinical Specimens
  Karacosta, L., Anchang, B., Ignatiadis, N., Kimmey, S., Benson, J., Shrager, J., 鈥� Plevritis, S. (2019). A Single-Cell Resolution Map of EMT and Drug Resistance States for Evaluating NSCLC Clinical Specimens. JOURNAL OF THORACIC ONCOLOGY, 14(10), S226鈥揝227.
- The Real-World Risk of Brain Metastases in Stage 3 Lung Cancer Patients in the Era of PET and MRI Staging
  Ko, R., Therkelsen, K., Von Eyben, R., Neal, J., Loo, B., & Nagpal, S. (2019). The Real-World Risk of Brain Metastases in Stage 3 Lung Cancer Patients in the Era of PET and MRI Staging. JOURNAL OF THORACIC ONCOLOGY, 14(10), S585鈥揝586.
- Antitumor Activity of the Oral EGFR/HER2 Inhibitor TAK-788 in NSCLC with EGFR Exon 20 Insertions
  Riely, G., Neal, J., Camidge, D. R., Spira, A., Piotrowska, Z., Horn, L., 鈥� Janne, P. (2019). Antitumor Activity of the Oral EGFR/HER2 Inhibitor TAK-788 in NSCLC with EGFR Exon 20 Insertions. JOURNAL OF THORACIC ONCOLOGY, 14(10), S412鈥揝413.
- Safety, tolerability and activity of autologous T-cells with enhanced T-cell receptors specific to NY ESO 1/LAGE 1a (GSK3377794) alone, or in combination with pembrolizumab, in advanced non-small cell lung cancer: A phase Ib/IIa randomised pilot study
  Reckamp, K. L., Akerley, W., Calvo, E., Clarke, J., Edelman, M. J., He, K., 鈥� Johnson, M. L. (2019). Safety, tolerability and activity of autologous T-cells with enhanced T-cell receptors specific to NY ESO 1/LAGE 1a (GSK3377794) alone, or in combination with pembrolizumab, in advanced non-small cell lung cancer: A phase Ib/IIa randomised pilot study. ANNALS OF ONCOLOGY, 30, 657-+.
- Long Term Efficacy and Safety of Ensartinib in Pre-Treated Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients (eXalt2)
  Leal, T., Wakelee, H., Reckamp, K. L., Chiappori, A., Oxnard, G. R., Waqar, S. N., 鈥� Horn, L. (2019). Long Term Efficacy and Safety of Ensartinib in Pre-Treated Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients (eXalt2). JOURNAL OF THORACIC ONCOLOGY, 14(11), S1171鈥揝1172.
- Circulating tumor DNA analysis to assess risk of progression after long-term response to PD-(L)1 blockade in NSCLC.
  Hellmann, M. D., Nabet, B. Y., Rizvi, H., Chaudhuri, A. A., Wells, D. K., Dunphy, M. P., 鈥� Diehn, M. (2020). Circulating tumor DNA analysis to assess risk of progression after long-term response to PD-(L)1 blockade in NSCLC. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research.
- Safety and anti-tumor effects of MAGE-A10c796 TCR T-cells in two clinical trials.
  Lam, V. K., Hong, D. S., Heymach, J. V., Blumenschein, G., Butler, M. O., Johnson, M., 鈥� Amado, R. G. (2018). Safety and anti-tumor effects of MAGE-A10c796 TCR T-cells in two clinical trials. Annals of Oncology : Official Journal of the European Society for Medical Oncology, 29 Suppl 8, viii731.
- Integrating genomic features for non-invasive early lung cancer detection
  Chabon, J. J., Hamilton, E. G., Kurtz, D. M., Esfahani, M. S., Moding, E. J., Stehr, H., 鈥� Diehn, M. (2020). Integrating genomic features for non-invasive early lung cancer detection. NATURE.
- Feasibility and design of a cloud-based digital platform in patients with advanced cancer.
  Roy, M., Hall, E. T., Velazquez, B., Shah, S., Fardeen, T., Cunanan, K., 鈥� Ramchandran, K. (2019). Feasibility and design of a cloud-based digital platform in patients with advanced cancer. JOURNAL OF CLINICAL ONCOLOGY, 37(27).
- Integrating genomic features for non-invasive early lung cancer detection.
  Chabon, J. J., Hamilton, E. G., Kurtz, D. M., Esfahani, M. S., Moding, E. J., Stehr, H., 鈥� Diehn, M. (2020). Integrating genomic features for non-invasive early lung cancer detection. Nature, 580(7802), 245鈥�251.
- Efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients harboring activating molecular alterations (ImmunoTarget).
  Mazieres, J., Drilon, A. E., Mhanna, L., Milia, J., Lusque, A., Cortot, A. B., 鈥� Gautschi, O. (2018). Efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients harboring activating molecular alterations (ImmunoTarget). JOURNAL OF CLINICAL ONCOLOGY, 36(15).
- Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small-cell lung cancer
  Moding, E. J., Liu, Y., Nabet, B. Y., Chabon, J. J., Chaudhuri, A. A., Hui, A. B., 鈥� Diehn, M. (2020). Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small-cell lung cancer. NATURE CANCER, 1.
- A PHASE IIA STUDY REPOSITIONING DESIPRAMINE IN SMALL CELL LUNG CANCER AND OTHER HIGH-GRADE NEUROENDOCRINE TUMORS.
  Riess, J. W., Jahchan, N. S., Das, M., Zach Koontz, M., Kunz, P. L., Wakelee, H. A., 鈥� Neal, J. W. (2020). A PHASE IIA STUDY REPOSITIONING DESIPRAMINE IN SMALL CELL LUNG CANCER AND OTHER HIGH-GRADE NEUROENDOCRINE TUMORS. Cancer Treatment and Research Communications, 23, 100174.
- Outcomes of EGFR-mutant lung adenocarcinomas (AC) that transform to small cell lung cancer (SCLC).
  Marcoux, N., Gettinger, S. N., O'Kane, G. M., Arbour, K. C., Neal, J. W., Husain, H., 鈥� Sequist, L. V. (2018). Outcomes of EGFR-mutant lung adenocarcinomas (AC) that transform to small cell lung cancer (SCLC). JOURNAL OF CLINICAL ONCOLOGY, 36(15).
- Facile single cell profiling and clonotype analysis of NSCLC immune microenvironments.
  Salahudeen, A. A., Zhu, J., Ju, J., Giangarra, V., Montesclaros, L., Sapida, J., 鈥� Kuo, C. J. (2018). Facile single cell profiling and clonotype analysis of NSCLC immune microenvironments. JOURNAL OF CLINICAL ONCOLOGY, 36(15).
- PD-1/PD-L1 Checkpoint Inhibitor Immunotherapy for Malignant Pleural Mesothelioma: Case Series and Literature Review.
  Zhou, M., Joshi, N., Raj, K. P., Wakelee, H., & Neal, J. W. (2020). PD-1/PD-L1 Checkpoint Inhibitor Immunotherapy for Malignant Pleural Mesothelioma: Case Series and Literature Review. Clinical Lung Cancer.
- First report of safety, PK, and preliminary antitumor activity of the oral EGFR/HER2 exon 20 inhibitor TAK-788 (AP32788) in non-small cell lung cancer (NSCLC).
  Doebele, R. C., Riely, G. J., Spira, A. I., Horn, L., Piotrowska, Z., Costa, D. B., 鈥� Janne, P. A. (2018). First report of safety, PK, and preliminary antitumor activity of the oral EGFR/HER2 exon 20 inhibitor TAK-788 (AP32788) in non-small cell lung cancer (NSCLC). JOURNAL OF CLINICAL ONCOLOGY, 36(15).
- Immune Checkpoint Inhibitor Cardiotoxicity: Understanding Basic Mechanisms and Clinical Characteristics and Finding a Cure.
  Waliany, S., Lee, D., Witteles, R. M., Neal, J. W., Nguyen, P., Davis, M. M., 鈥� Zhu, H. (2020). Immune Checkpoint Inhibitor Cardiotoxicity: Understanding Basic Mechanisms and Clinical Characteristics and Finding a Cure. Annual Review of Pharmacology and Toxicology.
- Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition.
  Nabet, B. Y., Esfahani, M. S., Moding, E. J., Hamilton, E. G., Chabon, J. J., Rizvi, H., 鈥� Diehn, M. (2020). Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition. Cell.
- KEAP1/NFE2L2 mutations to predict local recurrence after radiotherapy but not surgery in localized non-small cell lung cancer.
  Binkley, M. S., Jeon, Y.-J., Nesselbush, M., Moding, E. J., Nabet, B., Almanza, D. S., 鈥� Diehn, M. (2020). KEAP1/NFE2L2 mutations to predict local recurrence after radiotherapy but not surgery in localized non-small cell lung cancer. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.
- Discovery of a novel shared tumor antigen in human lung cancer.
  Tseng, D., Chiou, S.-H., Yang, X., Reuben, A., Wilhelmy, J., McSween, A., 鈥� Davis, M. (2020). Discovery of a novel shared tumor antigen in human lung cancer. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.
- A mid-chemoradiation dynamic risk model integrating tumor features and ctDNA analysis for lung cancer outcome prediction.
  Moding, E. J., Esfahani, M. S., Nabet, B., Liu, Y., Chabon, J. J., He, J., 鈥� Diehn, M. (2020). A mid-chemoradiation dynamic risk model integrating tumor features and ctDNA analysis for lung cancer outcome prediction. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.
- Distress screening through PROMIS at an academic cancer center and network site: Implementation of a hybrid model.
  Roy, M., Neal, J. W., Bugos, K., Sharp, C., Falconer, P., Rosenthal, E. L., 鈥� Ramchandran, K. (2020). Distress screening through PROMIS at an academic cancer center and network site: Implementation of a hybrid model. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.
- Osimertinib in non-small cell lung cancer (NSCLC) with atypical EGFR activating mutations: A retrospective multicenter study.
  Ji, J., Aredo, J., Piper-Vallillo, A., Huppert, L., Rotow, J. K., Husain, H., 鈥� Riess, J. W. (2020). Osimertinib in non-small cell lung cancer (NSCLC) with atypical EGFR activating mutations: A retrospective multicenter study. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.
- High-dose osimertinib for CNS progression in EGFR plus non-small cell lung cancer (NSCLC): A multi-institutional experience.
  Piper-Vallillo, A., Rotow, J. K., Aredo, J., Shaverdashvili, K., Luo, J., Carlisle, J. W., 鈥� Piotrowska, Z. (2020). High-dose osimertinib for CNS progression in EGFR plus non-small cell lung cancer (NSCLC): A multi-institutional experience. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.
- Indirect comparison of TAK-788 vs real-world data outcomes in refractory non-small cell lung cancer (NSCLC) with EGFR exon 20 insertions.
  Horn, L., Lin, H. M., Padda, S. K., Aggarwal, C., McCoach, C. E., Zhu, Y., 鈥� Neal, J. W. (2020). Indirect comparison of TAK-788 vs real-world data outcomes in refractory non-small cell lung cancer (NSCLC) with EGFR exon 20 insertions. JOURNAL OF CLINICAL ONCOLOGY, 38(15).
- Cabozantinib in combination with atezolizumab in non-small cell lung cancer (NSCLC) patients previously treated with an immune checkpoint inhibitor: Results from cohort 7 of the COSMIC-021 study.
  Neal, J. W., Lim, F. L., Felip, E., Gentzler, R. D., Patel, S. B., Baranda, J., 鈥� Ponce Aix, S. (2020). Cabozantinib in combination with atezolizumab in non-small cell lung cancer (NSCLC) patients previously treated with an immune checkpoint inhibitor: Results from cohort 7 of the COSMIC-021 study. JOURNAL OF CLINICAL ONCOLOGY, 38(15).
- KEAP1/NFE2L2 mutations predict lung cancer radiation resistance that can be targeted by glutaminase inhibition.
  Binkley, M. S., Jeon, Y.-J. J., Nesselbush, M., Moding, E. J., Nabet, B. Y., Almanza, D., 鈥� Diehn, M. (2020). KEAP1/NFE2L2 mutations predict lung cancer radiation resistance that can be targeted by glutaminase inhibition. Cancer Discovery.
- Updated results from a phase I/II study of mobocertinib (TAK788) in NSCLC with EGFR exon 20 insertions (exon20ins)
  Riely, G. J., Neal, J. W., Camidge, D. R., Spira, A., Piotrowska, Z., Horn, L., 鈥� Janne, P. A. (2020). Updated results from a phase I/II study of mobocertinib (TAK788) in NSCLC with EGFR exon 20 insertions (exon20ins). ANNALS OF ONCOLOGY, 31, S815鈥揝816.
- Comparison of clinical outcomes of patients with METDex14 NSCLC treated with first-line capmatinib in the GEOMETRY mono-1 study with those of a cohort of real-world patients
  Wolf, J., Neal, J. W., Mansfield, A. S., Doban, V., Kanakamedala, H., Wu, W.-H., 鈥� Baik, C. S. (2020). Comparison of clinical outcomes of patients with METDex14 NSCLC treated with first-line capmatinib in the GEOMETRY mono-1 study with those of a cohort of real-world patients. ANNALS OF ONCOLOGY, 31, S863.
- Impact of KRAS mutations and subtypes on efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC)
  Mazieres, J., Tomasini, P., Lusque, A., Boucekine, M., Gautschi, O., Cortot, A. B., 鈥� Barlesi, F. (2020). Impact of KRAS mutations and subtypes on efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC). ANNALS OF ONCOLOGY, 31, S826鈥揝827.
- Three-dimensional organoid model for acquired drug resistance in non-small cell lung cancer
  Shukla, N. D., Salahudeen, A. A., Padda, S. K., Neal, J. W., Wakelee, H. A., & Kuo, C. J. (2018). Three-dimensional organoid model for acquired drug resistance in non-small cell lung cancer. CLINICAL CANCER RESEARCH. AMER ASSOC CANCER RESEARCH.
- Opportunistic Invasive Fungal Infections Mimicking Progression of Non-Small-Cell Lung Cancer.
  Park, M., Ho, D. Y., Wakelee, H. A., & Neal, J. W. (2020). Opportunistic Invasive Fungal Infections Mimicking Progression of Non-Small-Cell Lung Cancer. Clinical Lung Cancer.
- Relative Impact of Anticancer Therapy on Unplanned Hospital Care in Patients With Non-Small-Cell Lung Cancer.
  Shah, M. P., & Neal, J. W. (2020). Relative Impact of Anticancer Therapy on Unplanned Hospital Care in Patients With Non-Small-Cell Lung Cancer. JCO Oncology Practice, OP2000612.
- Giant Magnetoresistive Nanosensor Analysis of Circulating Tumor DNA Epidermal Growth Factor Receptor Mutations for Diagnosis and Therapy Response Monitoring.
  Nesvet, J. C., Antilla, K. A., Pancirer, D. S., Lozano, A. X., Preiss, J. S., Ma, W., 鈥� Wang, S. X. (2021). Giant Magnetoresistive Nanosensor Analysis of Circulating Tumor DNA Epidermal Growth Factor Receptor Mutations for Diagnosis and Therapy Response Monitoring. Clinical Chemistry.
- Improved survival and disease control following pembrolizumab-induced immune-related adverse events in high PD-L1 expressing non-small cell lung cancer with brain metastases.
  Zhang, M., Rodrigues, A. J., Pollom, E. L., Gibbs, I. C., Soltys, S. G., Hancock, S. L., 鈥� Li, G. (2021). Improved survival and disease control following pembrolizumab-induced immune-related adverse events in high PD-L1 expressing non-small cell lung cancer with brain metastases. Journal of Neuro-Oncology.
- Immune Profiling and Causal Antigen Discovery in Mouse and Human Models of Immune Checkpoint Inhibitor-induced Myocarditis
  Zhu, H., Lee, D., Sarah, W., Galdos, F. X., D'Addabbo, J., Fowler, M. B., 鈥� Wu, S. M. (2020). Immune Profiling and Causal Antigen Discovery in Mouse and Human Models of Immune Checkpoint Inhibitor-induced Myocarditis. CIRCULATION RESEARCH. LIPPINCOTT WILLIAMS & WILKINS.
- Brief Report: Role of Consolidation Durvalumab in patients with EGFR and HER2 Mutant Unresectable Stage III NSCLC.
  Hellyer, J. A., Aredo, J. V., Das, M., Ramchandran, K., Padda, S. K., Neal, J. W., & Wakelee, H. A. (2021). Brief Report: Role of Consolidation Durvalumab in patients with EGFR and HER2 Mutant Unresectable Stage III NSCLC. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer.
- Durvalumab for Patients with Stage III EGFR-Mutated Non-Small Cell Lung Cancer Receiving Definitive Chemoradiotherapy
  Aredo, J. V., Hellyer, J. A., Neal, J. W., Padda, S. K., McCoach, C. E., Riess, J. W., 鈥� Wakelee, H. A. (2021). Durvalumab for Patients with Stage III EGFR-Mutated Non-Small Cell Lung Cancer Receiving Definitive Chemoradiotherapy. JOURNAL OF THORACIC ONCOLOGY, 16(1), S15.
- Durvalumab for Stage III EGFR-Mutated Non-Small Cell Lung Cancer After Definitive Chemoradiotherapy.
  Aredo, J. V., Mambetsariev, I., Hellyer, J. A., Amini, A., Neal, J. W., Padda, S. K., 鈥� Wakelee, H. A. (2021). Durvalumab for Stage III EGFR-Mutated Non-Small Cell Lung Cancer After Definitive Chemoradiotherapy. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer.
- Combining Osimertinib With Chemotherapy in EGFR-Mutant NSCLC at Progression.
  White, M. N., Piotrowska, Z., Stirling, K., Liu, S. V., Banwait, M. K., Cunanan, K., 鈥� Neal, J. W. (2021). Combining Osimertinib With Chemotherapy in EGFR-Mutant NSCLC at Progression. Clinical Lung Cancer.
- Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations From a Phase 1/2 Trial.
  Riely, G. J., Neal, J. W., Camidge, D. R., Spira, A. I., Piotrowska, Z., Costa, D. B., 鈥� Janne, P. A. (2021). Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations From a Phase 1/2 Trial. Cancer Discovery.
- A noninvasive approach for early prediction of therapeutic benefit from immune checkpoint inhibition for lung cancer
  Nabet, B. Y., Esfahani, M. S., Hamilton, E. G., Chabon, J. J., Moding, E. J., Rizvi, H., 鈥� Diehn, M. (2020). A noninvasive approach for early prediction of therapeutic benefit from immune checkpoint inhibition for lung cancer. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH.
- A phase II randomized study of telaglenastat, a glutaminase (GLS) inhibitor, versus placebo, in combination with pembrolizumab (Pembro) and chemotherapy as first-line treatment for KEAP1/NRF2-mutated non-squamous metastatic non-small cell lung cancer (mNSCLC).
  Skoulidis, F., Neal, J. W., Akerley, W. L., Paik, P. K., Papagiannakopoulos, T., Reckamp, K. L., 鈥� Rizvi, N. A. (2020). A phase II randomized study of telaglenastat, a glutaminase (GLS) inhibitor, versus placebo, in combination with pembrolizumab (Pembro) and chemotherapy as first-line treatment for KEAP1/NRF2-mutated non-squamous metastatic non-small cell lung cancer (mNSCLC). JOURNAL OF CLINICAL ONCOLOGY, 38(15).
- Global analysis of shared T听cell specificities in human non-small cell lung cancer enables HLA inference and antigen discovery.
  Chiou, S.-H. H., Tseng, D., Reuben, A., Mallajosyula, V., Molina, I. S., Conley, S., 鈥� Davis, M. M. (2021). Global analysis of shared T听cell specificities in human non-small cell lung cancer enables HLA inference and antigen discovery. Immunity, 54(3), 586鈥�602.e8.
- Myocarditis Surveillance with High-Sensitivity Troponin I During Cancer Treatment with Immune Checkpoint Inhibitors.
  Waliany, S., Neal, J. W., Reddy, S., Wakelee, H., Shah, S. A., Srinivas, S., 鈥� Zhu, H. (2021). Myocarditis Surveillance with High-Sensitivity Troponin I During Cancer Treatment with Immune Checkpoint Inhibitors. JACC. CardioOncology, 3(1), 137鈥�39.
- Distress Screening Through Patient-Reported Outcomes Measurement Information System (PROMIS) at an Academic Cancer Center and Network Site: Implementation of a Hybrid Model.
  Neal, J. W., Roy, M., Bugos, K., Sharp, C., Galatin, P. S., Falconer, P., 鈥� Ramchandran, K. (2021). Distress Screening Through Patient-Reported Outcomes Measurement Information System (PROMIS) at an Academic Cancer Center and Network Site: Implementation of a Hybrid Model. JCO Oncology Practice, OP2000473.
- Chemotherapy with or without immunotherapy or bevacizumab for EGFR-mutated lung cancer after progression on osimertinib
  White, M., Neal, J. W., Gardner, R. M., Cunanan, K. M., Das, M., Padda, S. K., 鈥� Wakelee, H. (2021). Chemotherapy with or without immunotherapy or bevacizumab for EGFR-mutated lung cancer after progression on osimertinib. JOURNAL OF THORACIC ONCOLOGY, 16(4), S773鈥揝774.
- LUNGMAP Master Protocol (LUNGMAP): Concordance Between Plasma ctDNA and Tissue Molecular Analysis
  Mack, P., Minichielle, K., Redman, M., Tolba, K., Kozono, D., Waqar, S., 鈥� Herbst, R. (2021). LUNGMAP Master Protocol (LUNGMAP): Concordance Between Plasma ctDNA and Tissue Molecular Analysis. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC.
- Healthcare Utilization with an Electronic Patient Reported Outcome (ePRO) tool for Symptom Management in Thoracic Cancers
  Roy, M., Fardeen, T., Generalova, O., Hall, E., Cunanan, K., Das, M., 鈥� Ramchandran, K. (2021). Healthcare Utilization with an Electronic Patient Reported Outcome (ePRO) tool for Symptom Management in Thoracic Cancers. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC.
- Tumor Mutation Burden (TMB) by Next Generation Sequencing (NGS) Associates with Survival (OS) in Lung-MAP Immunotherapy Trials S1400I and S1400A
  Hirsch, F., Hua, X., Wu, M., Neal, J., Cheng, H., Gettinger, S., 鈥� Kozono, D. (2021). Tumor Mutation Burden (TMB) by Next Generation Sequencing (NGS) Associates with Survival (OS) in Lung-MAP Immunotherapy Trials S1400I and S1400A. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC.
- Afatinib After Progression on Osimertinib in Patients with EGFR-Mutated Lung Adenocarcinoma
  Aredo, J., Wakelee, H. A., Neal, J., & Padda, S. (2021). Afatinib After Progression on Osimertinib in Patients with EGFR-Mutated Lung Adenocarcinoma. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC.
- Afatinib and Necitumumab in EGFR mutant NSCLC with Acquired Resistance to 1st or 3rd Generation EGFR Tyrosine Kinase Inhibitors
  Padda, S., Whisenant, J., Neal, J., York, S., Iams, W., Neuss, M., 鈥� Horn, L. (2021). Afatinib and Necitumumab in EGFR mutant NSCLC with Acquired Resistance to 1st or 3rd Generation EGFR Tyrosine Kinase Inhibitors. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC.
- Impact of Low-Dose CT Screening for Primary Lung Cancer on Subsequent Risk of Brain Metastasis: Secondary Analysis of NLST
  Su, C. C., Wu, J., Neal, J., Popat, R., Backhus, L., Leung, A., 鈥� Han, S. (2021). Impact of Low-Dose CT Screening for Primary Lung Cancer on Subsequent Risk of Brain Metastasis: Secondary Analysis of NLST. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC.
- ANSELMA: Antiangiogenic Second Line Lung Cancer Meta-Analysis on Individual Patient Data in Non-Small Cell Lung Cancer, Again Relevant in ICI Era
  Remon, J., Lacas, B., Herbst, R., Reck, M., Garon, E., Scagliotti, G., 鈥� Besse, B. (2021). ANSELMA: Antiangiogenic Second Line Lung Cancer Meta-Analysis on Individual Patient Data in Non-Small Cell Lung Cancer, Again Relevant in ICI Era. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC.
- Cabozantinib Plus Atezolizumab in NSCLC Patients Previously Treated with a Checkpoint Inhibitor: Results from COSMIC 021
  Neal, J., Lim, F., Felip, E., Gentzler, R., Patel, S., Baranda, J., 鈥� Ponce Aix, S. (2021). Cabozantinib Plus Atezolizumab in NSCLC Patients Previously Treated with a Checkpoint Inhibitor: Results from COSMIC 021. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC.
- Computational Biological Modeling Identifies PD-(L)1 Immunotherapy Sensitivity Among Molecular Subgroups of KRAS-Mutated Non-Small-Cell Lung Cancer
  Padda, S. K., Aredo, J., Vali, S., Singh, N. K., Vasista, S. M., Kumar, A., 鈥� Wakelee, H. A. (2021). Computational Biological Modeling Identifies PD-(L)1 Immunotherapy Sensitivity Among Molecular Subgroups of KRAS-Mutated Non-Small-Cell Lung Cancer. JCO PRECISION ONCOLOGY, 5, 153鈥�62.
- Randomized Phase II Study of 3 Months or 2 Years of Adjuvant Afatinib in Patients With Surgically Resected Stage I-III EGFR-Mutant Non-Small-Cell Lung Cancer
  Neal, J. W., Costa, D. B., Muzikansky, A., Shrager, J. B., Lanuti, M., Huang, J., 鈥� Chaft, J. E. (2021). Randomized Phase II Study of 3 Months or 2 Years of Adjuvant Afatinib in Patients With Surgically Resected Stage I-III EGFR-Mutant Non-Small-Cell Lung Cancer. JCO PRECISION ONCOLOGY, 5, 325鈥�32.
- Investigating gene expression profiles associated with clinical radiation resistance in KEAP1/NFE2L2 wildtype lung cancer.
  Binkley, M. S., Jeon, Y.-J., Nesselbush, M., Moding, E. J., Nabet, B., Almanza, D., 鈥� Diehn, M. (2021). Investigating gene expression profiles associated with clinical radiation resistance in KEAP1/NFE2L2 wildtype lung cancer. CLINICAL CANCER RESEARCH. AMER ASSOC CANCER RESEARCH.
- Circulating tumor DNA kinetics to identify genomic predictors of rapid response to chemoradiation in non-small cell lung cancer.
  Moding, E. J., Liu, Y., Hui, A. B., He, J., Qiao, Y., Xu, T., 鈥� Diehn, M. (2021). Circulating tumor DNA kinetics to identify genomic predictors of rapid response to chemoradiation in non-small cell lung cancer. CLINICAL CANCER RESEARCH. AMER ASSOC CANCER RESEARCH.
- Impact of Low-Dose CT Screening for Primary Lung Cancer on Subsequent Risk of Brain Metastasis.
  Su, C. C., Wu, J. T., Neal, J. W., Popat, R. A., Kurian, A. W., Backhus, L. M., 鈥� Han, S. S. (2021). Impact of Low-Dose CT Screening for Primary Lung Cancer on Subsequent Risk of Brain Metastasis. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer.
- EGFR exon 20 Insertion NSCLC and Response to Platinum-Based Chemotherapy.
  Shah, M. P., Aredo, J. V., Padda, S. K., Ramchandran, K. J., Wakelee, H. A., Das, M. S., & Neal, J. W. (2021). EGFR exon 20 Insertion NSCLC and Response to Platinum-Based Chemotherapy. Clinical Lung Cancer.
- The role of ramucirumab with docetaxel in epidermal growth factor receptor mutant and wild-type non-small cell lung cancer
  Ellis-Caleo, T., & Neal, J. W. (2021). The role of ramucirumab with docetaxel in epidermal growth factor receptor mutant and wild-type non-small cell lung cancer. JOURNAL OF THORACIC DISEASE.
- Radiological tumour classification across imaging modality and histology
  Wu, J., Li, C., Gensheimer, M., Padda, S., Kato, F., Shirato, H., 鈥� Li, R. (2021). Radiological tumour classification across imaging modality and histology. NATURE MACHINE INTELLIGENCE.
- Pharmacovigilance analysis of cardiac toxicities associated with targeted therapies for metastatic non-small cell lung carcinoma.
  Waliany, S., Zhu, H., Wakelee, H., Padda, S. K., Das, M., Ramchandran, K., 鈥� Neal, J. W. (2021). Pharmacovigilance analysis of cardiac toxicities associated with targeted therapies for metastatic non-small cell lung carcinoma. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer.
- Circulating Tumor DNA Dynamics Predict Benefit from Consolidation Immunotherapy in Locally Advanced Non-Small Cell Lung Cancer.
  Moding, E. J., Liu, Y., Nabet, B. Y., Chabon, J. J., Chaudhuri, A. A., Hui, A. B., 鈥� Diehn, M. (2020). Circulating Tumor DNA Dynamics Predict Benefit from Consolidation Immunotherapy in Locally Advanced Non-Small Cell Lung Cancer. Nature Cancer, 1(2), 176鈥�183.
- Implementation of a cloud-based electronic patient-reported outcome (ePRO) platform in patients with advanced cancer.
  Generalova, O., Roy, M., Hall, E., Shah, S. A., Cunanan, K., Fardeen, T., 鈥� Ramchandran, K. (2021). Implementation of a cloud-based electronic patient-reported outcome (ePRO) platform in patients with advanced cancer. Journal of Patient-Reported Outcomes, 5(1), 91.
- Immune Checkpoint Inhibitor Pneumonitis: Heterogeneity in Clinical Management
  Filsoof, D., Padda, S. K., Garcia, P., Stedman, M., Neal, J. W., Wakelee, H. A., 鈥� Katsumoto, T. R. (2021). Immune Checkpoint Inhibitor Pneumonitis: Heterogeneity in Clinical Management. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE. AMER THORACIC SOC.
- Pragmatic Application of Computed Tomography Lung Texture Analysis in Immune Checkpoint Inhibitor Pneumonitis: An Exploratory Study
  Filsoof, D., Im, J., Garcia, P., Stedman, M., Anand, S., Neal, J. W., 鈥� Raj, R. (2021). Pragmatic Application of Computed Tomography Lung Texture Analysis in Immune Checkpoint Inhibitor Pneumonitis: An Exploratory Study. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE. AMER THORACIC SOC.
- The role of ramucirumab with docetaxel in epidermal growth factor receptor mutant and wild-type non-small cell lung cancer.
  Ellis-Caleo, T., & Neal, J. W. (2021). The role of ramucirumab with docetaxel in epidermal growth factor receptor mutant and wild-type non-small cell lung cancer. Journal of Thoracic Disease, 13(8), 4864鈥�4871.
- Indirect comparison of mobocertinib and standard of care in platinum-pretreated patients with NSCLC with EGFR exon 20 insertion
  Ou, S.-H. I., Lin, H. M., Hong, J.-L., Yin, Y., Jin, S., Lin, J., 鈥� Neal, J. W. (2021). Indirect comparison of mobocertinib and standard of care in platinum-pretreated patients with NSCLC with EGFR exon 20 insertion. ANNALS OF ONCOLOGY. ELSEVIER.
- Patterns of Care in Patients With Isolated Nodal Recurrence After Definitive Stereotactic Ablative Radiotherapy for Non-Small Cell Lung Cancer.
  Devine, M., Merriott, D. J., Say, C., Yoo, C., Yi, E., Lau, B., 鈥� Vitzthum, L. (2021). Patterns of Care in Patients With Isolated Nodal Recurrence After Definitive Stereotactic Ablative Radiotherapy for Non-Small Cell Lung Cancer. International Journal of Radiation Oncology, Biology, Physics, 111(3S), e435.
- A Phase II Trial of Individualized Stereotactic Ablative Radiotherapy for Lung Tumors (iSABR).
  Gensheimer, M. F., Gee, H. E., Von Eyben, R., Shirato, H., Taguchi, H., Wong, S., 鈥� Diehn, M. (2021). A Phase II Trial of Individualized Stereotactic Ablative Radiotherapy for Lung Tumors (iSABR). International Journal of Radiation Oncology, Biology, Physics, 111(3S), S89鈥揝90.
- Use of a computer model and care coaches to increase advance care planning conversations for patients with metastatic cancer
  Gupta, D., Fardeen, T., Teuteberg, W., Seevaratnam, B., Asuncion, M. K., Alves, N., 鈥� Ramchandran, K. (2021). Use of a computer model and care coaches to increase advance care planning conversations for patients with metastatic cancer. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.
- A Predictive Model to Guide Brain MRI Surveillance in Patients With Metastatic Lung Cancer: Impact on Real World Outcomes
  Wu, J., Ding, V., Luo, S., Choi, E., Hellyer, J., Myall, N., 鈥� Han, S. (2021). A Predictive Model to Guide Brain MRI Surveillance in Patients With Metastatic Lung Cancer: Impact on Real World Outcomes. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC.
- Survival After Distant Recurrent Versus De Novo Stage IV Metastatic Lung Cancer Under Low-Dose Computed Tomography Screening
  Su, C., Choi, E., Wu, J., Neal, J., Kurian, A., Backhus, L., 鈥� Han, S. (2021). Survival After Distant Recurrent Versus De Novo Stage IV Metastatic Lung Cancer Under Low-Dose Computed Tomography Screening. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC.
- A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naive metastatic non-small cell lung cancer.
  Padda, S. K., Reckamp, K. L., Koczywas, M., Neal, J. W., Kawashima, J., Kong, S., 鈥� Wakelee, H. A. (2021). A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naive metastatic non-small cell lung cancer. Cancer Chemotherapy and Pharmacology.
- Mobocertinib in EGFR Exon 20 InsertionePositive Metastatic NSCLC Patients With Disease Control on Prior EGFR TKI Therapy
  Spira, A., Ramalingam, S., Neal, J., Piotrowska, Z., Mekhail, T., Tsao, A., 鈥� Janne, P. (2021). Mobocertinib in EGFR Exon 20 InsertionePositive Metastatic NSCLC Patients With Disease Control on Prior EGFR TKI Therapy. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC.
- Consolidation Durvalumab Should Not Be Administered to Patients With Stage III EGFR-Mutant NSCLC.
  Aredo, J. V., Hellyer, J. A., Neal, J. W., & Wakelee, H. A. (2021). Consolidation Durvalumab Should Not Be Administered to Patients With Stage III EGFR-Mutant NSCLC. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 16(12), 1994鈥�1998.
- Pulmonary Hemorrhage in Patients Treated With Thoracic Stereotactic Ablative Radiotherapy and Anti-Angiogenic Agents
  Lau, B., No, H. J., Wu, Y. F., Ko, R. B., Devine, M., Das, M., 鈥� Vitzthum, L. (2021). Pulmonary Hemorrhage in Patients Treated With Thoracic Stereotactic Ablative Radiotherapy and Anti-Angiogenic Agents. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. ELSEVIER SCIENCE INC.
- Patterns of Care in Patients With Isolated Nodal Recurrence After Definitive Stereotactic Ablative Radiotherapy for Non-Small Cell Lung Cancer
  Devine, M., Merriott, D. J., Say, C., Yoo, C., Yi, E., Lau, B., 鈥� Vitzthum, L. (2021). Patterns of Care in Patients With Isolated Nodal Recurrence After Definitive Stereotactic Ablative Radiotherapy for Non-Small Cell Lung Cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. ELSEVIER SCIENCE INC.
- A Phase II Trial of Individualized Stereotactic Ablative Radiotherapy for Lung Tumors (iSABR)
  Gensheimer, M. F., Gee, H. E., Von Eyben, R., Shirato, H., Taguchi, H., Wong, S., 鈥� Diehn, M. (2021). A Phase II Trial of Individualized Stereotactic Ablative Radiotherapy for Lung Tumors (iSABR). INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. ELSEVIER SCIENCE INC.
- Real-world response and outcomes in NSCLC patients with EGFR exon 20 insertion mutations.
  Ou, S.-H. I., Lin, H. M., Hong, J.-L., Yin, Y., Jin, S., Lin, J., 鈥� Neal, J. W. (2021). Real-world response and outcomes in NSCLC patients with EGFR exon 20 insertion mutations. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.
- CONTACT-01: A phase III, randomized study of atezolizumab plus cabozantinib versus docetaxel in patients with metastatic non-small cell lung cancer (mNSCLC) previously treated with PD-L1/PD-1 inhibitors and platinum-containing chemotherapy.
  Neal, J. W., Kundu, P., Tanaka, T., Enquist, I., Patel, S., Balestrini, A., 鈥� Kim, S.-W. (2021). CONTACT-01: A phase III, randomized study of atezolizumab plus cabozantinib versus docetaxel in patients with metastatic non-small cell lung cancer (mNSCLC) previously treated with PD-L1/PD-1 inhibitors and platinum-containing chemotherapy. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.
- Impact of Tumor Suppressor Gene Co-Mutations on Differential Response to EGFR TKI Therapy in EGFR L858R and Exon 19 Deletion Lung Cancer.
  Hellyer, J. A., White, M. N., Gardner, R. M., Cunanan, K., Padda, S. K., Das, M., 鈥� Wakelee, H. A. (2021). Impact of Tumor Suppressor Gene Co-Mutations on Differential Response to EGFR TKI Therapy in EGFR L858R and Exon 19 Deletion Lung Cancer. Clinical Lung Cancer.
- Radiological tumor classification across imaging modality and histology.
  Wu, J., Li, C., Gensheimer, M., Padda, S., Kato, F., Shirato, H., 鈥� Li, R. (2021). Radiological tumor classification across imaging modality and histology. Nature Machine Intelligence, 3, 787鈥�798.
- Chemotherapy Plus Immunotherapy Versus Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone in EGFR-Mutant NSCLC After Progression on Osimertinib.
  White, M. N., Piper-Vallillo, A. J., Gardner, R. M., Cunanan, K., Neal, J. W., Das, M., 鈥� Wakelee, H. A. (2021). Chemotherapy Plus Immunotherapy Versus Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone in EGFR-Mutant NSCLC After Progression on Osimertinib. Clinical Lung Cancer.
- The Survival Impact of Second Primary Lung Cancer in Patients with Lung Cancer.
  Choi, E., Luo, S. J., Aredo, J. V., Backhus, L. M., Wilkens, L. R., Su, C. C., 鈥� Han, S. S. (2021). The Survival Impact of Second Primary Lung Cancer in Patients with Lung Cancer. Journal of the National Cancer Institute.
- Afatinib After Progression on Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer.
  Aredo, J. V., Wakelee, H. A., Neal, J. W., & Padda, S. K. (1800). Afatinib After Progression on Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer. Cancer Treatment and Research Communications, 30, 100497.
- Computational Biological Modeling Identifies PD-(L)1 Immunotherapy Sensitivity Among Molecular Subgroups of KRAS-Mutated Non-Small-Cell Lung Cancer.
  Padda, S. K., Aredo, J. V., Vali, S., Singh, N. K., Vasista, S. M., Kumar, A., 鈥� Wakelee, H. A. (2021). Computational Biological Modeling Identifies PD-(L)1 Immunotherapy Sensitivity Among Molecular Subgroups of KRAS-Mutated Non-Small-Cell Lung Cancer. JCO Precision Oncology, 5, 153鈥�162.
- EGFR Genotyping of Matched Urine, Plasma, and Tumor Tissue in Patients With Non-Small-Cell Lung Cancer Treated With Rociletinib, an EGFR Tyrosine Kinase Inhibitor.
  Goldman, J. W., Karlovich, C., Sequist, L. V., Melnikova, V., Franovic, A., Gadgeel, S. M., 鈥� Wakelee, H. A. (2018). EGFR Genotyping of Matched Urine, Plasma, and Tumor Tissue in Patients With Non-Small-Cell Lung Cancer Treated With Rociletinib, an EGFR Tyrosine Kinase Inhibitor. JCO Precision Oncology, 2, 1鈥�13.
- Risk factors for immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer
  Chao, Y., Zhou, J., Hsu, S., Ding, N., Li, J., Zhang, Y., 鈥� Hu, J. (2022). Risk factors for immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer. TRANSLATIONAL LUNG CANCER RESEARCH.
- ANtiangiogenic Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer: ANSELMA.
  Remon, J., Lacas, B., Herbst, R., Reck, M., Garon, E. B., Scagliotti, G. V., 鈥� Besse, B. (2022). ANtiangiogenic Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer: ANSELMA. European Journal of Cancer (Oxford, England : 1990), 166, 112鈥�125.
- Risk factors for immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer.
  Chao, Y., Zhou, J., Hsu, S., Ding, N., Li, J., Zhang, Y., 鈥� Hu, J. (2022). Risk factors for immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer. Translational Lung Cancer Research, 11(2), 295鈥�306.
- Targeting Acquired and Intrinsic Resistance Mechanisms in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer.
  Shah, M. P., & Neal, J. W. (2022). Targeting Acquired and Intrinsic Resistance Mechanisms in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer. Drugs.
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma.
  Govindan, R., Aggarwal, C., Antonia, S. J., Davies, M., Dubinett, S. M., Ferris, A., 鈥� Herbst, R. S. (2022). Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma. Journal for Immunotherapy of Cancer, 10(5).
- High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience.
  Piper-Vallillo, A. J., Rotow, J. K., Aredo, J. V., Shaverdashvili, K., Luo, J., Carlisle, J. W., 鈥� Piotrowska, Z. (2022). High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience. JTO Clinical and Research Reports, 3(6), 100328.
- Characterization of Metastatic Non-Small Cell Lung Cancer and Oligometastatic Incidence in an Era of Changing Treatment Paradigms.
  No, H. J., Raja, N., Von Eyben, R., Das, M., Roy, M., Myall, N., 鈥� Vitzthum, L. K. (2022). Characterization of Metastatic Non-Small Cell Lung Cancer and Oligometastatic Incidence in an Era of Changing Treatment Paradigms. International Journal of Radiation Oncology, Biology, Physics.
- Identification of Pathogenic Immune Cell Subsets Associated With Checkpoint Inhibitor-Induced Myocarditis.
  Zhu, H., Galdos, F. X., Lee, D., Waliany, S., Vivian Huang, Y., Ryan, J., 鈥� Wu, S. M. (2022). Identification of Pathogenic Immune Cell Subsets Associated With Checkpoint Inhibitor-Induced Myocarditis. Circulation, 101161CIRCULATIONAHA121056730.
- Characterization of ERBB2 (HER2) Alterations in Metastatic Non-small Cell Lung Cancer and Comparison of Outcomes of Different Trastuzumab-based Regimens.
  Waliany, S., Wakelee, H., Ramchandran, K., Das, M., Huang, J., Myall, N., 鈥� Neal, J. W. (2022). Characterization of ERBB2 (HER2) Alterations in Metastatic Non-small Cell Lung Cancer and Comparison of Outcomes of Different Trastuzumab-based Regimens. Clinical Lung Cancer.
- Systematic pan-cancer analysis of mutation-treatment interactions using large real-world clinicogenomics data.
  Liu, R., Rizzo, S., Waliany, S., Garmhausen, M. R., Pal, N., Huang, Z., 鈥� Zou, J. (2022). Systematic pan-cancer analysis of mutation-treatment interactions using large real-world clinicogenomics data. Nature Medicine.
- Clinicopathological characteristics and prognostic significance of HDAC11 protein expression in non-small cell lung cancer: a retrospective study.
  Lu, D., Ma, Z., Huang, D., Zhang, J., Li, J., Zhi, P., 鈥� Wang, J. (2022). Clinicopathological characteristics and prognostic significance of HDAC11 protein expression in non-small cell lung cancer: a retrospective study. Translational Lung Cancer Research, 11(6), 1119鈥�1131.
- Isolated Nodal Recurrence After Definitive Stereotactic Ablative Radiotherapy for Non-Small Cell Lung Cancer.
  Devine, M., Merriott, D. J., No, H. J., Lau, B., Say, C., Yoo, C., 鈥� Vitzthum, L. K. (2022). Isolated Nodal Recurrence After Definitive Stereotactic Ablative Radiotherapy for Non-Small Cell Lung Cancer. Practical Radiation Oncology.
- Efficacy and safety of first-line anlotinib-based combinations for advanced non-small cell lung cancer: a three-armed prospective study.
  Chu, T., Zhang, W., Zhang, B., Zhong, R., Zhang, X., Gu, A., 鈥� Han, B. (2022). Efficacy and safety of first-line anlotinib-based combinations for advanced non-small cell lung cancer: a three-armed prospective study. Translational Lung Cancer Research, 11(7), 1394鈥�1404.
- Cabozantinib after prior checkpoint inhibitor therapy in patients with solid tumors: A systematic literature review.
  Graham, J., Vogel, A., Cheng, A.-L. L., Bjarnason, G. A., & Neal, J. W. (2022). Cabozantinib after prior checkpoint inhibitor therapy in patients with solid tumors: A systematic literature review. Cancer Treatment Reviews, 110, 102453.
- Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non-Small-Cell Lung Cancer Previously Treated With Immunotherapy-Lung-MAP S1800A (vol 40, pg 2295, 2022)
  Reckamp, K. L., Redman, M. W., Dragnev, K. H., Minichiello, K., Villaruz, L. C., Faller, B., 鈥� Herbst, R. S. (2022). Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non-Small-Cell Lung Cancer Previously Treated With Immunotherapy-Lung-MAP S1800A (vol 40, pg 2295, 2022). JOURNAL OF CLINICAL ONCOLOGY, 40(25), 3002.
- Predictive Model to Guide Brain Magnetic Resonance Imaging Surveillance in Patients With Metastatic Lung Cancer: Impact on Real-World Outcomes.
  Wu, J., Ding, V., Luo, S., Choi, E., Hellyer, J., Myall, N., 鈥� Han, S. S. (2022). Predictive Model to Guide Brain Magnetic Resonance Imaging Surveillance in Patients With Metastatic Lung Cancer: Impact on Real-World Outcomes. JCO Precision Oncology, 6, e2200220.
- Local control of brain metastases with osimertinib alone in patients with EGFR-mutant non-small cell lung cancer.
  Hui, C., Qu, V., Wang, J.-Y. Y., von Eyben, R., Chang, Y.-C. C., Chiang, P.-L. L., 鈥� Pollom, E. (2022). Local control of brain metastases with osimertinib alone in patients with EGFR-mutant non-small cell lung cancer. Journal of Neuro-Oncology.
- Phenotyping Malignant Pleural Effusions with Mass Cytometry: Evidence of EMT and MET States in Late-Stage NSCLC
  Karacosta, L. G., Pancirer, D., Preiss, J., Shrager, J. B., Sung, A. W., Neal, J. W., 鈥� Plevritis, S. K. (2022). Phenotyping Malignant Pleural Effusions with Mass Cytometry: Evidence of EMT and MET States in Late-Stage NSCLC. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC.
- Cabozantinib Plus Atezolizumab in First or Second-Line Advanced NSCLC and Previously-Treated EGFR Mutant Advanced NSCLC
  Neal, J. W., Lim, F. L., Aix, S. P., Viteri, S., Santoro, A., Spencer, K., 鈥� Felip, E. (2022). Cabozantinib Plus Atezolizumab in First or Second-Line Advanced NSCLC and Previously-Treated EGFR Mutant Advanced NSCLC. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC.
- Matching-adjusted indirect comparison (MAIC) of mobocertinib versus amivantamab in patients with non-small cell lung cancer (NSCLC) with EGFR exon 20 insertions (ex20ins).
  Ou, S.-H. I., Prawitz, T., Lin, H. M., Hong, J.-L., Tan, M., Proskorovsky, I., 鈥� Neal, J. W. (2022). Matching-adjusted indirect comparison (MAIC) of mobocertinib versus amivantamab in patients with non-small cell lung cancer (NSCLC) with EGFR exon 20 insertions (ex20ins). JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.
- Representativeness of patients enrolled in the Lung Cancer Master Protocol (Lung-MAP).
  Vaidya, R., Unger, J. M., Qian, L., Minichiello, K., Herbst, R. S., Gandara, D. R., 鈥� Redman, M. W. (2022). Representativeness of patients enrolled in the Lung Cancer Master Protocol (Lung-MAP). JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.
- Cabozantinib (C) plus atezolizumab (A) or C alone in patients (pts) with advanced non-small cell lung cancer (aNSCLC) previously treated with an immune checkpoint inhibitor (ICI): Results from Cohorts 7 and 20 of the COSMIC-021 study.
  Neal, J. W., Santoro, A., Viteri, S., Aix, S. P., Fang, B., Lim, F. L., 鈥� Felip, E. (2022). Cabozantinib (C) plus atezolizumab (A) or C alone in patients (pts) with advanced non-small cell lung cancer (aNSCLC) previously treated with an immune checkpoint inhibitor (ICI): Results from Cohorts 7 and 20 of the COSMIC-021 study. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.
- Phase 2 EVOKE-02 Study of Sacituzumab Govitecan and Pembrolizumab +/- Platinum in First-Line Metastatic NSCLC
  Reck, M., Liu, S. V., Owen, S. P., Garon, E. B., Neal, J. W., Vicente, D., 鈥� Mok, T. S. K. (2022). Phase 2 EVOKE-02 Study of Sacituzumab Govitecan and Pembrolizumab +/- Platinum in First-Line Metastatic NSCLC. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC.
- EVOKE-02: A phase 2 study of sacituzumab govitecan (SG) plus pembrolizumab (pembro) with or without platinum chemotherapy in first-line metastatic non-small cell lung cancer (NSCLC).
  Garon, E. B., Liu, S. V., Owen, S. P., Reck, M., Neal, J. W., Vicente, D., 鈥� Mok, T. S. K. (2022). EVOKE-02: A phase 2 study of sacituzumab govitecan (SG) plus pembrolizumab (pembro) with or without platinum chemotherapy in first-line metastatic non-small cell lung cancer (NSCLC). JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.
- Efficacy of osimertinib in patients with EGFR mutant lung cancer harboring the uncommon exon 19 deletion, L747_A750>P.
  Grant, M. J., Aredo, J. V., Starrett, J., Wurtz, A., Piotrowska, Z., Piper-Vallillo, A., 鈥� Goldberg, S. B. (2022). Efficacy of osimertinib in patients with EGFR mutant lung cancer harboring the uncommon exon 19 deletion, L747_A750>P. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.
- Neighborhood socioeconomic disadvantage, tobacco use, and cessation indicators among adults with cancer in the United States: Results from 10 ECOG-ACRIN trials.
  Walter, A. W., Lee, J.-W., Gareen, I. F., Kircher, S. M., Herman, B. A., Streck, J. M., 鈥� Park, E. R. (2022). Neighborhood socioeconomic disadvantage, tobacco use, and cessation indicators among adults with cancer in the United States: Results from 10 ECOG-ACRIN trials. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.
- Use of Machine Learning and Lay Care Coaches to Increase Advance Care Planning Conversations for Patients With Metastatic Cancer.
  Gensheimer, M. F., Gupta, D., Patel, M. I., Fardeen, T., Hildebrand, R., Teuteberg, W., 鈥� Ramchandran, K. (2022). Use of Machine Learning and Lay Care Coaches to Increase Advance Care Planning Conversations for Patients With Metastatic Cancer. JCO Oncology Practice, OP2200128.
- Induction EGFR tyrosine kinase inhibitors prior to definitive chemoradiotherapy in unresectable stage III EGFR-mutated non-small cell lung cancer.
  Aredo, J. V., Wakelee, H. A., Hui, A. B.-Y., Padda, S. K., Joshi, N. D., Guo, H. H., 鈥� Neal, J. W. (2022). Induction EGFR tyrosine kinase inhibitors prior to definitive chemoradiotherapy in unresectable stage III EGFR-mutated non-small cell lung cancer. Cancer Treatment and Research Communications, 33, 100659.
- Feasibility of large scale distress screening at an academic center and associated network sites using an adapted patient-reported outcome instrument and reflexive suicide screening.
  Gupta, D. M., Savadamuthu, V., Qin, F. F., Roy, M., Herring, J. B., Robinson, A., 鈥� Ramchandran, K. (2022). Feasibility of large scale distress screening at an academic center and associated network sites using an adapted patient-reported outcome instrument and reflexive suicide screening. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.
- The Role of Single-Cell Profiling and Deep Immunophenotyping in Understanding Immune Therapy Cardiotoxicity
  Huang, Y. V., Waliany, S., Lee, D., Galdos, F. X., Witteles, R. M., Neal, J. W., 鈥� Zhu, H. (2022). The Role of Single-Cell Profiling and Deep Immunophenotyping in Understanding Immune Therapy Cardiotoxicity. JACC: CardioOncology, 4(5).
- The Role of Single-Cell Profiling and Deep Immunophenotyping in Understanding Immune Therapy Cardiotoxicity.
  Huang, Y. V., Waliany, S., Lee, D., Galdos, F. X., Witteles, R. M., Neal, J. W., 鈥� Zhu, H. (2022). The Role of Single-Cell Profiling and Deep Immunophenotyping in Understanding Immune Therapy Cardiotoxicity. JACC. CardioOncology, 4(5), 629鈥�634.
- Diagnosis and treatment of pericardial mesothelioma by mediastinal mass resection: a case report
  Liang, L., Zhang, X., Ke, X., Song, Y., Brcic, L., Neal, J. W., 鈥� Chen, C. (2022). Diagnosis and treatment of pericardial mesothelioma by mediastinal mass resection: a case report. ANNALS OF TRANSLATIONAL MEDICINE.
- Diagnosis and treatment of pericardial mesothelioma by mediastinal mass resection: a case report.
  Liang, L., Zhang, X., Ke, X., Song, Y., Brcic, L., Neal, J. W., 鈥� Chen, C. (2022). Diagnosis and treatment of pericardial mesothelioma by mediastinal mass resection: a case report. Annals of Translational Medicine, 10(24), 1407.
- Amivantamab in combination with lazertinib in patients with atypical epidermal growth factor receptor (EGFR) mutations excluding exon 20 insertion mutations: Initial results from CHRYSALIS-2
  Cho, B. C., Wang, Y., Li, Y., Wu, L., Besse, B., Marmarelis, M. E., 鈥� Tomasini, P. (2022). Amivantamab in combination with lazertinib in patients with atypical epidermal growth factor receptor (EGFR) mutations excluding exon 20 insertion mutations: Initial results from CHRYSALIS-2. ANNALS OF ONCOLOGY. ELSEVIER.
- Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter Study.
  Ji, J., Aredo, J. V., Piper-Vallillo, A., Huppert, L., Rotow, J. K., Husain, H., 鈥� Riess, J. W. (2023). Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter Study. JTO Clinical and Research Reports, 4(3), 100459.
- Pharmacovigilance Analysis of HeartFailure Associated With Anti-HER2 Monotherapies and Combination Regimens for Cancer.
  Waliany, S., Caswell-Jin, J., Riaz, F., Myall, N., Zhu, H., Witteles, R. M., & Neal, J. W. (2023). Pharmacovigilance Analysis of HeartFailure Associated With Anti-HER2 Monotherapies and Combination Regimens for Cancer. JACC. CardioOncology, 5(1), 85鈥�98.
- Efficacy of osimertinib in patients with lung cancer positive for uncommon EGFR exon 19 deletion mutations.
  Grant, M. J., Aredo, J. V., Starrett, J. H., Stockhammer, P., van Alderwerelt van Rosenburgh, I. K., Wurtz, A., 鈥� Goldberg, S. B. (2023). Efficacy of osimertinib in patients with lung cancer positive for uncommon EGFR exon 19 deletion mutations. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research.
- Long term effect of radiotherapy on risk of second primary lung cancer and overall mortality among lung cancer patients
  Choi, E., Lam, V. T., Aredo, J. A., Kumar, A. V., Wampfler, J., Wu, J. T., 鈥� Han, S. S. (2022). Long term effect of radiotherapy on risk of second primary lung cancer and overall mortality among lung cancer patients. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH.
- Brief Report: High Levels of CD47 Expression in Thymic Epithelial Tumors.
  Sun, T. Y., Nguyen, B., Chen, S. B., Natkunam, Y., Padda, S., van de Rijn, M., 鈥� Riess, J. W. (2023). Brief Report: High Levels of CD47 Expression in Thymic Epithelial Tumors. JTO Clinical and Research Reports, 4(4), 100498.
- Real-world risk of brain metastases in stage III non-small cell lung cancer in the era of PET and MRI staging.
  Alhusaini, S., Lanman, T. A., Ko, R. B., Therkelsen, K. E., Eyben, R. V., Diehn, M., 鈥� Nagpal, S. (2023). Real-world risk of brain metastases in stage III non-small cell lung cancer in the era of PET and MRI staging. Frontiers in Oncology, 13, 1139940.
- Comparative effectiveness of mobocertinib and standard of care in patients with NSCLC with EGFR exon 20 insertion mutations: An indirect comparison.
  Ou, S.-H. I., Lin, H. M., Hong, J.-L. L., Yin, Y., Jin, S., Lin, J., 鈥� Neal, J. W. (2023). Comparative effectiveness of mobocertinib and standard of care in patients with NSCLC with EGFR exon 20 insertion mutations: An indirect comparison. Lung Cancer (Amsterdam, Netherlands), 179, 107186.
- Pulmonary Hemorrhage in Patients Treated with Thoracic Stereotactic Ablative Radiotherapy and Anti-Angiogenic Agents.
  Lau, B., Wu, Y. F., No, H. J., Ko, R. B., Devine, M., Das, M. S., 鈥� Vitzthum, L. K. (2023). Pulmonary Hemorrhage in Patients Treated with Thoracic Stereotactic Ablative Radiotherapy and Anti-Angiogenic Agents. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer.
- PROVIDER INSIGHTS ON MANAGING PATIENTS ON IMMUNOTHERAPY, BARRIERS TO CLINICAL TRIALS, AND BIOMARKER TESTING PREFERENCES
  Ackbarali, T., Neal, J., Janjigian, Y., & Overman, M. (2022). PROVIDER INSIGHTS ON MANAGING PATIENTS ON IMMUNOTHERAPY, BARRIERS TO CLINICAL TRIALS, AND BIOMARKER TESTING PREFERENCES. JOURNAL FOR IMMUNOTHERAPY OF CANCER. BMJ PUBLISHING GROUP.
- Dissecting metastasis using preclinical models and methods.
  Hebert, J. D., Neal, J. W., & Winslow, M. M. (2023). Dissecting metastasis using preclinical models and methods. Nature Reviews. Cancer.
- Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study.
  Saad, M. B., Hong, L., Aminu, M., Vokes, N. I., Chen, P., Salehjahromi, M., 鈥� Wu, J. (2023). Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study. The Lancet. Digital Health.
- Second Primary Lung Cancer among Lung Cancer Survivors Who Never Smoked
  Choi, E., Su, C., Wu, J., Aredo, J., Neal, J., Leung, A., 鈥� Han, S. (2023). Second Primary Lung Cancer among Lung Cancer Survivors Who Never Smoked. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC.
- CONTACT-01: Efficacy and safety from a phase III study of atezolizumab (atezo) plus cabozantinib (cabo) vs docetaxel (doc) monotherapy in patients (pts) with metastatic NSCLC (mNSCLC) previously treated with checkpoint inhibitors and chemotherapy
  Neal, J., Pavlakis, N., Kim, S.-W., Goto, Y., Lim, S. M., Mountzios, G., 鈥� Newsom-Davis, T. (2023). CONTACT-01: Efficacy and safety from a phase III study of atezolizumab (atezo) plus cabozantinib (cabo) vs docetaxel (doc) monotherapy in patients (pts) with metastatic NSCLC (mNSCLC) previously treated with checkpoint inhibitors and chemotherapy. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC.
- Early-Stage Lung Cancer: Using Circulating Tumor DNA to Get Personal.
  Bestvina, C. M., Garassino, M. C., Neal, J. W., Wakelee, H. A., Diehn, M., & Vokes, E. E. (2023). Early-Stage Lung Cancer: Using Circulating Tumor DNA to Get Personal. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO2300258.
- Cigarette and alternative tobacco product use among adult cancer survivors enrolled in 9 ECOG-ACRIN clinical trials.
  Streck, J. M., Lee, J.-W., Walter, A. W., Rosen, R. L., Gareen, I. F., Kircher, S. M., 鈥� Ostroff, J. S. (2023). Cigarette and alternative tobacco product use among adult cancer survivors enrolled in 9 ECOG-ACRIN clinical trials. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology.
- Phase II Randomized Trial of Carboplatin, Pemetrexed, and Bevacizumab With and Without Atezolizumab in Stage IV Nonsquamous Non-Small-Cell Lung Cancer Patients Who Harbor a Sensitizing EGFR Mutation or Have Never Smoked.
  Bodor, J. N., Patel, J. D., Wakelee, H. A., Levy, B. P., Borghaei, H., Pellini, B., 鈥� Treat, J. (2023). Phase II Randomized Trial of Carboplatin, Pemetrexed, and Bevacizumab With and Without Atezolizumab in Stage IV Nonsquamous Non-Small-Cell Lung Cancer Patients Who Harbor a Sensitizing EGFR Mutation or Have Never Smoked. Clinical Lung Cancer.
- Adjuvant osimertinib for resected EGFR-mutated non-small cell lung cancer: a game-changer?
  Patel, S. R., & Neal, J. W. (2023). Adjuvant osimertinib for resected EGFR-mutated non-small cell lung cancer: a game-changer? TRANSLATIONAL LUNG CANCER RESEARCH.
- Adjuvant osimertinib for resected EGFR-mutated non-small cell lung cancer: a game-changer?
  Patel, S. R., & Neal, J. W. (2023). Adjuvant osimertinib for resected EGFR-mutated non-small cell lung cancer: a game-changer? Translational Lung Cancer Research, 12(7), 1631鈥�1635.
- Representativeness of Patients Enrolled in the Lung Cancer Master Protocol (Lung-MAP).
  Vaidya, R., Unger, J. M., Qian, L., Minichiello, K., Herbst, R. S., Gandara, D. R., 鈥� Redman, M. W. (2023). Representativeness of Patients Enrolled in the Lung Cancer Master Protocol (Lung-MAP). JCO Precision Oncology, 7, e2300218.
- Individualized Stereotactic Ablative Radiotherapy for Lung Tumors: The iSABR Phase 2 Nonrandomized Controlled Trial.
  Gensheimer, M. F., Gee, H., Shirato, H., Taguchi, H., Snyder, J. M., Chin, A. L., 鈥� Diehn, M. (2023). Individualized Stereotactic Ablative Radiotherapy for Lung Tumors: The iSABR Phase 2 Nonrandomized Controlled Trial. JAMA Oncology.
- Real-World Response and Outcomes in Patients With NSCLC With EGFR Exon 20 Insertion Mutations.
  Ou, S.-H. I., Lin, H. M., Hong, J.-L. L., Yin, Y., Jin, S., Lin, J., 鈥� Neal, J. W. (2023). Real-World Response and Outcomes in Patients With NSCLC With EGFR Exon 20 Insertion Mutations. JTO Clinical and Research Reports, 4(10), 100558.
- Improved Survival Outcomes in Patients With MET-Dysregulated Advanced NSCLC Treated With MET Inhibitors: Results of a Multinational Retrospective Chart Review.
  Wolf, J., Souquet, P.-J. J., Goto, K., Cortot, A., Baik, C., Heist, R., 鈥� Awad, M. M. (2023). Improved Survival Outcomes in Patients With MET-Dysregulated Advanced NSCLC Treated With MET Inhibitors: Results of a Multinational Retrospective Chart Review. Clinical Lung Cancer.
- Overall Survival Among Patients With De Novo Stage IV Metastatic and Distant Metastatic Recurrent Non-Small Cell Lung Cancer.
  Su, C. C., Wu, J. T., Choi, E., Myall, N. J., Neal, J. W., Kurian, A. W., 鈥� Han, S. S. (2023). Overall Survival Among Patients With De Novo Stage IV Metastatic and Distant Metastatic Recurrent Non-Small Cell Lung Cancer. JAMA Network Open, 6(9), e2335813.
- EGFR tyrosine kinase inhibitors (TKIs) versus durvalumab (durva) following concurrent chemoradiation (CRT) in unresectable EGFR-mutant non-small-cell lung cancer (NSCLC)
  Nassar, A., Adib, E., Feng, J., Aredo, J. V., Parikh, K., Harris, J. P., 鈥� Kim, S. Y. (2023). EGFR tyrosine kinase inhibitors (TKIs) versus durvalumab (durva) following concurrent chemoradiation (CRT) in unresectable EGFR-mutant non-small-cell lung cancer (NSCLC). JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.
- The effect of ctDNA tumor fraction (TF) on overall survival and concordance between tissue genomics and ctDNA in Lung-MAP
  Mack, P. C., Redman, M. W., Kozono, D. E., Callis, S., Tukachinsky, H., Tolba, K. A., 鈥� Gandara, D. R. (2023). The effect of ctDNA tumor fraction (TF) on overall survival and concordance between tissue genomics and ctDNA in Lung-MAP. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.
- Risk factors for venous thromboembolism (VTE) among patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) receiving amivantamab plus lazertinib versus either agent alone.
  Girard, N., Cho, B. C., Spira, A. I., Shu, C. A., Sanborn, R. E., Neal, J. W., 鈥� Hayashi, H. (2023). Risk factors for venous thromboembolism (VTE) among patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) receiving amivantamab plus lazertinib versus either agent alone. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.
- Mobocertinib efficacy in patients with NSCLC and EGFR exon 20 insertion mutations (ex20ins) identified by next-generation sequencing (NGS) of circulating tumor DNA (ctDNA)
  Neal, J. W., Li, Y., Yu, Z., Fram, R. J., Danes, C., Vincent, S., & Piotrowska, Z. (2023). Mobocertinib efficacy in patients with NSCLC and EGFR exon 20 insertion mutations (ex20ins) identified by next-generation sequencing (NGS) of circulating tumor DNA (ctDNA). JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.
- ECOG-ACRIN LUNG-MAP S1900E substudy: A phase II study of sotorasib in participants (Pts) with previously treated stage IV or recurrent KRAS G12C mutant non-squamous (Non-sq) non-small cell lung cancer (NSCLC).
  Padda, S. K., Redman, M. W., Gerber, D. E., Stinchcombe, T., Waqar, S. N., Leal, T., 鈥� Neal, J. W. (2023). ECOG-ACRIN LUNG-MAP S1900E substudy: A phase II study of sotorasib in participants (Pts) with previously treated stage IV or recurrent KRAS G12C mutant non-squamous (Non-sq) non-small cell lung cancer (NSCLC). JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.
- CNS Control after First-Line Osimertinib in Patients with Metastatic EGFR-Mutant NSCLC.
  Hui, C., Wakelee, H. A., Neal, J. W., Ramchandran, K. J., Das, M., Nagpal, S., 鈥� Myall, N. (2023). CNS Control after First-Line Osimertinib in Patients with Metastatic EGFR-Mutant NSCLC. International Journal of Radiation Oncology, Biology, Physics, 117(2S), e110.
- The effect of neighborhood socioeconomic disadvantage on smoking status, quit attempts, and receipt of cessation support among adults with cancer: Results from nine ECOG-ACRIN Cancer Research Group (EA) trials.
  Walter, A. W., Lee, J.-W. W., Streck, J. M., Gareen, I. F., Herman, B. A., Kircher, S. M., 鈥� Park, E. R. (2023). The effect of neighborhood socioeconomic disadvantage on smoking status, quit attempts, and receipt of cessation support among adults with cancer: Results from nine ECOG-ACRIN Cancer Research Group (EA) trials. Cancer.
- Risk model-based management for second primary lung cancer among lung cancer survivors through a validated risk prediction model.
  Choi, E., Luo, S. J., Ding, V. Y., Wu, J. T., Kumar, A. V., Wampfler, J., 鈥� Han, S. S. (2023). Risk model-based management for second primary lung cancer among lung cancer survivors through a validated risk prediction model. Cancer.
- Osimertinib-Associated Cardiomyopathy In Patients With Non-Small Cell Lung Cancer: A Case Series
  Franquiz, M., Waliany, S., Xu, A., Hnatiuk, A., Wu, S., Cheng, P., 鈥� Zhu, H. (2023). Osimertinib-Associated Cardiomyopathy In Patients With Non-Small Cell Lung Cancer: A Case Series. JACC: CardioOncology, 839鈥�841.
- Risk Model-Based Lung Cancer Screening and Racial and Ethnic Disparities in the US.
  Choi, E., Ding, V. Y., Luo, S. J., Ten Haaf, K., Wu, J. T., Aredo, J. V., 鈥� Han, S. S. (2023). Risk Model-Based Lung Cancer Screening and Racial and Ethnic Disparities in the US. JAMA Oncology.
- Second Primary Lung Cancer Among Lung Cancer Survivors Who Never Smoked.
  Choi, E., Su, C. C., Wu, J. T., Aredo, J. V., Neal, J. W., Leung, A. N., 鈥� Han, S. S. (2023). Second Primary Lung Cancer Among Lung Cancer Survivors Who Never Smoked. JAMA Network Open, 6(11), e2343278.
- Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer: Protocol for a Bayesian Optimal Phase I/II Trial.
  Hui, C., Brown, E., Wong, S., Das, M., Wakelee, H., Neal, J., 鈥� Vitzthum, L. K. (2023). Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer: Protocol for a Bayesian Optimal Phase I/II Trial. Clinical Lung Cancer.
- Phenotyping EMT and MET cellular states in lung cancer patient liquid biopsies at a personalized level using mass cytometry.
  Karacosta, L. G., Pancirer, D., Preiss, J. S., Benson, J. A., Trope, W., Shrager, J. B., 鈥� Plevritis, S. K. (2023). Phenotyping EMT and MET cellular states in lung cancer patient liquid biopsies at a personalized level using mass cytometry. Scientific Reports, 13(1), 21781.
- Patient Selection and Outcomes for Hypofractionated Accelerated Radiation and Concurrent Chemotherapy for Non-Small-Cell Lung Cancer.
  Hui, C., Marquez, C., Lau, B., Das, M., Myall, N. J., Roy, M., 鈥� Vitzthum, L. K. (2023). Patient Selection and Outcomes for Hypofractionated Accelerated Radiation and Concurrent Chemotherapy for Non-Small-Cell Lung Cancer. Clinical Lung Cancer.
- Immunotherapy-Associated Atherosclerosis: A Comprehensive Review of Recent Findings and Implications for Future Research
  Chan, A., Torelli, S., Cheng, E., Batchelder, R., Waliany, S., Neal, J., 鈥� Zhu, H. (2023). Immunotherapy-Associated Atherosclerosis: A Comprehensive Review of Recent Findings and Implications for Future Research. Current Treatment Options in Cardiovascular Medicine.
- Efficacy of Mobocertinib and Amivantamab in Patients With Advanced Non-Small Cell Lung Cancer With EGFR Exon 20 Insertions Previously Treated With Platinum-Based Chemotherapy: An Indirect Treatment Comparison.
  Ou, S.-H. I., Prawitz, T., Lin, H. M., Hong, J.-L. L., Tan, M., Proskorovsky, I., 鈥� Neal, J. W. (2023). Efficacy of Mobocertinib and Amivantamab in Patients With Advanced Non-Small Cell Lung Cancer With EGFR Exon 20 Insertions Previously Treated With Platinum-Based Chemotherapy: An Indirect Treatment Comparison. Clinical Lung Cancer.
- Immunotherapy-Associated Atherosclerosis: A Comprehensive Review of Recent Findings and Implications for Future Research.
  Chan, A., Torelli, S., Cheng, E., Batchelder, R., Waliany, S., Neal, J., 鈥� Zhu, H. (2023). Immunotherapy-Associated Atherosclerosis: A Comprehensive Review of Recent Findings and Implications for Future Research. Current Treatment Options in Cardiovascular Medicine, 25(12), 715鈥�735.
- Molecular Distribution of Patients with Non-Small Cell Lung Cancer Eligible for Lung Cancer Screening
  Aredo, J. V., Neal, J. W., Kunder, C. A., Ramchandran, K. J., Das, M. S., Myall, N. J., 鈥� Wakelee, H. A. (2023). Molecular Distribution of Patients with Non-Small Cell Lung Cancer Eligible for Lung Cancer Screening. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC.
- Demographic and Genomic Characteristics of Non-Small Cell Lung Cancer Patients with ARID1A Alterations
  Al-Obeidi, E., Williams, A., Burkert, N., Pepin, K., Hicks, J. K., Gray, J. E., 鈥� Gandara, D. (2023). Demographic and Genomic Characteristics of Non-Small Cell Lung Cancer Patients with ARID1A Alterations. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC.
- Consolidation Osimertinib versus Durvalumab versus Observation following Concurrent Chemoradiation in Unresectable EGFR-Mutant Non-Small-Cell Lung Cancer: A Multicenter Retrospective Cohort Study.
  Nassar, A. H., Kim, S. Y., Aredo, J. V., Feng, J., Shepherd, F., Xu, C., 鈥� Goldberg, S. B. (2024). Consolidation Osimertinib versus Durvalumab versus Observation following Concurrent Chemoradiation in Unresectable EGFR-Mutant Non-Small-Cell Lung Cancer: A Multicenter Retrospective Cohort Study. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer.
- HER2-Mutant Advanced and/or Metastatic Non-Small-Cell Lung Cancer: A US Electronic Health Records Database Analysis of Clinical Characteristics, Treatment Practice Patterns, and Outcomes.
  Waliany, S., Neal, J. W., Engel-Nitz, N., Lam, C., Lin, F., Park, L., 鈥� Nagasaka, M. (2024). HER2-Mutant Advanced and/or Metastatic Non-Small-Cell Lung Cancer: A US Electronic Health Records Database Analysis of Clinical Characteristics, Treatment Practice Patterns, and Outcomes. Clinical Lung Cancer.
- Systematic analysis of off-label and off-guideline cancer therapy usage in a real-world cohort of 165,912US patients.
  Liu, R., Wang, L., Rizzo, S., Garmhausen, M. R., Pal, N., Waliany, S., 鈥� Zou, J. (2024). Systematic analysis of off-label and off-guideline cancer therapy usage in a real-world cohort of 165,912US patients. Cell Reports. Medicine, 101444.
- CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non-Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy.
  Neal, J., Pavlakis, N., Kim, S.-W. W., Goto, Y., Lim, S. M., Mountzios, G., 鈥� Newsom-Davis, T. (2024). CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non-Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO2302166.
- A process to reanalyze clinical DNA sequencing data for biomarker matching in the Lung-MAP Master Protocol.
  Neal, J. W., Minichiello, K., Brennick, R., Huang, R. S., Hiemenz, M. C., Amler, C., 鈥� Kozono, D. E. (2024). A process to reanalyze clinical DNA sequencing data for biomarker matching in the Lung-MAP Master Protocol. The Oncologist.
- Molecular Characteristics and Pretreatment Neutrophil-to-Lymphocyte Ratio as Predictors of Durable Clinical Benefit from Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer.
  Shah, A. T., Blanchard, I., Padda, S. K., Wakelee, H. A., & Neal, J. W. (2024). Molecular Characteristics and Pretreatment Neutrophil-to-Lymphocyte Ratio as Predictors of Durable Clinical Benefit from Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer. Clinical Lung Cancer.
- Efficacy and safety of sintilimab in combination with chemotherapy for recurrent extensive-stage small cell lung cancer: a real-world retrospective study.
  Wang, J., Liang, S., Xu, L., Kong, Y., Seki, N., Ganti, A. K., 鈥� Chen, B. (2024). Efficacy and safety of sintilimab in combination with chemotherapy for recurrent extensive-stage small cell lung cancer: a real-world retrospective study. Journal of Thoracic Disease, 16(6), 3897鈥�3908.
- Association of napsin A-specific T cell clonotypes with durable clinical benefit to immunotherapy in patients with metastatic NSCLC
  Miller, N. J., Baik, C. S., Neal, J. W., Houghton, A. M. G., Nair, V. S., Santana-Davila, R., 鈥� Tseng, D. (2024). Association of napsin A-specific T cell clonotypes with durable clinical benefit to immunotherapy in patients with metastatic NSCLC. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.
- Global retrospective study comparing consolidation ALK tyrosine kinase inhibitors (TKI) to durvalumab (durva) or observation (obs) after chemoradiation (CRT) in unresectable locally-advanced ALK plus non-small cell lung cancer (NSCLC)
  Jayakrishnan, R., Nassar, A., Shepherd, F. A., Lin, J. J., Lin, S. H., Shakya, P., 鈥� Kim, S. Y. (2024). Global retrospective study comparing consolidation ALK tyrosine kinase inhibitors (TKI) to durvalumab (durva) or observation (obs) after chemoradiation (CRT) in unresectable locally-advanced ALK plus non-small cell lung cancer (NSCLC). JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.
- Sacituzumab govitecan (SG) plus pembrolizumab (pembro) in first-line (1L) metastatic non-small cell lung cancer (mNSCLC) with PD-L1 = 50%: Cohort A of EVOKE-02
  Patel, J. D., Cho, B. C., Cobo, M., Cabanillas, R. R., Vicente, D., Pradera, J. F., 鈥� Reck, M. (2024). Sacituzumab govitecan (SG) plus pembrolizumab (pembro) in first-line (1L) metastatic non-small cell lung cancer (mNSCLC) with PD-L1 = 50%: Cohort A of EVOKE-02. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.
- Amivantamab plus lazertinib in atypical <i>EGFR</i>-mutated advanced non-small cell lung cancer (NSCLC): Results from CHRYSALIS-2
  Cho, B. C., Wang, Y., Felip, E., Cui, J., Spira, A. I., Neal, J. W., 鈥� Tomasini, P. (2024). Amivantamab plus lazertinib in atypical EGFR-mutated advanced non-small cell lung cancer (NSCLC): Results from CHRYSALIS-2. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.
- Racial and Ethnic Differences in Second Primary Lung Cancer Risk among Lung Cancer Survivors.
  Choi, E., Hua, Y., Su, C. C., Wu, J. T., Neal, J. W., Leung, A. N., 鈥� Han, S. S. (2024). Racial and Ethnic Differences in Second Primary Lung Cancer Risk among Lung Cancer Survivors. JNCI Cancer Spectrum.
- Consolidation ALK Tyrosine Kinase Inhibitors versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK+ Non-Small Cell Lung Cancer.
  Nassar, A. H., Jayakrishnan, R., Feng, J., Shepherd, F., Adib, E., Cheung, J. M., 鈥� Kim, S. Y. (2024). Consolidation ALK Tyrosine Kinase Inhibitors versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK+ Non-Small Cell Lung Cancer. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer.
- Cabozantinib Plus Atezolizumab or Cabozantinib Alone in Patients With Advanced NSCLC Previously Treated With an Immune Checkpoint Inhibitor: Results From the Phase 1b COSMIC-021 Study.
  Neal, J. W., Santoro, A., Gonzalez-Cao, M., Lim, F. L., Fang, B., Gentzler, R. D., 鈥� Felip, E. (2024). Cabozantinib Plus Atezolizumab or Cabozantinib Alone in Patients With Advanced NSCLC Previously Treated With an Immune Checkpoint Inhibitor: Results From the Phase 1b COSMIC-021 Study. JTO Clinical and Research Reports, 5(10), 100666.
- Smoking and the Risk of Second Primary Lung Cancer Among Breast Cancer Survivors from the Population-Based UK Biobank Study.
  Graber-Naidich, A., Choi, E., Wu, J. T., Ellis-Caleo, T. J., Neal, J., Wakelee, H. A., 鈥� Han, S. S. (2024). Smoking and the Risk of Second Primary Lung Cancer Among Breast Cancer Survivors from the Population-Based UK Biobank Study. Clinical Lung Cancer.
- Impact of Troponin Monitoring on Cardiac Outcomes in Patients Receiving Immune Checkpoint Inhibitors
  Ivanovic, M., Chan, A., Franquiz, M., Xu, S., Lee, C., Fazal, M., 鈥� Zhu, H. (2023). Impact of Troponin Monitoring on Cardiac Outcomes in Patients Receiving Immune Checkpoint Inhibitors. ARTHRITIS & RHEUMATOLOGY. WILEY.
- A phase 2 single-arm trial of high-dose precision targeted radiotherapy added to immunotherapy for patients with metastatic non-small cell lung cancer.
  Gensheimer, M. F., Kotha, N. V., Vitzthum, L. K., Chin, A. L., Jackson, S., 't Erve, I. van, 鈥� Neal, J. W. (2024). A phase 2 single-arm trial of high-dose precision targeted radiotherapy added to immunotherapy for patients with metastatic non-small cell lung cancer. International Journal of Radiation Oncology, Biology, Physics.
- CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.
  Skoulidis, F., Araujo, H. A., Do, M. T., Qian, Y., Sun, X., Cobo, A. G., 鈥� Heymach, J. V. (2024). CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors. Nature.
- The Society of Thoracic Surgeons Expert Consensus on the Multidisciplinary Management and Resectability of Locally Advanced Non-Small Cell Lung Cancer.
  Kim, S. S., Cooke, D. T., Kidane, B., Tapias, L. F., Lazar, J. F., Awori Hayanga, J. W., 鈥� Shrager, J. B. (2024). The Society of Thoracic Surgeons Expert Consensus on the Multidisciplinary Management and Resectability of Locally Advanced Non-Small Cell Lung Cancer. The Annals of Thoracic Surgery.
- Consolidation osimertinib for unresectable stage III epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer: redefining standard care.
  Wu, F., Zeng, Y., & Neal, J. W. (2024). Consolidation osimertinib for unresectable stage III epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer: redefining standard care. Translational Lung Cancer Research, 13(10), 2853鈥�2855.
- Classes of Antineoplastic Agents Associated with Increased Risk of Cancer Therapy-associated Hypertension and Management Strategies.
  Sayegh, H., Zagouras, A., Neal, J. W., Witteles, R. M., Zhu, H., & Waliany, S. (2025). Classes of Antineoplastic Agents Associated with Increased Risk of Cancer Therapy-associated Hypertension and Management Strategies. Cardiology Clinics, 43(1), 31鈥�42.
- Safety and Tolerability of Letetresgene Autoleucel (Lete-cel; GSK3377794): Pilot Studies in Patients With Advanced Non-Small Cell Lung Cancer.
  Altan, M., Lopes, G., Hiltermann, T. J., Govindan, R., Villaruz, L. C., Calvo, E., 鈥� Schoenfeld, A. J. (2024). Safety and Tolerability of Letetresgene Autoleucel (Lete-cel; GSK3377794): Pilot Studies in Patients With Advanced Non-Small Cell Lung Cancer. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research.
- Phase II Trial of Regorafenib and Oral Methotrexate in Previously Treated Advanced <i>KRAS</i>-Mutant NSCLC
  Aredo, J., Wakelee, H. A., Ramchandran, K. J., Neal, J. W., Diehn, M., Hui, A. B.-Y., 鈥� Padda, S. K. (2024). Phase II Trial of Regorafenib and Oral Methotrexate in Previously Treated Advanced KRAS-Mutant NSCLC. JTO CLINICAL AND RESEARCH REPORTS, 5(12).
- Phase II Trial of Regorafenib and Oral Methotrexate in Previously Treated Advanced KRAS-Mutant NSCLC.
  Aredo, J. V., Wakelee, H. A., Ramchandran, K. J., Neal, J. W., Diehn, M., Hui, A. B.-Y., 鈥� Padda, S. K. (2024). Phase II Trial of Regorafenib and Oral Methotrexate in Previously Treated Advanced KRAS-Mutant NSCLC. JTO Clinical and Research Reports, 5(12), 100741.
- Smoking and the Risk of Second Primary Lung Cancer Among Breast Cancer Survivors from the Population-Based UK Biobank Study
  Graber-Naidich, A., Choi, E., Wu, J. T., Ellis-Caleo, T. J., Neal, J., Wakelee, H. A., 鈥� Han, S. S. (2024). Smoking and the Risk of Second Primary Lung Cancer Among Breast Cancer Survivors from the Population-Based UK Biobank Study. CLINICAL LUNG CANCER, 25(8).
- A Phase 2 Single-Arm Trial of High -Dose Radiotherapy Added to Immunotherapy for Patients with Metastatic Non Small Cell Lung Cancer
  Kotha, N. V., Vitzthum, L., Chin, A. L., Jackson, S., Pratapneni, A., Le-Budka, M. L., 鈥� Gensheimer, M. F. (2024). A Phase 2 Single-Arm Trial of High -Dose Radiotherapy Added to Immunotherapy for Patients with Metastatic Non Small Cell Lung Cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. ELSEVIER SCIENCE INC.
- Real-World Prevalence, Treatment Patterns, and Outcomes for Patients With HER2 (ERBB2)-Mutant Metastatic Non-Small Cell Lung Cancer, From a US-Based Clinico-Genomic Database.
  Waliany, S., Nagasaka, M., Park, L., Lam, C., Jiang, Z., Lin, F., & Neal, J. W. (2024). Real-World Prevalence, Treatment Patterns, and Outcomes for Patients With HER2 (ERBB2)-Mutant Metastatic Non-Small Cell Lung Cancer, From a US-Based Clinico-Genomic Database. Cancer Medicine, 13(24), e70272.
- Impact of Using Smoking Duration in Place of PackYears as Eligibility Criteria for Lung Cancer Screening to Reduce Racial and Ethnic Disparities
  Su, C. C., Ding, V. Y., Haaf, K. T., Wu, J. T., Freedman, N. D., Backhus, L. M., 鈥� Han, S. S. (2024). Impact of Using Smoking Duration in Place of PackYears as Eligibility Criteria for Lung Cancer Screening to Reduce Racial and Ethnic Disparities. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC.
- Effect of De Novo Co-Mutations on Clinical Outcomes in Patients Receiving First-Line Osimertinib for EGFRMutated NSCLC
  Sun, F., Banwait, M. K., Herrmann, A., Piotrowska, Z., Yun, K., Bazhenova, L. A., 鈥� Myall, N. J. (2024). Effect of De Novo Co-Mutations on Clinical Outcomes in Patients Receiving First-Line Osimertinib for EGFRMutated NSCLC. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC.
- Central Nervous System (CNS) Progression on CNS Penetrable ALK TKI: Real-World Practice Patterns and Patient Outcomes
  Singhal, S., Hui, C., Neal, J., Roy, M., Das, M., Ramchandran, K., 鈥� Myall, N. (2024). Central Nervous System (CNS) Progression on CNS Penetrable ALK TKI: Real-World Practice Patterns and Patient Outcomes. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC.
- Sacituzumab Govitecan plus Pembrolizumab plus Carboplatin in 1L Metastatic Non-Small Cell Lung Cancer: The EVOKE-02 Study
  Gray, J., Neal, J., Patel, J. D., Liu, S. V., Girard, N., Reck, M., 鈥� Garon, E. B. (2024). Sacituzumab Govitecan plus Pembrolizumab plus Carboplatin in 1L Metastatic Non-Small Cell Lung Cancer: The EVOKE-02 Study. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC.
- Amivantamab Plus Lazertinib in Patients With EGFR-mutant Non-small Cell Lung Cancer (NSCLC) After Progression on Osimertinib and Platinum-based Chemotherapy: Results From CHRYSALIS-2 Cohort A.
  Besse, B., Goto, K., Wang, Y., Lee, S.-H. H., Marmarelis, M. E., Ohe, Y., 鈥� Cho, B. C. (2025). Amivantamab Plus Lazertinib in Patients With EGFR-mutant Non-small Cell Lung Cancer (NSCLC) After Progression on Osimertinib and Platinum-based Chemotherapy: Results From CHRYSALIS-2 Cohort A. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer.
- A vision-language foundation model for precision oncology.
  Xiang, J., Wang, X., Zhang, X., Xi, Y., Eweje, F., Chen, Y., 鈥� Li, R. (2025). A vision-language foundation model for precision oncology. Nature.
- Afatinib and Necitumumab in EGFR-Mutant NSCLC with Acquired Resistance to Tyrosine Kinase Inhibitors
  Myall, N. J., Whisenant, J. G., Neal, J. W., Iams, W. T., Reckamp, K. L., York, S., 鈥� Padda, S. K. (2025). Afatinib and Necitumumab in EGFR-Mutant NSCLC with Acquired Resistance to Tyrosine Kinase Inhibitors. JTO CLINICAL AND RESEARCH REPORTS, 6(2).
- Afatinib and Necitumumab in EGFR-Mutant NSCLC with Acquired Resistance to Tyrosine Kinase Inhibitors.
  Myall, N. J., Whisenant, J. G., Neal, J. W., Iams, W. T., Reckamp, K. L., York, S., 鈥� Padda, S. K. (2025). Afatinib and Necitumumab in EGFR-Mutant NSCLC with Acquired Resistance to Tyrosine Kinase Inhibitors. JTO Clinical and Research Reports, 6(2), 100757.
- Determinants of 5-year survival in patients with advanced NSCLC with PD-L1=50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry.
  Cortellini, A., Brunetti, L., Di Fazio, G. R., Garbo, E., Pinato, D. J., Naidoo, J., 鈥� Ricciuti, B. (2025). Determinants of 5-year survival in patients with advanced NSCLC with PD-L1=50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry. Journal for Immunotherapy of Cancer, 13(2).
- First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients WithEGFRExon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer in the Phase III EXCLAIM-2 Trial.
  Janne, P. A., Wang, B.-C., Cho, B. C., Zhao, J., Li, J., Hochmair, M., 鈥� Mok, T. S. (2025). First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients WithEGFRExon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer in the Phase III EXCLAIM-2 Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO2401269.
- Novel Therapeutic Approach Targeting CXCR3 to Treat Immunotherapy Myocarditis.
  Huang, Y. V., Sun, Y., Chou, H., Wagner, N., Vitale, M. R., Bayer, A. L., 鈥� Zhu, H. (2025). Novel Therapeutic Approach Targeting CXCR3 to Treat Immunotherapy Myocarditis. Circulation Research.
- Treatment (Tx) patterns and clinical outcomes in unresectable (UR) stg III EGFR-mutation positive (EGFRm) NSCLC treated with chemoradiotherapy (CRT): Final analysis of a global real-world (rw) study
  Ahn, M.-J., Lin, S. H., Yang, C.-T., Lee, J. B., Neal, J., Okishio, K., 鈥� Kim, Y. J. (2024). Treatment (Tx) patterns and clinical outcomes in unresectable (UR) stg III EGFR-mutation positive (EGFRm) NSCLC treated with chemoradiotherapy (CRT): Final analysis of a global real-world (rw) study. ANNALS OF ONCOLOGY. ELSEVIER.
- Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.
  Skoulidis, F., Araujo, H. A., Do, M. T., Qian, Y., Sun, X., Cobo, A. G., 鈥� Heymach, J. V. (2025). Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors. Nature.
- Phase I/II ARROS-1 study of zidesamtinib (NVL-520) in ROS1 fusion-positive solid tumours
  Besse, B., Drilon, A. E., Cho, B. C., Camidge, D. R., Neal, J., Lin, C.-C., 鈥� Lin, J. J. (2024). Phase I/II ARROS-1 study of zidesamtinib (NVL-520) in ROS1 fusion-positive solid tumours. ANNALS OF ONCOLOGY. ELSEVIER.
- Unveiling Exarafenib's Role in BRAF-Mutated NSCLC Through Genomic Analysis and Combined Preclinical, Clinical Outcomes
  Manabe, T., Severson, P., Wang, T., Miller, N., Zhang, N., Donderici, E., 鈥� Bivona, T. (2025). Unveiling Exarafenib's Role in BRAF-Mutated NSCLC Through Genomic Analysis and Combined Preclinical, Clinical Outcomes. CANCER SCIENCE. WILEY.
- An ultrasensitive method for detection of cell-free RNA.
  Nesselbush, M. C., Luca, B. A., Jeon, Y.-J. J., Jabara, I., Meador, C. B., Garofalo, A., 鈥� Diehn, M. (2025). An ultrasensitive method for detection of cell-free RNA. Nature.

View More Publications

Clinical Trials

Clinical trials are 糖心传媒 studies that evaluate a new medical approach, device, drug, or other treatment. As a 糖心传媒 patient, you may have access to the latest, advanced clinical trials.

Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.

Open Trials Closed Trials

A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers

A Phase 1/2 Study to Evaluate MEDI4736

A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer

LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib

Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer

Radical-Dose Image Guided Radiation Therapy in Treating Patients With Metastatic Non-small Cell Lung Cancer Undergoing Immunotherapy

A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer

A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors

A Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced Solid Malignancies

A Phase 2 Study of Amrubicin in Relapsed or Refractory Thymic Malignancies

Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-cells in New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1)/ LAGE-1a-positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab

Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)

Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy

Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients

TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

Study of Two Doses of Pembrolizumab (MK-3475) Versus Docetaxel in Previously Treated Participants With Non-Small Cell Lung Cancer (MK-3475-010/KEYNOTE-010)

Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)

Molecular Analysis of Thoracic Malignancies

SABR-ATAC: A Trial of TGF-beta Inhibition and Stereotactic Ablative Radiotherapy for Early Stage Non-small Cell Lung Cancer

TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy

A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer

Manuka Honey in Preventing Esophagitis-Related Pain in Patients Receiving Chemotherapy and Radiation Therapy For Lung Cancer

Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer

Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma

Screening Protocol for Tumor Antigen Expression Profiling and HLA Typing for Eligibility Determination

A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck

Clinical Study of BYM338 for the Treatment of Unintentional Weight Loss in Patients With Cancer of the Lung or the Pancreas

A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges

An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)

Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC

Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer

Phase I Vorinostat Concurrent With Stereotactic Radiosurgery (SRS) in Brain Metastases From Non-Small Cell Lung Cancer

Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer

Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation

BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery

A Study of Atezolizumab in Participants With Programmed Death - Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor

Erlotinib in Patients With Resected, Early Stage NSCLC With Confirmed Mutations in the EGFR

Study of Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy in Patients With Stage III Non-small Cell Lung Cancer

Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC)

Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer

A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors

Radiation Therapy in Treating Patients With Extensive Stage Small Cell Lung Cancer

Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations

Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer

A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]

Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010MA in Advanced Non Small Cell Lung Cancer

Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

Phase 2a Desipramine in Small Cell Lung Cancer and Other High-Grade Neuroendocrine Tumors

Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141)

Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery

Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors

Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer

Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer

Study is Designed to Assess the Safety and Tolerability of AZD4547 at Increasing Doses in Patients With Advanced Tumours

Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line Chemotherapy

PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients

Pembrolizumab in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer

Specializing In

Practice Locations

Thoracic Cancer Program in Palo Alto Palo Alto, CA

Palo Alto, CA

Thoracic Cancer Program in Palo Alto

875 Blake Wilbur Dr

Palo Alto , CA 94304

(650) 498-6000

More Clinic Information

Cancer Immunotherapy Program Palo Alto, CA

Palo Alto, CA

Cancer Immunotherapy Program

875 Blake Wilbur Dr

Palo Alto , CA 94304

(650) 498-6000

More Clinic Information

Important Information about Our Organizations and Physician Affiliation

糖心传媒, 糖心传媒 Tri-Valley, and Stanford Medicine Partners are each independent nonprofit organizations that are affiliated with but separate from each other and from Stanford University. The physicians who provide care at facilities operated by 糖心传媒, 糖心传媒 Tri-Valley, and Stanford Medicine Partners are faculty, foundation, or community physicians who are not employees, representatives, or agents of 糖心传媒, 糖心传媒 Tri- Valley, or Stanford Medicine Partners. 糖心传媒, 糖心传媒 Tri-Valley, and Stanford Medicine Partners do not exercise control over the care provided by such faculty, foundation, and community physicians and are not responsible for their actions.

Patient Ratings

(43 Ratings)

Overall Rating

5.0/5

View Ratings by Category

5.0/5

Friendliness

5.0/5

Explanations

5.0/5

Listens

5.0/5

Care provider's efforts to include you in decisions about your care

5.0/5

Recommended to others

0.0/5

Wait times

How Our Ratings Work

The Patients Ratings and comments are gathered from our Patient Satisfaction Survey and displayed in their entirety.

Patient Satisfaction Survey Disclaimer

Patient Reviews

(237 reviews)

Excellent rapport with patient and family member, allowed discussion of all our concerns, able to make your health seem his primary concern!

Mar 2025

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

He is a very good and professional Doctor

Feb 2025

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr Neal is awesome and the best!! Thank you for all that you do! I would recommend everyone I know to Stanford healthcare

Jan 2025

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

I trust Dr. Neal芒鈧劉s guidance and very much appreciate that we can about the course of treatment (the serious stuff), as well as moments in life to celebrate (like travel). I芒鈧劉m glad for the balance.

Jan 2025

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Neal has been my medical oncologist for 6 years. His diagnostic and treatment strategy literally saved my life. He inspires great respect for his medical and scientific knowledge, and his persona inspires trust, warmth and comfort. I am a very lucky man to have been in his care, with the collaboration of Dr. Loo and the support of a fabulous team of fellows, residents, interns, NP/PAs, nurses and techicians.

Jan 2025

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Nice Doctor

Jan 2025

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Once again excellent visit, all treatment options discussed in depth, realistic expectations discussed and hopeful outcomes

Dec 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Neal, is a extremely good doctor, and looks out for the patient.

Nov 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Very good doctor.

Nov 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

The professional level is very high and He treats patients very patiently芒鈧�

Nov 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Just an awesome doctor芒拢茂赂

Oct 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

We greatly appreciate all the kind care we received from Dr Neal and his team.

Oct 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

I felt reassured by the visit and hopeful by Dr. Joe Neil said

Sep 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Nice, knowledgeable, kind, funny

Sep 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Joel Neal is a great doctor. He is really good at answering all questions and explaining treatment.

Sep 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Outstanding physician, a beacon in the sea of medicine and science! My wife and I feel so fortunate to be cared for by such a caring and knowledgeable doctor, thank you!

Aug 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Thank you Dr. Neal,

Jul 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Neal saved my life. Full stop. Without his treatment strategy and his orchestration of Stanford health diagnostic and therapeutic resources, and Asta Zeneca's drug Tagrisso, I would be long gone. He and his team have been realistic but encouraging throughout this difficult journey. He has a charming sense of humor that puts my wife and me at ease. I would not want to leave out Dr. Billy Loo and his team. The SABR treatment that he applied and the he and Dr. Neal recommended put a definitive end to the remains of my tumor, which completed the main treatment cycle.

Jun 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

All my questions were answered. This was an effective visit.

Jun 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr Neal is the best really appreciate him

Jun 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Very through doctor.

May 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

He seems knowledgable and personable.

May 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Excellent doctor! He explains everything

May 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Excellent

Apr 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Extremely knowledgeable and helpful. Also kind.

Mar 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Great doctor!

Mar 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Appreciate his expertise

Mar 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

excellent doctor, great listener, able to create a treatment plan that offers hope and addresses all concerns!

Mar 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Neal is so obviously competent in his job, and has great backup. Like from Matthew today. But his upbeat, engaging personality also makes him outstanding in my experience.

Mar 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

I consider myself to be very fortunate to receive medical care from Dr. Neal and his great team. I wish that everyone could receive this type of care. I pray for him and his team.

Mar 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr Neal is very knowledgeable of the newest medications and techniques. He is patient and kind and very truthful.

Mar 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr Neal is an excellent oncologist. He is approachable, caring and provides the right level of information to me. I would recommend him to anyone who needs a thoracic oncologist.

Feb 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Excellent positive attitude and clinician

Feb 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Neal is extremely professional. To me, he is the best doctor. I would like to recommend him to other people who need a doctor in 糖心传媒.

Feb 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Very knowledgeable and straightforward person

Feb 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr Neal is particularly wonderful in his ability to explain all the detailed aspects of my cancer and the treatment he has ordered. His compassionate and deep attention to my mental and emotional health is greatly apprecisted. His suggestions for enhancing and attaining the best quality of life are reminders of universal truths and his supportive, nonjudgmental delivery of all related advice is the hallmark of his style and professionalism. His assistant Judy Patigma (sp?)is attentive to my questions and very clear in her answers. She briefs Dr Neal thoroughly and I appreciate the time she takes to listen. I芒鈧劉m appreciative of assistant Clare芒鈧劉s transcriptions of my appointment. I am extremely grateful and proud to be under Dr Neal芒鈧劉s care. Mitzi Konevich

Feb 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

He is a premier doctor and human. I believe in his expertise explicitly

Feb 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Great doctor! Thorough, understanding, knowledgeable, quick.

Feb 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Just to thank Dr. Neal for his suggestions and help.

Feb 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr Neal is an excellent doctor. After a surprising and difficult diagnosis over 5 years ago, he has kept me moving forward with good health, optimism, and great confidence in him. Thank you!

Jan 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Neal is so good at listening. I appreciate that very much.

Jan 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Joel Neal is a very caring and professional doctor He is taking care of me for the past 4 years and I am extremely happy with his care for my disease. I will recommend him to all . Thank you Dr. Neal

Jan 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Neal is a extremely competent physician with an excellent manner and I would recommend him to anyone and everyone.

Jan 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Even though I had not seen Dr Neal since 2016, the conversation was like I had just been in. He had my history at his disposal and is very personable.

Jan 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Neal saved my life. By which I mean, he orchestrated the amazing resources of Stanford Health to diagnose, plan and treat my Stage 4 non small-cell lung cancer definitively. I was lucky that the biopsy revealed that I had EGFR Exon 19 deletion, but Dr. Neal made it happen for me to get Tagrisso immediately for first line treatment. I felt that I was in the care of someone who would marshall the best available treatments to get me through that dark time. Later, when the tumor had retreated 75% and I had been stable for several years, he collaborated with Dr. Loo, who attacked the remaining tumor with SABR. Now, with "no evidence of disease," but knowing that NSCLC or some other cancer could appear in the future, I am confident that I am in the best possible hands with Dr. Neal and his colleagues at Stanford Health.

Jan 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Good Provider with Love & Care

Jan 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Neal has been my favorite doctor for sometime now!

Jan 2024

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr Neal once again exceeded all of my expectations by clearly answering my many questions and especially by providing advice relevant to my care and referring me to various specific sp脙漏cialis脙漏d resources to help me get involved proactively in the management of my care treatment and all aspects of my wellbeing. I am very grateful to Dr Neal for his attention and compassion. Dr Neal芒鈧劉s team is excellent. The team was very helpful to inquire about my questions to expediently prepare Dr Neal to meet with me.

Nov 2023

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Is able to consolidate medical information so it can be understood and assist with a treatment plan

Nov 2023

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Wonderful caring doctor. Excellent skills

Nov 2023

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Neal is awesome!

Oct 2023

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Excellent visit with Dr Neal. He brief me on my upcoming treatment and the choices I have to make . Everything was clear and uderstanderable.

Oct 2023

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Excellent Doctor

Oct 2023

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr Neal is kind, considerate, knowledgeable, precise and informative, logical and compassionate. I trust his opinion and treatment plans implicitly. I can rely on him completely to suggest and provide the best possible care for my health issues. His professionalism and kind personality are extraordinary.

Oct 2023

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Neal is the best doctor I ever met.

Oct 2023

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Excellent presentation - Dr. Neal made me feel better about my circumstances overall.

Oct 2023

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Neal and his team is the BEST! He is not only an excellent clinician, but a lovely person who really cares about his patients.

Sep 2023

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

wonderful doctor

Sep 2023

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Stanford is the best when it comes to health care.

Sep 2023

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Very good!

Aug 2023

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

So knowledgeable. Willing to explain and even continue looking at my case.

Aug 2023

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr Neal listens and answers all my questions .

Aug 2023

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

The best

Aug 2023

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

concerned, courteous, informative , feel fortunate to have him on my team!

Jul 2023

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Joel Neal is a fantastic doctor! I feel so very lucky to have him managing my cancer treatment. He is completely honest, empathetic, and kind, as well as being humorous, and he is excellent at explaining CT scans and treatment options. Having Dr. Neal gives me great peace of mind! I could not be more thankful and grateful to have him as my doctor!

Jul 2023

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Excellent pre-session with a fellow on his last day and had good meeting with doctor Neal. Always very positive approach to treatment which must be hard seeing so many people with an incurable cancer.

Jul 2023

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Neal was very friendly, courteous and informative. I got answers to my questions and have decided on a path forward. I did not feel rushed or that any of my concerns were dismissed.

Jun 2023

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Neal n his staffs are thorough throughout the process. A staff member reviewed and updated my clinical progress/changes, received our questions/concerns, and presented/discussed with Dr. Neal before he came on live. Dr Neal delivered great cares in addressing our concerns, answering our questions, and recommending his plan of care for the future.

Jun 2023

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

As always, he was entirely understanding and helpful.

Jun 2023

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr Neal answered my questions and was very pleasant. Would definitely recommend his practice to friends and family.

Jun 2023

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Neal was great. Thank you for your time.

May 2023

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

An excellent doctor who cares deeply about his patients. I am so grateful he's on my care team.

Apr 2023

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr Neal is very kind and knowledgeable. I especially value His wisdom and empathy as I navigate life post treatment. He is an extraordinary medical professional and I appreciate his strong positive character and integrity as a fellow human in the journey of life

Apr 2023

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

I have no comment. I appreciated having the conversation and learned a few things that will be helpful.

Apr 2023

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Fine physican, excellent rapport, knowledgeable, great personality, encouraging, great!

Apr 2023

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Neal is a very knowledgeable and compassionate oncologist. I am extremely grateful to him!

Mar 2023

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr Neal and his team are great and I rave to anyone who will listen.

Jan 2023

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

He is very professional and easy to talk with.

Jan 2023

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

I visited him for a second opinion and he helped to lay out the options very clearly and explained the pros and cons better than anyone has so far. It was very helpful.

Jan 2023

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

The call went well and all my questions were answered.

Dec 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Compassionate, knowledgeable, personable, able to provide excellent medical care for complex medical issues! No matter what the outcome we always feel stronger after our appointments! A true gentleman and a humble physician.

Dec 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

A very professional and personal physician. He is very interested in the benefits of his patients.

Dec 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr Neal is amazing! Experienced, knowledgeable, kind, and extremely helpful. I feel that he has my best interests at heart.

Dec 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Always a pleasant encounter

Dec 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Neal was very kind, considerate, warm and engaging. I like his expertise and also his positive attitude. He said he would do the worrying for me, and I really appreciated that comment. It is such a scary thing to have cancer, and having someone this good on my team makes me feel hopeful. Thank you.

Nov 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Neal is the BEST! Caring, very thorough in explaining conditions and treatments. Was not at all made to feel rushed. Overall, I芒鈧劉d give Dr Neal a 5 star recommendation.

Oct 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Very professional and friendly

Oct 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

My visit with Dr. Joel Neal was affirming and very informative. He was very kind and I am grateful for the advice and support. I feel uplifted and energized to deal with my future and my health status. He's the BEST!

Oct 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

He saved my life, for which I am of courseI eternally grateful. He has been an immense pleasure to work with as well as full of reality-based insight, counsel and recommendations. We have worked together for nearly 4 years and I am now on a really good path.

Oct 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr Neal made me feel I had his full attention in n, was generous with information on possible treatments. He was

Sep 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

excellent support

Sep 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

The whole team has been most helpful, courteous and caring.

Sep 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Thank you Dr. Neal!

Sep 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Compassion

Sep 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

had a great visit

Sep 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

I am satisfied with the time he gave me as well as his expert opinion on my situation

Aug 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Personable, informative, caring engaging!

Aug 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Being with Dr. Neal for 5 years I have the most respect and love for his tender care of me andI know everyone else he treats.

Aug 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

I had a very good experience with this second opinion visit with Dr. Neal

Jul 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

We are grateful for Dr Neal's guidance regarding treatment/immunotherapy going forward and his discussion of PET scan results. We believe God has blessed us with Dr Neal.

Jul 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr, Neal is the epitome of kindness and care. He is more than a doctor, he is a healer.

Jul 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

He was very informative and helpful.

Jul 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Really clear, empathic, informed, and hoping he can help me on this (unwanted) journey. Also very human.

Jul 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Caring, professional and kind!

Jun 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Neal is just wonderful! He is extremely knowledgeable and specific and truly seems to care. I deeply appreciate his expertise in my lung cancer.

Jun 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

The doctor is very nice! He untied some of my heart and made me more confident. I sincerely thank him.

Jun 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Neal is very caring and does understand the patient芒鈧劉s condition and point of view.

Jun 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

I am very impressed with the whole entire team.

Jun 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Best care ever - The medical team and I have a great relationship. I feel very fortunate

May 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Joel seems like a very nice person. He was personable. He talked to me so I understood what he was talking about. I would recommend him.

May 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Knowledgeable, professional, interacts well with patient and assistant. Would strongly recommend him to those whom are in need of his abilities!

May 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Neal and his team were exceptional at building rapport via video and addressing my concerns, Although I had several questions, the team and Dr. Neal took the time to answer all my questions and explain treatment options. At no point did I feel rushed or that my questions were trivial. Dr. Neal was also great at addressing the emotional aspect of living with cancer.

Apr 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

He was great.

Apr 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Neal is the best. I don芒鈧劉t wish cancer on anyone but if you are unfortunately diagnosed with lung cancer Dr. Neal is the person to see.

Mar 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Great staff

Mar 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

He explained purpose of visit clearly, and made me feel very much at ease.

Mar 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Excellent ! Very caring and extremely professional and he is a treasure!

Mar 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr.Neal is the best, he took time asking questions & explained clearly all my concerns. He provided the future plans of treatment really carefully for my health. Thank you so much Dr. Neal 冒鸥鈩� 冒鸥录冒鸥藴鈧�

Feb 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Excellent rapport with the patient, shows genuine concern and empathy. Knowledgeable and able to impart this to the patient, in this case myself. Thorough in regards to present findings as well as actions to be taken in the future. In short he rocks!!!!!!!

Feb 2022

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

I appreciated the thoroughness and detail of the consultation. His recommendations were a good option that had not be considered before.

Oct 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

He芒鈧劉s terrific!!

Oct 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Just great! And the NP (Judy) working with Dr. Neal was excellent as well.

Oct 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Neal communicates very effectively.

Sep 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Very helpful, listened and gave clear opinions. Easy to understand.

Sep 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Neal took the time to review my file and prior surgeries/scans/reports, before continuing the video session. Three things stood out: 1) He took the time to study my case and formulated a clear and concise opinion. 2) Based on the given facts, he explained his assessments, as well as recommend another 2nd opinion with Stanford radiology, before proceeding with cyberknife procedure. 3) Because Dr. Neal had plenty of time to study my case, I felt reassured that his assessment was formulated after careful consideration and joint consultation with Dr. Thomas Sun.

Sep 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Very comfortable to converse with. Very thorough. Very clear.

Sep 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

excellent Doctor

Aug 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Excellent doctor providing second opinion on lung tumor advise to my Honolulu doctor. Working as a team. His opinion is priceless.

Aug 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

We continue to appreciate your professional comments to help treat my cancer.

Aug 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Excellent give excellent guidance and advice

Jul 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

He did a great job and explained the problems and possible solutions.

Jul 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

He is very nice , friendly and knowledgeable. He helped coordinate with the Tumor Board to provide good treatment advices.

Jul 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Great doctor

Jul 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Very knowledgeable and very kind.

Jul 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Very engaging and attentive. Gave very good explanations to all of my questions.

Jul 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Both Dr. Neal and Dr. Wu were professional, knowledgeable, caring and helpful. Very pleased with the visit.

Jun 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

accommodating care provider and listen to your needs

Jun 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Doctor Joel Neal provided answers to questions and hope for continual treatment outside of whole brain treatment. His character provided a caring person who has knowledge and experience with the type of cancer. We appreciated his time! Sincerely The Lindsey's

Jun 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

I am extremely grateful to have a doctor like Joel Neal in charge of my care. I fully trust Dr. Neal's judgement and appreciate the time he takes to discuss and answer my questions.

Jun 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Very warm and personable individual. Explains everything quite easily. I would recommend him to any lung ca patient looking for care at Stanford.

Jun 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

I am extremely fortunate to have Dr. Neal as my oncologist. His clinical judgment has been unerring and his professional and caring demeanor are an ideal combination. He is as responsive to my wife's questions as to mine, which is wonderful as she and I are a team in this.

Jun 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Friendly engaged professional; I芒鈧劉m glad he芒鈧劉s my doc!

Jun 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Neal explained and answered all of my question about my illness. He was very thorough and positive.

Jun 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

He is my hero and my friend. I芒鈧劉m so fortunate to have found him.

Jun 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Joel Neal he is a good Doctor and he is a good complete explanation whatever I芒鈧劉ll asking about my health or my results... He is a good smile to me even he knows its so pain inside my mind, but he gave you a positive thoughts:) Thanks

May 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

He was extremely knowledgeable, caring, nice and respectful. He explained everything with great details, answered all our questions patiently and in a way that was easy to understand even the complicated medical situations. We really appreciate his caring and heartfelt approach.

May 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Smart and compassionate doctor who was well prepared for my second opinion appointment. I appreciated his input about whether I would benefit a particular treatment. He was articulate, u hurried and gave great explanations. I felt he was very personable especially when he stated that if I could he would like to hear from me once a year about how I芒鈧劉m doing...a little check in via email. This was amazing.

May 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Very confident in Dr. Neal

May 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Extremely happy with call. He explained everything perfectly and answered questions I had. Very professional as well as personal

May 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Neal is a provider that will think of patients health and condition not only physical but boost our emtions by making me smile. I truly admired Dr. Neal for his cocerned.

May 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Excellent service!

May 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Neal was highly recommended, and I was very happy with him!

May 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

I feel secure in his opinion it seems more realistic than his residents.

Apr 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Excellent Thoracic Oncologist.

Apr 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr Neal is great. He explains things well, answers all questions, and shows caring and compassion.

Apr 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Thanks so much for a really informative call. I am very impressed with you as being a very well trained physician with a terrific 芒鈧揵edside芒鈧� manner. I芒鈧劉ll look forward to a f/u call after my next set of scans.

Apr 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

He has been Awesome - the best!

Apr 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr Neal is a caring, respectful person, take time to make sure I understand all procedures. He's flexible to the my need. Thanks a lot Dr. Neal!芒拧藴冒鸥藴

Apr 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Met & exceeded ALL expectations.

Jan 2021

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Joel Neal is the best!

Nov 2020

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Joel Neal is the best!

Sep 2020

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Neal is the best!

Jun 2020

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

It has been a blessing to have Dr. Neal & his team guiding us through a very difficult time. Every visit, every call & every e-mail gave us confidence that we were in the BEST hands possible. I will forever be grateful to Dr. Neal, & to all of the Stanford Cancer Center - an amazing & inspiring place of HOPE. Thank you to ALL.

Apr 2020

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Katin was very thorough and caring. He did a great work up then heard Dr. Neal went over everything in detail. They explained everything in great detail.

Mar 2020

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Judy and Dr. Neal are excellent in the care administered. They are very attentive and concerned of my well being.

Nov 2019

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Neal was very thorough, thoughtful my appointment, I understood my situation clearly.

Oct 2019

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Joel Neal is a special person. He has been blessed with special talents. No matter how my situation turns out, I know I have received the best, up to date, care possible. God bless all of you!

Jul 2019

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Neal works hard for his patients & is always good natured about answering any questions. He's tops in my book.

Jun 2019

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Neal is the best!

Jun 2019

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Always courteous & engaging.

Jun 2019

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Neal and his team are all excellent! It's wonderful knowing you're getting the best medical care & from someone who really cares.

May 2019

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Neal is wonderful.

May 2019

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Neal & NP Connie spent so much time with us & showed such care & compassion. Dr. Neal drew a diagram of treatment plan options so we could understand. We were so impressed.

May 2019

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Neal & PA Rodriguez are excellent. They listen, give clinical perspective and clear instructions/advice, and are compassionate and encouraging.

Apr 2019

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Neal, Joel is an exceptional physician and an amazing human being who took the time to be present during every encounter w/my husband & us!!

Mar 2019

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

amazing professionals - worth the wait & other bureaucratic issues...

Mar 2019

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Neal is a wonderful doctor in all respects - he is knowledgeable & very caring.

Feb 2019

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

We have seen a full team of care providers now & they are nothing but amazing. Despite the complexity of my condition, I have comfort I am getting the best care possible.

Oct 2018

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Joel Neal exceeds our expectations. He's very knowledgeable, very caring, understanding. He's always make you comfortable. Thank you Dr. Neal and also to your team of doctors & NP you bring in. Excellent!

Oct 2018

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

We were not rushed. Everything explained. Gave time for us to understand and react some of the decisions. Gave us visual present situation. Very caring.

Jun 2018

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Excellent experience!!

Jun 2018

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Courteous, showed compassion & took time to answer all our concerns.

Mar 2018

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Extreme clarity, lots of openness during visit, really wonderful physician.

Mar 2018

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

I love Dr. Neal.

Feb 2018

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Neal is intelligent compassionate & friendly.

Feb 2018

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

I am very happy with the care I am receiving.

Jan 2018

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Neal is the best!!

Oct 2017

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

May our Almighty God continue to bless Dr. Neal so he can continue helping people that are sick like me. Thank you Dr. Neal. We love you!! You're the best!!

Sep 2017

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Neal was outstanding; caring, easy to understand, detailed explanations; took time to explain everything - never felt rushed, and even gave a departing hug to me and my family. I have a high degree of confidence in him.

Sep 2017

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Neal is excellent!

Aug 2017

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Neal & Judy are the greatest! Always friendly, personable, & explain any information in understandable language.

Jul 2017

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Welcoming - Clear speaking, positive feedback, good listener, positive thinker, friendly natured, thorough reviews -

Jul 2017

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

I would recommend my care providers and Stanford to everyone. Everyone I talked to told me I'm right where I need to be at Stanford for my medical issues.

Jul 2017

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Neal is the best!!!

Apr 2017

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Neal and staff is wonderful, wonderful, wonderful.

Mar 2017

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

I have sent many to Stanford, you the best. Out of the ball park.

Feb 2017

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Excellent.

Dec 2016

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Neal is very busy and often runs late. He is, however, excellent.

Nov 2016

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

The doctor is very kind, he made me feel much confidence.

Nov 2016

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Neal is outstanding & I understand how busy he is.

Oct 2016

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Neal & his future staff are extremely knowledgeable; professional; pleasant and courteous. Although I have a serious lung caner, my question's were all answered & future direction now much cleaner.

Sep 2016

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Wonderful, wonderful, wonderful, I can't say enough good things about Dr. Neal, and he and staff are a 10 in my book.

Sep 2016

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Compared to Kaiser, Dr. Neal was much more informed., Had much better communication skills. Gave better advice and had much more empathy. Gave me hope.

Aug 2016

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Neal together w/the doctors or NP he brings with him are very professional & knowledgeable.

Aug 2016

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Excellent professional visit!

Jul 2016

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

He addressed my personal concerns, locations & explicit questions completely clearly.

Jul 2016

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

The most professional & sincere doctor I have ever met. Dr. Neal focus on customer satisfaction is world class.

Jun 2016

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

My mom (patient) loves Dr. Neal and Dr. Judy, NP. She trusts them fully as they are always on top of everything, but most importantly, they are genuinely compassionate.

Apr 2016

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr Neal is an extremely personable and caring physician. He answered my questions, gave me answers to questions I hadn't even thought to ask. When I left 'Dr. Neal's' office I felt better than I had in a very long time.

Apr 2016

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

My opinion is Dr. Neal is at the top of his field.

Mar 2016

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Professional, yet friendly and concerned.

Mar 2016

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Very detailed and comprehensive explanations.

Mar 2016

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Have been seeing Dr. Neal for 5 yrs. and have been blessed to be able to so. Excellent!

Mar 2016

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Neal and the PA were so very easy to understand and attentive. Felt so good with both of them! Thank you.

Mar 2016

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr Neal thank you.

Mar 2016

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

This time I felt the doctor was rushed and could have been more supportive.

Feb 2016

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Neal is the best! This man saved my life! He has a good manner about him, ease of understanding and makes a person feel completely at ease.

Jan 2016

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

We really appreciate Dr. Neal's help and have confidence in his expertise and treatment. Dr. Neal is awesome! Highly recommend!

Dec 2015

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Neal, Allison and Judy are all wonderful.

Dec 2015

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Need translator since patient only speaks Chinese. But, overall experience is excellent.

Dec 2015

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Provider gave words of comfort during lengthy problem.

Nov 2015

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

I think they are all awesome!!

Nov 2015

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Neal is an amazing doctor. He put my worries to ease about my illness.

Nov 2015

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Very good +'s.

Nov 2015

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Neal's assistant is wonderful. She is clear & thorough and VERY easy to talk to.

Aug 2015

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Joel Neal, Dr. Jody Chuang, and NP Judy Pagtama are wonderful!

Jul 2015

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

All of them are very friendly, kind and professional. I love them.

Jun 2015

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Good.

Mar 2015

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Pack and Dr. Neal spent a lot of time with me (and my husband) - they gave me hope and both have excellent "people skills." I ope I can participate in the medication trial!

Nov 2014

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Neal took his time to explain what needs to be done and possible treatments in the future. Highly professional doctor, intelligent and I see why my cousin strongly recommended to me.

Sep 2014

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

He was great!!

Sep 2014

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Have total confidence in Dr. Neal.

Aug 2014

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

A very impressive MD, PhD.

Aug 2014

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Dr. Neal was straightforward and to the point. I appreciated all the information he provided. I highly recommend him to anyone needing this type of specialist.

Apr 2014

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Doctor Neal, Joel is great and he took care of me very well.

Apr 2014

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Excellent - uplifting.

Mar 2014

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

Spent a great deal of time with me and my wife.

Feb 2014

&苍产蝉辫;鈥�&苍产蝉辫;

Verified SHC Patient

View More Patient Reviews

Referring Physicians

PHYSICIAN HELPLINE

Phone:听1-866-742-4811
Fax: 650-320-9443
Monday鈥揊riday, 8 a.m.鈥�5 p.m.

糖心传媒 provides comprehensive services to听refer听and听track patients, as well as the latest information and news for physicians and office staff.听For help with all referral needs and questions, visit Referral Information.

You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.

听

Send referrals online
Place radiology and lab orders
View referral status
Access medical records

Learn More About MedLink

糖心传媒

New to MyHealth?

ALREADY HAVE AN ACCESS CODE?

DON'T HAVE AN ACCESS CODE?

NEED MORE DETAILS?

MyHealth for Mobile

Joel Neal, MD, PhD

Medical oncologist, Thoracic specialist

Get In Touch

Biography

Professional Summary

Education & Certifications

Publications

Clinical Trials

Specializing In

Practice Locations

Thoracic Cancer Program in Palo Alto Palo Alto, CA

Thoracic Cancer Program in Palo Alto

Cancer Immunotherapy Program Palo Alto, CA

Cancer Immunotherapy Program

Important Information about Our Organizations and Physician Affiliation

Patient Ratings

How Our Ratings Work

Patient Reviews

(237 reviews)

Referring Physicians

PHYSICIAN HELPLINE

糖心传媒

New to MyHealth?

ALREADY HAVE AN ACCESS CODE?

DON'T HAVE AN ACCESS CODE?

NEED MORE DETAILS?

MyHealth for Mobile

WELCOME BACK

Joel Neal, MD, PhD

Medical oncologist, Thoracic specialist

Get In Touch

Biography

Professional Summary

Education & Certifications

Publications

Clinical Trials

Specializing In

Practice Locations

Thoracic Cancer Program in Palo Alto Palo Alto, CA

Thoracic Cancer Program in Palo Alto

Cancer Immunotherapy Program Palo Alto, CA

Cancer Immunotherapy Program

Important Information about Our Organizations and Physician Affiliation

Patient Ratings

How Our Ratings Work

Patient Reviews

(237 reviews)

Referring Physicians

PHYSICIAN HELPLINE